

Recorder's Office Cover Sheet

Recording Requested By:

Name: Doug Ritchie

Department: District Attorney's Office



SHAWNYNE GARREN, RECORDER

Type of Document: (please select one)

- Agreement
- Contract
- Grant
- Change Order
- Easement
- Other specify: _____

FILED

NO. 2023-201

11/10/23
DATE

DOUGLAS COUNTY CLERK
MINDEN, NV

SETTLEMENT AGREEMENT

This Settlement Agreement ("Agreement" or "Masters Settlement Agreement") is entered by and between Plaintiffs (as identified in Exhibit A) effective as of ^{AL}8/3/2023 ^{DEPUTY}2023, Masters Pharmaceutical, LLC fka Masters Pharmaceutical, Inc., d/b/a River City Pharma, and River City Pharma, LLC (collectively "Masters"). Plaintiffs and Masters are referred to as the "Parties."

I. RECITALS

WHEREAS, Plaintiffs have filed lawsuits against Masters, or against other entities with the intention to name Masters, bearing case numbers identified in Exhibit A (the "Actions" and each an "Action") raising Claims (defined below) and/or allegations concerning, related to, based upon, or in connection with the Alleged Harms (defined below) or Released Conduct (defined below);

WHEREAS, the MDL 2804 Plaintiffs' Executive Committee and Masters have entered into a Term Sheet dated June 14, 2023 (Exhibit B attached), which contains the basic terms of this settlement, and which is hereby incorporated in this agreement;

WHEREAS, Masters (i) denies each and all of the Claims and allegations of wrongdoing made by Plaintiffs in the Actions and maintains that it has meritorious defenses; (ii) denies all assertions of wrongdoing or liability against Masters arising out of any of the conduct, statements, acts or omissions alleged, or that could have been alleged, in the Actions already brought or that could be brought by Plaintiffs related to the Released Conduct;

WHEREAS, the Parties have investigated the facts and analyzed the relevant legal issues regarding the Claims and defenses that have been or could have been asserted in the Actions;

WHEREAS, without any admission of wrongdoing, fault, culpability or liability of any kind, and without any concession as to the strength or weakness of any actual or potential Claims or defenses, the Parties desire to (a) avoid the delay, uncertainty, inconvenience, and expense of litigation, and (b) fully and finally resolve, settle, release and discharge any and all Claims Plaintiffs brought or could have brought against Masters in the Actions and all Claims related in any way to the Alleged Harms or Released Conduct;

WHEREAS, the Parties have agreed to the terms herein for the sole purpose of settlement, and nothing herein may be taken as or construed to be an admission or concession of any violation of law, rule, or regulation, or of any other matter of fact or law, or of any liability or wrongdoing or lack thereof;

WHEREAS, no part of this Agreement, including its statements and commitments, shall constitute evidence of any liability, fault, or wrongdoing, or of any lack thereof;

WHEREAS, unless the contrary is expressly stated, this Agreement is not intended for use by any Party or any third party for any purpose not expressly stated herein, including submission to

any court for any purpose other than any required court approval(s) associated with this Agreement and the enforcement of this Agreement;

WHEREAS, the Parties acknowledge, agree to, and understand the terms set forth herein;

WHEREAS, Plaintiffs have determined the terms of this Agreement are fair, reasonable and adequate and in the public interest; and

WHEREAS, the Parties engaged in arm's-length negotiations between counsel in good faith, intending to be legally bound.

NOW, THEREFORE, in consideration of the above recitals and the promises and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

II. AGREEMENT

1. Recitals Incorporated. The foregoing Recitals are incorporated herein and constitute express terms of this Agreement.

2. Definitions.

a. "Alleged Harms" means any alleged past, present, and future financial and societal harms and related expenditures arising out of the alleged misuse and abuse of Products (defined below), and/or any alleged injuries sustained by individuals suffering from opioid-related addiction, abuse, other related diseases and disorders, and death, that allegedly have been caused by Masters, non-exclusive examples of which are described in the reports and opinions submitted in connection with the case captioned In re: National Prescription Opiate Litigation, No. 1:17-md-2804 (N.D. Ohio),

b. "Claim" means any past, present or future cause of action, claim for relief, cross-claim or counterclaim, theory of liability, demand, derivative claim, request, assessment, charge, covenant, damage, debt, lien, loss, penalty, judgment, right, obligation, dispute, suit, contract, controversy, agreement, parens patriae claim, promise, performance, warranty, omission, or grievance of any nature whatsoever, whether legal, equitable, statutory, regulatory or administrative, whether arising under federal, state or local common law, statute, regulation, guidance, ordinance or principles of equity, whether filed or unfiled, whether asserted or unasserted, whether known or unknown, whether accrued or unaccrued, whether foreseen, unforeseen or unforeseeable, whether discovered or undiscovered, whether suspected or unsuspected, whether fixed or contingent, and whether existing or hereafter arising, in all such cases, including but not limited to any request for declaratory, injunctive, or equitable relief, compensatory, punitive, or statutory damages, absolute liability, strict liability, restitution, abatement, subrogation, contribution, indemnity, apportionment, disgorgement, reimbursement, attorney

fees, expert fees, consultant fees, fines, penalties, expenses, costs or any other legal, equitable, civil, administrative, or regulatory remedy whatsoever.

c. “Released Conduct” means any actual or alleged act, failure to act, negligence, creation of any public or private nuisance, statement, error, omission, breach of any duty, conduct, event, transaction, agreement, misstatement, misleading statement or other activity of any kind whatsoever from the beginning of time through the Effective Date (and any past, present, or future consequence of any such act, failure to act, negligence, statement, error, omission, breach of duty, conduct, event, transaction, agreement, misstatement, misleading statement or other activity) relating in any way to: (a) the distribution, dispensing, delivery, monitoring, reporting, supply, sale, prescribing, physical security, warehousing, coverage, purchases, reimbursement, discovery, development, manufacture, packaging, repackaging, marketing, promotion, advertising, labeling, recall, withdrawal, or use or abuse of any Product; (b) orders, prescriptions, formularies, guidelines, payments or rebates for any Product; (c) policies, practices and/or operating procedures, insurance, claim or benefit administration, claim adjudication, plan design, data and/or sales thereof, relating to, any Product; (d) any system, plan, policy or advocacy relating to any Product, including, but not limited to, any promotion, marketing, programs, or campaigns relating to any Product; (e) the characteristics, properties, risks, or benefits of any Product; (f) the reporting, disclosure, nonreporting or non-disclosure to federal, state or other regulators of orders or prescriptions; (g) the purchasing, selling, acquiring, disposing of, importing, exporting, handling, processing, packaging, supplying, distributing, or converting of any Product; or (h) controls against diversion, corresponding responsibility, and/or suspicious order monitoring.

d. “Effective Date” means the date that Masters receives executed Masters’ Settlement Participation Agreements and/or dismissals with prejudice as to all actions identified on Exhibit A. In the event that fewer than all Plaintiffs identified on Exhibit A execute the Masters’ Settlement Participation Agreement and/or provide dismissals with prejudice, this Agreement shall not become effective and none of the payments described herein shall be made.

e. “Product” means any chemical substance, whether used for medicinal or non-medicinal purposes, and whether natural, synthetic, or semi-synthetic, or any finished pharmaceutical product made from or with such substance, that is (1) an opioid or opiate, as well as any product containing any such substance; (2) a benzodiazepine, a muscle relaxer, carisoprodol, zolpidem, or gabapentin; or (3) a combination or “cocktail” of any stimulant or other chemical substance prescribed, sold, bought, or dispensed to be used together that includes opioids or opiates. “Product” shall include, but is not limited to, any substance consisting of or containing buprenorphine, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone,

oxymorphone, tapentadol, tramadol, opium, heroin, carfentanil, alprazolam, chlordiazepoxide, clobazam, clorazepate, diazepam, estazolam, lorazepam, quazepam, alprazolam, clonazepam, oxazepam, flurazepam, triazolam, temazepam, midazolam, carisoprodol, cyclobenzaprine, orphenadrine, tizanidine, gabapentin, or any variant of these substances or any similar substance.

f. "Released Claims" means any and all Claims that directly or indirectly are based on, arise out of, or in any way relate to or concern the Released Conduct and/or Alleged Harms occurring prior to the Effective Date. Without limiting the foregoing, "Released Claims" include any Claims that have been asserted against the Released Entities by Releasers (whether judicial, arbitral, or administrative) based on, arising out of, or relating to, in whole or in part, the Released Conduct and/or Alleged Harms, or any such Claims that could be or could have been asserted, now or in the future, in those actions or in any comparable action or proceeding brought by Plaintiffs or Releasers. The Parties intend that "Released Claims" be interpreted broadly.

g. "Released Entities" means Masters Pharmaceutical, Inc., Masters Pharmaceutical, LLC, "River City Pharma," River City Pharma, LLC and: (1) all of their past and present direct or indirect parents, subsidiaries, divisions, affiliates, predecessors, successors, and assigns (2) the past and present direct or indirect subsidiaries, divisions, affiliates, predecessors, successors, and assigns of any of the foregoing; and (3) the foregoing entities' respective past and present officers, directors, members, shareholders (solely in their capacity as shareholders of the foregoing entities), partners, trustees, employees, agents, representatives, insurers and attorneys (for actions that occurred during and related to their work for, or employment with, Masters).

h. "Releasers" means and includes each private or public Plaintiff and, as applicable, its employees, officers, parents, subsidiaries, shareholders, members, heirs and assigns, departments, agencies, divisions, boards, commissions, subdivisions, districts, corporations, courts, institutes, offices, instrumentalities of any kind, attorneys, and any entities over which such Plaintiff exercises governing, fiscal or budgetary authority or control, and any person in their official capacity whether elected or appointed to serve any of the foregoing and any agency, person, or other entity claiming by or through any of the foregoing. Each Plaintiff also shall sign and deliver to Masters the Masters Settlement Participation Agreement (Exhibit C, hereto) providing for a release to the fullest extent of such Plaintiff's authority or a file a dismissal with prejudice of any pending Action.

3. Settlement Amount. Within thirty (30) days after the Effective Date, Masters shall cause to be paid \$3,339,547.49 to Peter H. Weinberger, Liaison Counsel to the Plaintiffs' Executive Committee ("Weinberger") in the form of a check payable to the Spangenberg, Shibley, and Liber LLP IOLTA Account ("Trust Account"). Weinberger shall then allocate those funds to the Plaintiffs in accordance with a formula agreed upon by the Plaintiffs, and said amount shall be net

of the Common Benefit Surcharge to the MDL Common Benefit fund pursuant to Doc #4428 in MDL 2804 in the amount of 7.5% of the amount, to wit \$250,466.06, which shall be paid by Liaison Counsel for Plaintiffs. The Parties agree that, subject to all of the terms, conditions, recitals, and provisions of this Agreement, the Settlement Amount is a reasonable compromise of the matters in dispute. Plaintiffs shall provide a W-9 with respect to the above-mentioned payment at the time they provide a signed copy of this Agreement.

4. Settlement Amount Holdbacks and/or Additional Payments. The parties agree that in addition to the Settlement Amount described in paragraph 3, Masters shall cause its insurer, Federal Insurance Company (“Federal”) to make the following payments:

a. Within 30 days of the Effective Date \$100,000.00 will be paid to the trust account of Garvey Shearer Nordstrom to pay for Masters’ attorneys’ fees associated with work performed in furtherance of this settlement. After the payment of those attorneys’ fees, any remaining balance, if any, will be payable to Weinberger. Weinberger shall distribute those funds to Plaintiffs using the same formula (including Common Benefit surcharge) as described in paragraph 3.

b. Within 30 days of the Effective Date, \$200,000.00 will be paid to the trust account of Garvey Shearer Nordstrom to pay to defend and/or settle any Claim for Released Conduct asserted against Masters by any party not listed in Exhibit A prior to: (1) the date that is 60 days after all Plaintiffs on Exhibit A have submitted dismissals with prejudice and/or signed participation agreements; or (2) January 31, 2024, whichever is later (a “New Claim”). In the event any such New Claim is asserted, then Masters will use such funds to defend and/or settle all such New Claim(s). After the full and final resolution of any such New Claim, or if no New Claim is asserted, any remaining balance of such funds, if any, will be payable to Weinberger. Weinberger shall distribute those funds to Plaintiffs on Exhibit A using the same formula (including Common Benefit surcharge) as described in paragraph 3.

c. \$400,000.00 will be paid to Acuity Insurance Company in settlement of claims by Acuity Insurance Company in the action entitled *Acuity, a Mutual Insurance Company v. Federal Insurance Company and Masters Pharmaceutical, Inc.*, Case No. A 2300745 in the Court of Common Pleas, Hamilton County, Ohio (the “Acuity Action”) in accordance with the terms of a separate settlement agreement among the parties to the Acuity Action

d. Any funds distributed to Weinberger pursuant to this paragraph 4 shall be considered “Settlement Amounts.”

5. Nature of Payment. The Parties acknowledge and agree that, notwithstanding anything to the contrary in this Agreement, including, but not limited to, the scope of the Released Claims:

a. They have entered into this Agreement to avoid the delay, expense, inconvenience, and uncertainty of further litigation;

b. For the avoidance of doubt: (1) no portion of the Settlement Amounts represents reimbursement to Plaintiffs or any Releasor for the fees or costs of any investigation or litigation, including without limitation attorneys' fees, (2) no portion of the Settlement Amounts represents the disgorgement of any allegedly ill-gotten gains, and (3) no portion of the Settlement Amounts is paid for or in place of any fine, penalty, punitive damages, or other punitive assessments.

6. Release.

a. *Scope.* As of the Effective Date, the Released Entities are hereby released and forever discharged from all of the Releasors' Released Claims. Plaintiffs (for themselves and the Releasors) hereby absolutely, unconditionally, and irrevocably covenant not to bring, file, or claim; or to cause, assist in bringing or permit to be brought, filed, or claimed; or to otherwise seek to establish liability for any Released Claim against any Released Entity in any forum whatsoever. The releases provided for in this Agreement are broad, shall be interpreted so as to give the Released Entities the broadest possible bar against any liability relating in any way to any Released Claim and any Alleged Harms within Plaintiffs' territorial boundaries, and extend to the full extent of the power of Plaintiffs to release claims. This Agreement shall be a complete bar to any Released Claim.

b. *Sole Payment.* It is the intent of the Parties that:

(1) the payments made under this Agreement shall be the sole payments made by the Released Entities to the Releasors involving, arising out of, or related to Alleged Harms and/or Released Conduct (or conduct that would be Released Conduct if engaged in by a Released Entity);

(2) Claims by Releasors against non-Parties shall not result in additional payments by Released Entities, whether through contribution, indemnification or any other means; and

(3) the Agreement meets the requirements of the Uniform Contribution Among Joint Tortfeasors Act and any similar state law or doctrine that reduces or discharges a released party's liability to any other parties.

c. *General Release.* In connection with the releases provided for in this Agreement, each Plaintiff (for itself and its Releasors) expressly waives, releases, and forever discharges any and all provisions, rights, and benefits conferred by any law of any State or territory of the United States or other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to § 1542 of the California Civil Code, which reads:

General Release; extent. A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

d. A Releasor may hereafter discover facts other than or different from those which it knows, believes, or assumes to be true with respect to the Released Claims and/or Alleged Harms, but each Plaintiff hereby expressly waives and fully, finally, and forever settles, releases and discharges, upon the Effective Date, any and all Released Claims that may exist as of such date even if Releasors do not know or suspect such claims to exist, whether through ignorance, oversight, error, negligence or through no fault whatsoever, and even if knowledge of the existence of such claims would materially affect each Plaintiff's decision to enter into this Agreement.

e. *Res Judicata.* Nothing in this Agreement shall be deemed to reduce the scope of the res judicata or claim preclusive effect that the settlement memorialized in this Agreement gives rise to under applicable law.

f. *Representation and Warranty.* Each Plaintiff expressly represents and warrants that it has authority to settle and release all Released Claims of Releasors.

g. *Effectiveness.* The releases set forth in this Agreement shall not be impacted in any way by any dispute that exists, has existed, or may later exist between or among the Releasors. Nor shall such releases be impacted in any way by any current or future law, regulation, ordinance, or court or agency order limiting, seizing, or controlling the distribution or use of the Settlement Amount or any portion thereof, or by the enactment of future laws, or by any seizure of the Settlement Amount or any portion thereof.

h. Plaintiffs represent that, as of the Effective Date, and other than the Actions, they have not prepared or brought, and have no intention of preparing or bringing, any other case(s) or claim(s) against any Released Party.

i. *Cooperation.* Releasors (i) will not encourage any person or entity to bring or maintain any Released Claim against any Released Entity, and (ii) will reasonably cooperate with and not oppose any effort by a Released Entity to secure the prompt dismissal of any and all Released Claims.

7. Dismissal with Prejudice. Within fourteen (14) days after the execution of a Masters' Settlement Participation Agreement, each Plaintiff will dismiss its respective Action as to Masters with prejudice. To the extent necessary or useful, Masters will join Plaintiffs' submissions to effectuate the dismissals with prejudice of the Actions.

8. Expenses. Except as otherwise set forth in this Agreement, each Party shall bear its own costs (including but not limited to legal fees and expenses) incurred in connection with this Agreement and in prosecuting or defending the Actions. The dismissal with prejudice referred to

in Paragraph 7 above shall state that each Party is to bear its own costs, fees and expenses, including attorney fees.

9. No Admission. The Parties intend the settlement as described herein to be a final and complete resolution of all disputes between Masters and all Releasors. Masters is entering into this Agreement solely for the purposes of settlement, to resolve each Action and all Released Claims and thereby avoid significant expense, inconvenience and uncertainty. Masters denies the allegations in the Actions and denies any civil or other liability in the Actions. Nothing contained herein may be taken as or deemed to be an admission or concession by Masters of: (i) any violation of any law, regulation, or ordinance; (ii) any fault, liability, or wrongdoing; (iii) the strength or weakness of any Claim or defense or allegation made in any Action, or in any other past, present or future proceeding relating to any Released Conduct, Alleged Harms, or any Product; (iv) the legal viability of the claims and theories in any Action, including but not limited to the legal viability of the relief sought; or (v) any other matter of fact or law. Nothing in this Agreement shall be construed or used to prohibit any Released Entity from engaging in the conduct of its business relating to any Product.

10. Public Disclosure. After the Execution Date, this Settlement Agreement will be subject to public disclosure pursuant to public records laws, open meetings laws, and/or other laws or regulations that require disclosure to the public of information about Plaintiffs ("Public Disclosure Laws"). Nothing herein shall prevent any Party from disclosing the terms of this Settlement Agreement prior to the Execution Date (a) as required by law, or (b) to its actual or prospective attorneys, accountants, auditors, insurers, lenders, acquirers, investors, shareholders, or financial advisors.

11. Statements to the Press; No Solicitation of Publicity. No Party or attorney, agent or representative acting and communicating on behalf of any Party may make public statements that contradict provisions in this Settlement Agreement, including without limitation Paragraph 17 (Non-Admissibility). It is agreed that the Parties' private counsel shall not make any comments or statements to the press, issue any press release, convene any press conference or otherwise initiate publicity with the media, including but not limited to newspapers, publications, or other mass media, nor post to internet websites or any social media information concerning the terms of the Agreement.

12. Third-Party Beneficiaries. Nothing in this Agreement is intended to or shall confer upon any third party any legal or equitable right, benefit, or remedy of any nature whatsoever, other than the right of each Released Entity to use and enforce this Agreement as if it were a party hereto.

13. No Waiver. This Agreement is made without trial or adjudication of any issue of fact or law or finding of liability of any kind. No waiver of any breach, waiver of any failure of any condition, or waiver of any right or remedy contained in or granted by this Agreement shall be effective unless in writing and signed by the Party waiving the breach, failure, right, or remedy. No waiver of any breach, failure, right, or remedy shall be deemed a waiver of any other prior,

subsequent, or contemporaneous breach, failure, right, or remedy, whether or not similar; nor shall any waiver constitute a continuing waiver unless the writing so specifies.

14. Entire Agreement; Integration. This Agreement constitutes the entire understanding and agreement of the Parties with respect to the matters addressed herein. This Agreement supersedes any prior agreements or understandings, whether written or oral, between or among the Parties. No representations, warranties, covenants, or inducements have been made to any Party concerning this Agreement other than those contained herein. Each Party to this Agreement represents that it freely and voluntarily enters into this Agreement without any degree of duress or compulsion. No reliance was placed upon any representation other than those contained in this Agreement.

15. Construction. None of the Parties shall be considered to be the drafter of this Agreement or of any of its provisions for the purpose of any statute, case law, or rule of interpretation or construction that would or might cause any provision to be construed against the drafter of this Agreement. The headings of the provisions of this Agreement are not binding and are for reference only and do not affect the meaning of this Agreement.

16. No Prevailing Party. The Parties each agree that they are not the prevailing party in this action, for purposes of any claim for fees, costs, or expenses as prevailing parties arising under common law or under the terms of any statute, because the Parties have reached a good faith settlement.

17. Non-Admissibility. Neither this Agreement nor any act performed or document executed pursuant to or in furtherance of this Agreement: (1) is or may be deemed to be or may be used as an admission or evidence relating to any matter of fact or law alleged in the Actions, the strength or weakness of any claim or defense or allegation made in those cases, or any wrongdoing, fault, or liability of any Released Entities; or (2) is or may be deemed to be or may be used as an admission or evidence relating to any liability, fault or omission of Released Entities in any civil, criminal or administrative proceeding in any court, administrative agency or other tribunal. Neither this Agreement nor any act performed or document executed pursuant to or in furtherance of this Agreement shall be admissible in any proceeding for any purpose, except to enforce the terms of this Agreement, and except that Released Entities may file or use this Agreement in any action (1) involving a determination regarding insurance coverage, provided that the characterizations in this Agreement of the alleged harms, claims, and conduct covered by the Agreement shall not be admissible against any insurer to show that the harms, claims, or conduct falls within the scope of the coverage grant or outside the scope of any exclusion in any insuring agreement; (2) involving a determination of the taxable income or tax liability of any Released Entities; (3) to support a defense or counterclaim based on principles of res judicata, collateral estoppel, release, good-faith settlement, judgment bar or reduction or on any other theory of claim preclusion or issue preclusion or similar defense or counterclaim; (4) to support a claim for contribution and/or indemnification; or (5) to support any other argument or defense by a Released Entity that the Settlement Amounts (including the Common Benefit Fund Holdbacks) provide a measure of compensation for Alleged Harms or otherwise satisfy the relief sought.

18. Amendment; Modification. This Agreement shall not be varied, modified or amended in any respect, except by a subsequent written agreement executed by all Parties through their authorized representatives.

19. Authority to Enter Agreement and Ownership of Released Claims. Each Party specifically represents and warrants that this Agreement constitutes a legal, valid, and binding obligation of such Party. Each signatory to this Agreement on behalf of a Party specifically represents and warrants that they have full authority to enter into this Agreement on behalf of such Party. Each Plaintiff for itself and its related Releasors specifically represent and warrant that they have concluded that the terms of this Agreement are fair, reasonable, adequate, and in the public interest, and that they have satisfied all conditions and taken all actions required by law in order to validly enter into this Agreement. Each Plaintiff for itself and its related Releasors further represent and warrant that (a) they are the owner and holder of the Released Claims; (b) they have not sold, assigned, conveyed, pledged, encumbered, or otherwise in any way transferred the Released Claims, or any portion thereof or rights related thereto, to any third party nor have they granted or shall they grant any license or other right that would conflict with the rights and obligations set forth herein; and (c) through this Agreement they have the power and authority to bind all persons and entities with an interest in the Released Claims.

20. Dispute Resolution. In the event of a dispute arising out of or relating to the Agreement, the Parties shall first seek settlement of that dispute by mediation before Jed Melnick (or another mediator if agreed by the Parties). If the dispute is not settled by mediation, the dispute shall be referred to and finally resolved by arbitration before Jed Melnick (or another single arbitrator if agreed by the Parties) under the AAA Commercial Rules and Mediation Procedures.

21. Notices. All notices under this Agreement shall be provided in writing to the following via email and overnight delivery through a recognized national courier:

As to Plaintiffs:

Peter H. Weinberger
Spangenberg, Shibley & Liber LLP
1001 Lakeside Avenue East, Suite 1700
Cleveland, OH 44114
pweinberger@spanglaw.com

As to Masters:

Richard T. Lauer, Esq.
Lauer Law, LLC
335 West Fourth St.
Cincinnati, OH 45202
rick@lauerlawllc.com

Any Party may change or add the contact information of the persons designated to receive notice on its behalf by notice given (effective upon the giving of such notice) as provided in this Paragraph.

24. Further Assurances. Each Party agrees to take all reasonable steps necessary to effectuate the terms of this Agreement.

25. Counterparts. This Agreement may be executed in counterparts, and a facsimile or .pdf signature shall be deemed to be, and shall have the same force and effect as, an original signature.

[signatures on page(s) to follow]

IN WITNESS WHEREOF, this Agreement has been read and signed by the duly authorized representatives of each of the Parties.

On Behalf of Plaintiffs' Executive Committee:



Peter H. Weinberger
Plaintiffs' Liaison Counsel

Dated: _____

On Behalf of All Masters Entities:



Richard T. Lauer, Esq.
Attorney for all Masters Entities

Dated: 8/3/23

EXHIBIT C to Masters Pharmaceutical Settlement Agreement

Masters Pharmaceutical Settlement Participation Agreement

Governmental Entity: Douglas County

State: Nevada

Authorized Official: Jenifer Davidson, County Manager

Address 1: 1594 Esmeralda Avenue

Address 2:

City, State, Zip: Minden, Nevada 89423

Phone: 775-782-9821

Email: jrdaavidson@douglasnv.us

The governmental entity identified above ("Governmental Entity"), in order to obtain and in consideration for the benefits provided to the Governmental Entity pursuant to the Masters Pharmaceutical Settlement Agreement (Exhibit A and the Allocation Schedule (Exhibit D), and acting through the undersigned authorized official, hereby elects to participate in the Masters Pharmaceutical Settlement Agreement and release all Released Claims against all Released Entities,¹ and agrees as follows.

1. The Governmental Entity is aware of and has reviewed the Masters Pharmaceutical Settlement Agreement, understands all terms in the Masters Pharmaceutical Settlement Agreement, and agrees that by the Masters Pharmaceutical Settlement Agreement, the Governmental Entity elects to become a Releasor as defined therein.
2. The Governmental Entity shall promptly, and in any event within 7 business days of the Effective Date and payment of the settlement funds dismiss with prejudice any Released Claims that it has filed.
3. The Governmental Entity agrees to the terms of the Masters Pharmaceutical Settlement Agreement pertaining to Releasors as defined therein.
4. The Governmental Entity has the right to enforce the Masters Pharmaceutical Settlement Agreement as provided therein.
5. The Governmental Entity, as a Party to the Masters Pharmaceutical Settlement Agreement, hereby becomes a Releasor for all purposes in the Masters Pharmaceutical Settlement Agreement, including but not limited to all provisions of Section 5 of the Masters Pharmaceutical Settlement

¹ Capitalized terms shall have the same meaning as in the Meijer Settlement Agreement.

Agreement, and along with all departments, agencies, divisions, boards, commissions, subdivisions, districts, corporations, courts, institutes, offices, instrumentalities of any kind, attorneys, and any entities over which such Governmental Entity exercises governing, fiscal, or budgetary authority or control, and any person in their official capacity elected or appointed to serve any of the foregoing and any agency, person, or other entity claiming by or through any of the foregoing, and any other entity identified in the definition of Releasor, provides for a release to the fullest extent of its authority. As a Releasor, the Governmental Entity hereby absolutely, unconditionally, and irrevocably covenants not to bring, file, or claim, or to cause, assist or permit to be brought, filed, or claimed, or to otherwise seek to establish liability for any Released Claims against any Released Entity in any forum whatsoever. The releases provided for in the Masters Pharmaceutical Settlement Agreement are intended by the Parties to be broad and shall be interpreted so as to give the Released Entities the broadest possible bar against any liability relating in any way to Released Claims and extend to the full extent of the power of the Governmental Entity to release claims. The Masters Pharmaceutical Settlement Agreement shall be a complete bar to any Released Claim.

6. Nothing herein is intended to modify in any way the terms of the Masters Pharmaceutical Settlement Agreement, to which the Governmental Entity hereby agrees. To the extent this form is interpreted differently from the Masters Pharmaceutical Settlement Agreement in any respect, the Masters Pharmaceutical Settlement Agreement controls.

IN WITNESS WHEREOF, this Masters Pharmaceutical Settlement Participation Agreement has been read and signed by the duly authorized representative of the Governmental Entity signing below.

Signed:



By:

Jenifer Davidson

Its:

County Manager

Date:

10/19/2023

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-03-2023)

State of Nevada - Actual and Estimated Deposits to the Fund for a Resilient Nevada

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
McKinsey	2021	September	\$ 28,461,750.49	\$ 5,407,732.59	\$ -	\$ 23,054,017.90
Janssen - J&J	2022	July	\$ 18,612,345.20	\$ 3,536,345.59	\$ -	\$ 15,075,999.61
Distributors	2022	August	\$ 4,340,895.22	\$ 824,770.09	\$ -	\$ 3,516,125.13
Distributors	2022	September	\$ 4,562,069.29	\$ 866,793.17	\$ -	\$ 3,695,276.12
American Drug Stores	2022	December	\$ 657,900.01	\$ 131,580.00	\$ -	\$ 526,320.01
Mallinckrodt (BK)	2022	December	\$ 811,293.19	\$ 162,258.64	\$ -	\$ 649,034.55
Janssen - J&J (Fee Fund)	2023	July	\$ -	\$ (4,603,844.83)	\$ -	\$ 4,603,844.83
Distributors	2023	July	\$ 4,562,069.29	\$ 866,793.17	\$ -	\$ 3,695,276.12
Allergan	2023	July	\$ 1,660,972.77	\$ 123,850.76	\$ 1,458,406.49	\$ 1,537,122.01
CVS	2023	August	\$ 6,877,247.99	\$ -	\$ 5,731,040.01	\$ 6,877,247.99
Distributors (Fee Fund)	2023	August	\$ -	\$ (15,432,662.80)	\$ -	\$ 15,432,662.80
Mallinckrodt (BK)	2023	September	\$ -	\$ (162,258.64)	\$ -	\$ 162,258.64
Walmart	2023	September	\$ 14,136,532.91	\$ -	\$ 1,511,506.58	\$ 14,136,532.91
Walgreens	2023	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Janssen - J&J (Fee Fund)	2024	July	\$ -	\$ (302,274.46)	\$ -	\$ 302,274.46
Distributors (Fee Fund)	2024	July	\$ -	\$ (735,956.63)	\$ -	\$ 735,956.63
Distributors	2024	July	\$ 5,710,075.94	\$ 1,084,914.43	\$ -	\$ 4,625,161.51
Allergan	2024	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2024	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
CVS	2024	August	\$ 6,877,247.99	\$ -	\$ 5,731,040.01	\$ 6,877,247.99
Purdue (BK)	2024	July	\$ 24,561,600.00	\$ 5,280,744.00	\$ -	\$ 19,280,856.00
Walgreens	2024	December	\$ 6,541,719.00	\$ -	\$ 6,718,803.74	\$ 6,541,719.00
Janssen - J&J	2025	April	\$ 1,173,447.81	\$ 222,955.08	\$ -	\$ 950,492.73
Distributors	2025	July	\$ 5,710,075.94	\$ 1,084,914.43	\$ -	\$ 4,625,161.51
Allergan	2025	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2025	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
CVS	2025	August	\$ 6,877,247.99	\$ -	\$ 5,731,040.01	\$ 6,877,247.99
Walgreens	2025	December	\$ 6,541,719.00	\$ -	\$ 6,718,803.74	\$ 6,541,719.00
Distributors	2026	July	\$ 5,710,075.94	\$ 1,084,914.43	\$ -	\$ 4,625,161.51
Allergan	2026	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2026	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
CVS	2026	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2026	December	\$ 6,541,719.00	\$ -	\$ 6,718,803.74	\$ 6,541,719.00
Distributors	2027	July	\$ 5,710,075.94	\$ 1,084,914.43	\$ -	\$ 4,625,161.51
Allergan	2027	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2027	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2027	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2027	December	\$ 6,541,719.00	\$ -	\$ 6,718,803.75	\$ 6,541,719.00
Distributors	2028	July	\$ 6,715,737.27	\$ 1,275,990.08	\$ -	\$ 5,439,747.19
Allergan	2028	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2028	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2028	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2028	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2029	July	\$ 6,715,737.27	\$ 1,275,990.08	\$ -	\$ 5,439,747.19
Allergan	2029	July	\$ 1,660,972.77	\$ 123,850.76	\$ -	\$ 1,537,122.01
Teva	2029	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2029	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2029	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2030	July	\$ 6,715,737.27	\$ 1,275,990.08	\$ -	\$ 5,439,747.19
Teva	2030	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2030	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2030	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2031	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2031	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2031	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2031	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2032	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2032	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2032	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2032	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2033	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2033	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2033	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2033	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2034	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2034	July	\$ 670,038.92	\$ -	\$ 2,239,601.25	\$ 670,038.92
CVS	2034	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2034	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2035	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2035	July	\$ 3,137,299.64	\$ -	\$ -	\$ 3,137,299.64
CVS	2035	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2035	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2036	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2036	July	\$ 3,137,299.64	\$ -	\$ -	\$ 3,137,299.64
CVS	2036	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2036	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2037	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2037	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
CVS	2037	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2037	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2038	July	\$ 5,645,254.94	\$ 1,072,598.44	\$ -	\$ 4,572,656.50
Teva	2038	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
CVS	2038	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2038	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2039	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2039	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
CVS	2039	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2039	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2040	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2040	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
CVS	2040	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2040	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2041	July	\$ 12,101,012.85	\$ -	\$ -	\$ 12,101,012.85
Teva	2041	July	\$ 12,101,012.85	\$ -	\$ -	\$ 12,101,012.85
CVS	2041	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2041	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
Distributors	2042	July	\$ 12,101,012.85	\$ -	\$ -	\$ 12,101,012.85
Teva	2042	July	\$ 12,101,012.85	\$ -	\$ -	\$ 12,101,012.85
CVS	2042	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2042	December	\$ 6,541,718.99	\$ -	\$ -	\$ 6,541,718.99
TOTAL			\$ 433,971,722.79	\$ 13,678,345.77	\$ 64,955,058.06	\$ 420,293,377.02

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Carson City - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 432,300.73	\$ 64,845.11	\$ -	\$ 367,455.62
Distributors	2022	August	\$ 100,824.06	\$ 15,123.61	\$ -	\$ 85,700.45
Distributors	2022	September	\$ 105,961.17	\$ 15,894.18	\$ -	\$ 90,066.99
American Drug Stores	2022	December	\$ 15,280.75	\$ 3,820.19	\$ -	\$ 11,460.56
Mallinckrodt (BK)	2022	December	\$ 18,843.55	\$ 4,710.89	\$ -	\$ 14,132.66
Distributors	2023	July	\$ 105,961.17	\$ 15,894.18	\$ -	\$ 90,066.99
Allergan	2023	July	\$ 38,578.68	\$ 4,805.56	\$ 33,873.76	\$ 33,773.12
CVS	2023	August	\$ 124,105.30	\$ -	\$ 166,390.42	\$ 124,105.30
Mallinckrodt (BK)	2023	September	\$ -	\$ (4,710.89)	\$ -	\$ 4,710.89
Walmart	2023	September	\$ 328,343.01	\$ -	\$ 43,883.87	\$ 328,343.01
Walgreens	2023	December	\$ 90,700.91	\$ -	\$ -	\$ 90,700.91
Distributors	2024	July	\$ 132,625.41	\$ 19,893.81	\$ -	\$ 112,731.60
Allergan	2024	July	\$ 38,578.68	\$ 4,805.56	\$ -	\$ 33,773.12
Teva	2024	July	\$ 33,308.92	\$ -	\$ -	\$ 33,308.92
CVS	2024	August	\$ 124,105.30	\$ -	\$ 166,390.42	\$ 124,105.30
Purdue (BK)	2024	July	\$ 570,481.44	\$ 142,620.36	\$ -	\$ 427,861.08
Walgreens	2024	December	\$ 90,700.91	\$ -	\$ 181,458.94	\$ 90,700.91
Janssen - J&J	2025	April	\$ 27,255.15	\$ 4,088.27	\$ -	\$ 23,166.88
Distributors	2025	July	\$ 132,625.41	\$ 19,893.81	\$ -	\$ 112,731.60
Allergan	2025	July	\$ 38,578.68	\$ 4,805.56	\$ -	\$ 33,773.12
Teva	2025	July	\$ 33,308.92	\$ -	\$ -	\$ 33,308.92
CVS	2025	August	\$ 124,105.30	\$ -	\$ 166,390.42	\$ 124,105.30
Walgreens	2025	December	\$ 90,700.91	\$ -	\$ 181,458.94	\$ 90,700.91
Distributors	2026	July	\$ 132,625.41	\$ 19,893.81	\$ -	\$ 112,731.60
Allergan	2026	July	\$ 38,578.68	\$ 4,805.56	\$ -	\$ 33,773.12
Teva	2026	July	\$ 33,308.92	\$ -	\$ -	\$ 33,308.92
CVS	2026	August	\$ 149,751.38	\$ -	\$ -	\$ 149,751.38
Walgreens	2026	December	\$ 145,167.15	\$ -	\$ 181,458.94	\$ 145,167.15
Distributors	2027	July	\$ 132,625.41	\$ 19,893.81	\$ -	\$ 112,731.60
Allergan	2027	July	\$ 38,578.68	\$ 4,805.56	\$ -	\$ 33,773.12
Teva	2027	July	\$ 14,868.82	\$ -	\$ 60,486.31	\$ 14,868.82
CVS	2027	August	\$ 149,751.38	\$ -	\$ -	\$ 149,751.38
Walgreens	2027	December	\$ 145,167.15	\$ -	\$ 181,458.94	\$ 145,167.15
Distributors	2028	July	\$ 155,983.47	\$ 23,397.52	\$ -	\$ 132,585.95
Allergan	2028	July	\$ 38,578.68	\$ 4,805.56	\$ -	\$ 33,773.12
Teva	2028	July	\$ 14,868.82	\$ -	\$ 60,486.31	\$ 14,868.82
CVS	2028	August	\$ 149,751.38	\$ -	\$ -	\$ 149,751.38
Walgreens	2028	December	\$ 145,167.15	\$ -	\$ -	\$ 145,167.15
Distributors	2029	July	\$ 155,983.47	\$ 23,397.52	\$ -	\$ 132,585.95
Allergan	2029	July	\$ 38,578.68	\$ 4,805.56	\$ -	\$ 33,773.12
Teva	2029	July	\$ 14,868.82	\$ -	\$ 60,486.31	\$ 14,868.82
CVS	2029	August	\$ 149,751.38	\$ -	\$ -	\$ 149,751.38
Walgreens	2029	December	\$ 145,167.15	\$ -	\$ -	\$ 145,167.15
Distributors	2030	July	\$ 155,983.47	\$ 23,397.52	\$ -	\$ 132,585.95
Teva	2030	July	\$ 14,868.82	\$ -	\$ 60,486.31	\$ 14,868.82
CVS	2030	August	\$ 149,751.38	\$ -	\$ -	\$ 149,751.38
Walgreens	2030	December	\$ 145,167.15	\$ -	\$ -	\$ 145,167.15
Distributors	2031	July	\$ 131,119.84	\$ 19,667.98	\$ -	\$ 111,451.86
Teva	2031	July	\$ 14,868.82	\$ -	\$ 60,486.31	\$ 14,868.82
CVS	2031	August	\$ 149,751.38	\$ -	\$ -	\$ 149,751.38
Walgreens	2031	December	\$ 145,167.15	\$ -	\$ -	\$ 145,167.15
Distributors	2032	July	\$ 131,119.84	\$ 19,667.98	\$ -	\$ 111,451.86
Teva	2032	July	\$ 14,868.82	\$ -	\$ 60,486.31	\$ 14,868.82
CVS	2032	August	\$ 149,751.38	\$ -	\$ -	\$ 149,751.38
Walgreens	2032	December	\$ 145,167.15	\$ -	\$ -	\$ 145,167.15
Distributors	2033	July	\$ 131,119.84	\$ 19,667.98	\$ -	\$ 111,451.86
Teva	2033	July	\$ 14,868.82	\$ -	\$ 60,486.31	\$ 14,868.82
Walgreens	2033	December	\$ 145,167.15	\$ -	\$ -	\$ 145,167.15
Distributors	2034	July	\$ 131,119.84	\$ 19,667.98	\$ -	\$ 111,451.86
Teva	2034	July	\$ 14,868.82	\$ -	\$ 60,486.31	\$ 14,868.82
Walgreens	2034	December	\$ 145,167.15	\$ -	\$ -	\$ 145,167.15
Distributors	2035	July	\$ 131,119.84	\$ 19,667.98	\$ -	\$ 111,451.86
Teva	2035	July	\$ 69,619.75	\$ -	\$ -	\$ 69,619.75
Walgreens	2035	December	\$ 145,167.15	\$ -	\$ -	\$ 145,167.15
Distributors	2036	July	\$ 131,119.84	\$ 19,667.98	\$ -	\$ 111,451.86
Teva	2036	July	\$ 69,619.75	\$ -	\$ -	\$ 69,619.75
Walgreens	2036	December	\$ 145,167.15	\$ -	\$ -	\$ 145,167.15
Distributors	2037	July	\$ 131,119.84	\$ 19,667.98	\$ -	\$ 111,451.86
Teva	2037	July	\$ 89,511.11	\$ -	\$ -	\$ 89,511.11
Walgreens	2037	December	\$ 145,167.15	\$ -	\$ -	\$ 145,167.15
Distributors	2038	July	\$ 131,119.84	\$ 19,667.98	\$ -	\$ 111,451.86
Teva	2038	July	\$ 89,511.11	\$ -	\$ -	\$ 89,511.11
Teva	2039	July	\$ 89,511.11	\$ -	\$ -	\$ 89,511.11
Teva	2040	July	\$ 89,511.11	\$ -	\$ -	\$ 89,511.11
Teva	2041	July	\$ 89,511.11	\$ -	\$ -	\$ 89,511.11
Teva	2041	July	\$ 268,533.33	\$ -	\$ -	\$ 268,533.33
Teva	2042	July	\$ 268,533.33	\$ -	\$ -	\$ 268,533.33
		TOTAL	\$ 8,800,135.68	\$ 603,036.46	\$ 1,786,655.16	\$ 8,197,099.22

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Churchill County - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 167,075.18	\$ 25,061.28	\$ -	\$ 142,013.90
Distributors	2022	August	\$ 38,966.39	\$ 5,844.96	\$ -	\$ 33,121.43
Distributors	2022	September	\$ 40,951.77	\$ 6,142.77	\$ -	\$ 34,809.00
American Drug Stores	2022	December	\$ 5,905.69	\$ 1,476.42	\$ -	\$ 4,429.27
Mallinckrodt (BK)	2022	December	\$ 7,282.64	\$ 1,820.66	\$ -	\$ 5,461.98
Distributors	2023	July	\$ 40,951.77	\$ 6,142.77	\$ -	\$ 34,809.00
Allergan	2023	July	\$ 14,909.85	\$ 1,857.25	\$ 13,091.50	\$ 13,052.60
CVS	2023	August	\$ 47,964.10	\$ -	\$ 64,306.41	\$ 47,964.10
Mallinckrodt (BK)	2023	September	\$ -	\$ (1,820.66)	\$ -	\$ 1,820.66
Walmart	2023	September	\$ 126,897.70	\$ -	\$ 16,960.20	\$ 126,897.70
Walgreens	2023	December	\$ 35,054.01	\$ -	\$ -	\$ 35,054.01
Distributors	2024	July	\$ 51,256.95	\$ 7,688.54	\$ -	\$ 43,568.41
Allergan	2024	July	\$ 14,909.85	\$ 1,857.25	\$ -	\$ 13,052.60
Teva	2024	July	\$ 12,873.20	\$ -	\$ -	\$ 12,873.20
CVS	2024	August	\$ 47,964.10	\$ -	\$ 64,306.41	\$ 47,964.10
Purdue (BK)	2024	July	\$ 220,479.13	\$ 55,119.78	\$ -	\$ 165,359.35
Walgreens	2024	December	\$ 35,054.01	\$ -	\$ 70,130.08	\$ 35,054.01
Janssen - J&J	2025	April	\$ 10,533.55	\$ 1,580.03	\$ -	\$ 8,953.52
Distributors	2025	July	\$ 51,256.95	\$ 7,688.54	\$ -	\$ 43,568.41
Allergan	2025	July	\$ 14,909.85	\$ 1,857.25	\$ -	\$ 13,052.60
Teva	2025	July	\$ 12,873.20	\$ -	\$ -	\$ 12,873.20
CVS	2025	August	\$ 47,964.10	\$ -	\$ 64,306.41	\$ 47,964.10
Walgreens	2025	December	\$ 35,054.01	\$ -	\$ 70,130.08	\$ 35,054.01
Distributors	2026	July	\$ 51,256.95	\$ 7,688.54	\$ -	\$ 43,568.41
Allergan	2026	July	\$ 14,909.85	\$ 1,857.25	\$ -	\$ 13,052.60
Teva	2026	July	\$ 12,873.20	\$ -	\$ -	\$ 12,873.20
CVS	2026	August	\$ 57,875.77	\$ -	\$ -	\$ 57,875.77
Walgreens	2026	December	\$ 56,104.07	\$ -	\$ 70,130.08	\$ 56,104.07
Distributors	2027	July	\$ 51,256.95	\$ 7,688.54	\$ -	\$ 43,568.41
Allergan	2027	July	\$ 14,909.85	\$ 1,857.25	\$ -	\$ 13,052.60
Teva	2027	July	\$ 5,746.49	\$ -	\$ 23,376.69	\$ 5,746.49
CVS	2027	August	\$ 57,875.77	\$ -	\$ -	\$ 57,875.77
Walgreens	2027	December	\$ 56,104.07	\$ -	\$ 70,130.08	\$ 56,104.07
Distributors	2028	July	\$ 60,284.34	\$ 9,042.65	\$ -	\$ 51,241.69
Allergan	2028	July	\$ 14,909.85	\$ 1,857.25	\$ -	\$ 13,052.60
Teva	2028	July	\$ 5,746.49	\$ -	\$ 23,376.69	\$ 5,746.49
CVS	2028	August	\$ 57,875.77	\$ -	\$ -	\$ 57,875.77
Walgreens	2028	December	\$ 56,104.07	\$ -	\$ -	\$ 56,104.07
Distributors	2029	July	\$ 60,284.34	\$ 9,042.65	\$ -	\$ 51,241.69
Allergan	2029	July	\$ 14,909.85	\$ 1,857.25	\$ -	\$ 13,052.60
Teva	2029	July	\$ 5,746.49	\$ -	\$ 23,376.69	\$ 5,746.49
CVS	2029	August	\$ 57,875.77	\$ -	\$ -	\$ 57,875.77
Walgreens	2029	December	\$ 56,104.07	\$ -	\$ -	\$ 56,104.07
Distributors	2030	July	\$ 60,284.34	\$ 9,042.65	\$ -	\$ 51,241.69
Teva	2030	July	\$ 5,746.49	\$ -	\$ 23,376.69	\$ 5,746.49
CVS	2030	August	\$ 57,875.77	\$ -	\$ -	\$ 57,875.77
Walgreens	2030	December	\$ 56,104.07	\$ -	\$ -	\$ 56,104.07
Distributors	2031	July	\$ 50,675.07	\$ 7,601.26	\$ -	\$ 43,073.81
Teva	2031	July	\$ 5,746.49	\$ -	\$ 23,376.69	\$ 5,746.49
CVS	2031	August	\$ 57,875.77	\$ -	\$ -	\$ 57,875.77
Walgreens	2031	December	\$ 56,104.07	\$ -	\$ -	\$ 56,104.07
Distributors	2032	July	\$ 50,675.07	\$ 7,601.26	\$ -	\$ 43,073.81
Teva	2032	July	\$ 5,746.49	\$ -	\$ 23,376.69	\$ 5,746.49
CVS	2032	August	\$ 57,875.77	\$ -	\$ -	\$ 57,875.77
Walgreens	2032	December	\$ 56,104.07	\$ -	\$ -	\$ 56,104.07
Distributors	2033	July	\$ 50,675.07	\$ 7,601.26	\$ -	\$ 43,073.81
Teva	2033	July	\$ 5,746.49	\$ -	\$ 23,376.69	\$ 5,746.49
Walgreens	2033	December	\$ 56,104.07	\$ -	\$ -	\$ 56,104.07
Distributors	2034	July	\$ 50,675.07	\$ 7,601.26	\$ -	\$ 43,073.81
Teva	2034	July	\$ 5,746.49	\$ -	\$ 23,376.69	\$ 5,746.49
Walgreens	2034	December	\$ 56,104.07	\$ -	\$ -	\$ 56,104.07
Distributors	2035	July	\$ 50,675.07	\$ 7,601.26	\$ -	\$ 43,073.81
Teva	2035	July	\$ 26,906.58	\$ -	\$ -	\$ 26,906.58
Walgreens	2035	December	\$ 56,104.07	\$ -	\$ -	\$ 56,104.07
Distributors	2036	July	\$ 50,675.07	\$ 7,601.26	\$ -	\$ 43,073.81
Teva	2036	July	\$ 26,906.58	\$ -	\$ -	\$ 26,906.58
Walgreens	2036	December	\$ 56,104.07	\$ -	\$ -	\$ 56,104.07
Distributors	2037	July	\$ 50,675.07	\$ 7,601.26	\$ -	\$ 43,073.81
Teva	2037	July	\$ 34,594.17	\$ -	\$ -	\$ 34,594.17
Walgreens	2037	December	\$ 56,104.07	\$ -	\$ -	\$ 56,104.07
Distributors	2038	July	\$ 50,675.07	\$ 7,601.26	\$ -	\$ 43,073.81
Teva	2038	July	\$ 34,594.17	\$ -	\$ -	\$ 34,594.17
Teva	2039	July	\$ 34,594.17	\$ -	\$ -	\$ 34,594.17
Teva	2040	July	\$ 34,594.17	\$ -	\$ -	\$ 34,594.17
Teva	2041	July	\$ 34,594.17	\$ -	\$ -	\$ 34,594.17
Teva	2041	July	\$ 103,782.51	\$ -	\$ -	\$ 103,782.51
Teva	2042	July	\$ 103,782.51	\$ -	\$ -	\$ 103,782.51
		TOTAL	\$ 3,401,068.26	\$ 233,060.95	\$ 690,504.80	\$ 3,168,007.31

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Clark County - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 15,943,805.18	\$ 2,391,570.78	\$ -	\$ 13,552,234.40
Distributors	2022	August	\$ 3,718,520.54	\$ 557,778.08	\$ -	\$ 3,160,742.46
Distributors	2022	September	\$ 3,907,983.81	\$ 586,197.57	\$ -	\$ 3,321,786.24
American Drug Stores	2022	December	\$ 563,573.76	\$ 140,893.44	\$ -	\$ 422,680.32
Mallinckrodt (BK)	2022	December	\$ 694,974.25	\$ 173,743.56	\$ -	\$ 521,230.69
Distributors	2023	July	\$ 3,907,983.81	\$ 586,197.57	\$ -	\$ 3,321,786.24
Allergan	2023	July	\$ 1,422,831.22	\$ 177,235.26	\$ 1,249,307.85	\$ 1,245,595.96
CVS	2023	August	\$ 4,577,162.37	\$ -	\$ 6,136,692.09	\$ 4,577,162.37
Mallinckrodt (BK)	2023	September	\$ -	\$ (173,743.56)	\$ -	\$ 173,743.56
Walmart	2023	September	\$ 12,109,711.28	\$ -	\$ 1,618,493.41	\$ 12,109,711.28
Walgreens	2023	December	\$ 3,345,165.82	\$ -	\$ -	\$ 3,345,165.82
Distributors	2024	July	\$ 4,891,395.33	\$ 733,709.30	\$ -	\$ 4,157,686.03
Allergan	2024	July	\$ 1,422,831.22	\$ 177,235.26	\$ -	\$ 1,245,595.96
Teva	2024	July	\$ 1,228,475.81	\$ -	\$ -	\$ 1,228,475.81
CVS	2024	August	\$ 4,577,162.37	\$ -	\$ 6,136,692.09	\$ 4,577,162.37
Purdue (BK)	2024	July	\$ 21,040,087.16	\$ 5,260,021.79	\$ -	\$ 15,780,065.37
Walgreens	2024	December	\$ 3,345,165.82	\$ -	\$ 6,692,438.44	\$ 3,345,165.82
Janssen - J&J	2025	April	\$ 1,005,205.06	\$ 150,780.76	\$ -	\$ 854,424.30
Distributors	2025	July	\$ 4,891,395.33	\$ 733,709.30	\$ -	\$ 4,157,686.03
Allergan	2025	July	\$ 1,422,831.22	\$ 177,235.26	\$ -	\$ 1,245,595.96
Teva	2025	July	\$ 1,228,475.81	\$ -	\$ -	\$ 1,228,475.81
CVS	2025	August	\$ 4,577,162.37	\$ -	\$ 6,136,692.09	\$ 4,577,162.37
Walgreens	2025	December	\$ 3,345,165.82	\$ -	\$ 6,692,438.44	\$ 3,345,165.82
Distributors	2026	July	\$ 4,891,395.33	\$ 733,709.30	\$ -	\$ 4,157,686.03
Allergan	2026	July	\$ 1,422,831.22	\$ 177,235.26	\$ -	\$ 1,245,595.96
Teva	2026	July	\$ 1,228,475.81	\$ -	\$ -	\$ 1,228,475.81
CVS	2026	August	\$ 5,523,022.84	\$ -	\$ -	\$ 5,523,022.84
Walgreens	2026	December	\$ 5,353,950.75	\$ -	\$ 6,692,438.44	\$ 5,353,950.75
Distributors	2027	July	\$ 4,891,395.33	\$ 733,709.30	\$ -	\$ 4,157,686.03
Allergan	2027	July	\$ 1,422,831.22	\$ 177,235.26	\$ -	\$ 1,245,595.96
Teva	2027	July	\$ 548,381.17	\$ -	\$ 2,230,812.81	\$ 548,381.17
CVS	2027	August	\$ 5,523,022.84	\$ -	\$ -	\$ 5,523,022.84
Walgreens	2027	December	\$ 5,353,950.75	\$ -	\$ 6,692,438.44	\$ 5,353,950.75
Distributors	2028	July	\$ 5,752,870.23	\$ 862,930.53	\$ -	\$ 4,889,939.70
Allergan	2028	July	\$ 1,422,831.22	\$ 177,235.26	\$ -	\$ 1,245,595.96
Teva	2028	July	\$ 548,381.17	\$ -	\$ 2,230,812.81	\$ 548,381.17
CVS	2028	August	\$ 5,523,022.84	\$ -	\$ -	\$ 5,523,022.84
Walgreens	2028	December	\$ 5,353,950.75	\$ -	\$ -	\$ 5,353,950.75
Distributors	2029	July	\$ 5,752,870.23	\$ 862,930.53	\$ -	\$ 4,889,939.70
Allergan	2029	July	\$ 1,422,831.22	\$ 177,235.26	\$ -	\$ 1,245,595.96
Teva	2029	July	\$ 548,381.17	\$ -	\$ 2,230,812.81	\$ 548,381.17
CVS	2029	August	\$ 5,523,022.84	\$ -	\$ -	\$ 5,523,022.84
Walgreens	2029	December	\$ 5,353,950.75	\$ -	\$ -	\$ 5,353,950.75
Distributors	2030	July	\$ 5,752,870.23	\$ 862,930.53	\$ -	\$ 4,889,939.70
Teva	2030	July	\$ 548,381.17	\$ -	\$ 2,230,812.81	\$ 548,381.17
CVS	2030	August	\$ 5,523,022.84	\$ -	\$ -	\$ 5,523,022.84
Walgreens	2030	December	\$ 5,353,950.75	\$ -	\$ -	\$ 5,353,950.75
Distributors	2031	July	\$ 4,835,868.02	\$ 725,380.20	\$ -	\$ 4,110,487.82
Teva	2031	July	\$ 548,381.17	\$ -	\$ 2,230,812.81	\$ 548,381.17
CVS	2031	August	\$ 5,523,022.84	\$ -	\$ -	\$ 5,523,022.84
Walgreens	2031	December	\$ 5,353,950.75	\$ -	\$ -	\$ 5,353,950.75
Distributors	2032	July	\$ 4,835,868.02	\$ 725,380.20	\$ -	\$ 4,110,487.82
Teva	2032	July	\$ 548,381.17	\$ -	\$ 2,230,812.81	\$ 548,381.17
CVS	2032	August	\$ 5,523,022.84	\$ -	\$ -	\$ 5,523,022.84
Walgreens	2032	December	\$ 5,353,950.75	\$ -	\$ -	\$ 5,353,950.75
Distributors	2033	July	\$ 4,835,868.02	\$ 725,380.20	\$ -	\$ 4,110,487.82
Teva	2033	July	\$ 548,381.17	\$ -	\$ 2,230,812.81	\$ 548,381.17
CVS	2033	December	\$ 5,353,950.76	\$ -	\$ -	\$ 5,353,950.76
Walgreens	2034	July	\$ 4,835,868.02	\$ 725,380.20	\$ -	\$ 4,110,487.82
Teva	2034	July	\$ 548,381.17	\$ -	\$ 2,230,812.81	\$ 548,381.17
CVS	2034	December	\$ 5,353,950.76	\$ -	\$ -	\$ 5,353,950.76
Distributors	2035	July	\$ 4,835,868.02	\$ 725,380.20	\$ -	\$ 4,110,487.82
Teva	2035	July	\$ 2,567,665.74	\$ -	\$ -	\$ 2,567,665.74
Walgreens	2035	December	\$ 5,353,950.76	\$ -	\$ -	\$ 5,353,950.76
Distributors	2036	July	\$ 4,835,868.02	\$ 725,380.20	\$ -	\$ 4,110,487.82
Teva	2036	July	\$ 2,567,665.74	\$ -	\$ -	\$ 2,567,665.74
Walgreens	2036	December	\$ 5,353,950.76	\$ -	\$ -	\$ 5,353,950.76
Distributors	2037	July	\$ 4,835,868.02	\$ 725,380.20	\$ -	\$ 4,110,487.82
Teva	2037	July	\$ 3,301,284.50	\$ -	\$ -	\$ 3,301,284.50
Walgreens	2037	December	\$ 5,353,950.76	\$ -	\$ -	\$ 5,353,950.76
Distributors	2038	July	\$ 4,835,868.02	\$ 725,380.20	\$ -	\$ 4,110,487.82
Teva	2038	July	\$ 3,301,284.50	\$ -	\$ -	\$ 3,301,284.50
Teva	2039	July	\$ 3,301,284.50	\$ -	\$ -	\$ 3,301,284.50
Teva	2040	July	\$ 3,301,284.50	\$ -	\$ -	\$ 3,301,284.50
Teva	2041	July	\$ 3,301,284.50	\$ -	\$ -	\$ 3,301,284.50
Teva	2041	July	\$ 9,903,853.51	\$ -	\$ -	\$ 9,903,853.51
Teva	2042	July	\$ 9,903,853.51	\$ -	\$ -	\$ 9,903,853.51
TOTAL			\$ 324,560,290.85	\$ 22,240,757.20	\$ 65,894,133.80	\$ 302,319,533.65

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)						
Douglas County - Actual and Estimated Allocations						
<i>(assumes no default in payments)</i>						
<i>(CMS Medicaid costs, if any, not deducted)</i>						
<i>(assumes no administrative fees for court appointed third-party administrators)</i>						
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 395,504.32	\$ 59,325.65	\$ -	\$ 336,178.67
Distributors	2022	August	\$ 92,242.15	\$ 13,836.32	\$ -	\$ 78,405.83
Distributors	2022	September	\$ 96,942.01	\$ 14,541.30	\$ -	\$ 82,400.71
American Drug Stores	2022	December	\$ 13,980.09	\$ 3,495.02	\$ -	\$ 10,485.07
Mallinckrodt (BK)	2022	December	\$ 17,239.63	\$ 4,309.91	\$ -	\$ 12,929.72
Distributors	2023	July	\$ 96,942.01	\$ 14,541.30	\$ -	\$ 82,400.71
Allergan	2023	July	\$ 35,294.96	\$ 4,396.52	\$ 30,990.51	\$ 30,898.44
CVS	2023	August	\$ 113,541.75	\$ -	\$ 152,227.66	\$ 113,541.75
Mallinckrodt (BK)	2023	September	\$ -	\$ (4,309.91)	\$ -	\$ 4,309.91
Walmart	2023	September	\$ 300,395.23	\$ -	\$ 40,148.58	\$ 300,395.23
Walgreens	2023	December	\$ 82,980.66	\$ -	\$ -	\$ 82,980.66
Distributors	2024	July	\$ 121,336.65	\$ 18,200.50	\$ -	\$ 103,136.15
Allergan	2024	July	\$ 35,294.96	\$ 4,396.52	\$ -	\$ 30,898.44
Teva	2024	July	\$ 30,473.74	\$ -	\$ -	\$ 30,473.74
CVS	2024	August	\$ 113,541.75	\$ -	\$ 152,227.66	\$ 113,541.75
Purdue (BK)	2024	July	\$ 521,923.42	\$ 130,480.86	\$ -	\$ 391,442.56
Walgreens	2024	December	\$ 82,980.66	\$ -	\$ 166,013.59	\$ 82,980.66
Janssen - J&J	2025	April	\$ 24,935.26	\$ 3,740.29	\$ -	\$ 21,194.97
Distributors	2025	July	\$ 121,336.65	\$ 18,200.50	\$ -	\$ 103,136.15
Allergan	2025	July	\$ 35,294.96	\$ 4,396.52	\$ -	\$ 30,898.44
Teva	2025	July	\$ 30,473.74	\$ -	\$ -	\$ 30,473.74
CVS	2025	August	\$ 113,541.75	\$ -	\$ 152,227.66	\$ 113,541.75
Walgreens	2025	December	\$ 82,980.66	\$ -	\$ 166,013.59	\$ 82,980.66
Distributors	2026	July	\$ 121,336.65	\$ 18,200.50	\$ -	\$ 103,136.15
Allergan	2026	July	\$ 35,294.96	\$ 4,396.52	\$ -	\$ 30,898.44
Teva	2026	July	\$ 30,473.74	\$ -	\$ -	\$ 30,473.74
CVS	2026	August	\$ 137,004.90	\$ -	\$ -	\$ 137,004.90
Walgreens	2026	December	\$ 132,810.87	\$ -	\$ 166,013.59	\$ 132,810.87
Distributors	2027	July	\$ 121,336.65	\$ 18,200.50	\$ -	\$ 103,136.15
Allergan	2027	July	\$ 35,294.96	\$ 4,396.52	\$ -	\$ 30,898.44
Teva	2027	July	\$ 13,603.22	\$ -	\$ 55,337.86	\$ 13,603.22
CVS	2027	August	\$ 137,004.90	\$ -	\$ -	\$ 137,004.90
Walgreens	2027	December	\$ 132,810.87	\$ -	\$ 166,013.59	\$ 132,810.87
Distributors	2028	July	\$ 142,706.52	\$ 21,405.98	\$ -	\$ 121,300.54
Allergan	2028	July	\$ 35,294.96	\$ 4,396.52	\$ -	\$ 30,898.44
Teva	2028	July	\$ 13,603.22	\$ -	\$ 55,337.86	\$ 13,603.22
CVS	2028	August	\$ 137,004.90	\$ -	\$ -	\$ 137,004.90
Walgreens	2028	December	\$ 132,810.87	\$ -	\$ -	\$ 132,810.87
Distributors	2029	July	\$ 142,706.52	\$ 21,405.98	\$ -	\$ 121,300.54
Allergan	2029	July	\$ 35,294.96	\$ 4,396.52	\$ -	\$ 30,898.44
Teva	2029	July	\$ 13,603.22	\$ -	\$ 55,337.86	\$ 13,603.22
CVS	2029	August	\$ 137,004.90	\$ -	\$ -	\$ 137,004.90
Walgreens	2029	December	\$ 132,810.87	\$ -	\$ -	\$ 132,810.87
Distributors	2030	July	\$ 142,706.52	\$ 21,405.98	\$ -	\$ 121,300.54
Teva	2030	July	\$ 13,603.22	\$ -	\$ 55,337.86	\$ 13,603.22
CVS	2030	August	\$ 137,004.90	\$ -	\$ -	\$ 137,004.90
Walgreens	2030	December	\$ 132,810.87	\$ -	\$ -	\$ 132,810.87
Distributors	2031	July	\$ 119,959.23	\$ 17,993.88	\$ -	\$ 101,965.35
Teva	2031	July	\$ 13,603.22	\$ -	\$ 55,337.86	\$ 13,603.22
CVS	2031	August	\$ 137,004.90	\$ -	\$ -	\$ 137,004.90
Walgreens	2031	December	\$ 132,810.87	\$ -	\$ -	\$ 132,810.87
Distributors	2032	July	\$ 119,959.23	\$ 17,993.88	\$ -	\$ 101,965.35
Teva	2032	July	\$ 13,603.22	\$ -	\$ 55,337.86	\$ 13,603.22
CVS	2032	August	\$ 137,004.90	\$ -	\$ -	\$ 137,004.90
Walgreens	2032	December	\$ 132,810.87	\$ -	\$ -	\$ 132,810.87
Distributors	2033	July	\$ 119,959.23	\$ 17,993.88	\$ -	\$ 101,965.35
Teva	2033	July	\$ 13,603.22	\$ -	\$ 55,337.86	\$ 13,603.22
Walgreens	2033	December	\$ 132,810.87	\$ -	\$ -	\$ 132,810.87
Distributors	2034	July	\$ 119,959.23	\$ 17,993.88	\$ -	\$ 101,965.35
Teva	2034	July	\$ 13,603.22	\$ -	\$ 55,337.86	\$ 13,603.22
Walgreens	2034	December	\$ 132,810.87	\$ -	\$ -	\$ 132,810.87
Distributors	2035	July	\$ 119,959.23	\$ 17,993.88	\$ -	\$ 101,965.35
Teva	2035	July	\$ 63,693.88	\$ -	\$ -	\$ 63,693.88
Walgreens	2035	December	\$ 132,810.87	\$ -	\$ -	\$ 132,810.87
Distributors	2036	July	\$ 119,959.23	\$ 17,993.88	\$ -	\$ 101,965.35
Teva	2036	July	\$ 63,693.88	\$ -	\$ -	\$ 63,693.88
Walgreens	2036	December	\$ 132,810.87	\$ -	\$ -	\$ 132,810.87
Distributors	2037	July	\$ 119,959.23	\$ 17,993.88	\$ -	\$ 101,965.35
Teva	2037	July	\$ 81,892.14	\$ -	\$ -	\$ 81,892.14
Walgreens	2037	December	\$ 132,810.87	\$ -	\$ -	\$ 132,810.87
Distributors	2038	July	\$ 119,959.23	\$ 17,993.88	\$ -	\$ 101,965.35
Teva	2038	July	\$ 81,892.14	\$ -	\$ -	\$ 81,892.14
Teva	2039	July	\$ 81,892.14	\$ -	\$ -	\$ 81,892.14
Teva	2040	July	\$ 81,892.14	\$ -	\$ -	\$ 81,892.14
Teva	2041	July	\$ 81,892.14	\$ -	\$ -	\$ 81,892.14
Teva	2041	July	\$ 245,676.41	\$ -	\$ -	\$ 245,676.41
Teva	2042	July	\$ 245,676.41	\$ -	\$ -	\$ 245,676.41
TOTAL			\$ 8,051,089.07	\$ 551,707.36	\$ 1,634,579.33	\$ 7,499,381.71

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Elko County - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 257,906.74	\$ -	\$ -	\$ 257,906.74
Distributors	2022	August	\$ 60,150.73	\$ -	\$ -	\$ 60,150.73
Distributors	2022	September	\$ 63,215.48	\$ -	\$ -	\$ 63,215.48
American Drug Stores	2022	December	\$ 9,116.36	\$ -	\$ -	\$ 9,116.36
Mallinckrodt (BK)	2022	December	\$ 11,241.89	\$ -	\$ -	\$ 11,241.89
Distributors	2023	July	\$ 63,215.48	\$ -	\$ -	\$ 63,215.48
Allergan	2023	July	\$ 23,015.69	\$ -	\$ -	\$ 23,015.69
CVS	2023	August	\$ 98,720.14	\$ -	\$ -	\$ 98,720.14
Mallinckrodt (BK)	2023	September	\$ -	\$ -	\$ -	\$ -
Walmart	2023	September	\$ 195,886.49	\$ -	\$ -	\$ 195,886.49
Walgreens	2023	December	\$ 72,148.46	\$ -	\$ -	\$ 72,148.46
Distributors	2024	July	\$ 79,123.13	\$ -	\$ -	\$ 79,123.13
Allergan	2024	July	\$ 23,015.69	\$ -	\$ -	\$ 23,015.69
Teva	2024	July	\$ 26,495.74	\$ -	\$ -	\$ 26,495.74
CVS	2024	August	\$ 98,720.14	\$ -	\$ -	\$ 98,720.14
Purdue (BK)	2024	July	\$ 340,344.11	\$ -	\$ -	\$ 340,344.11
Walgreens	2024	December	\$ 72,148.46	\$ -	\$ -	\$ 72,148.46
Janssen - J&J	2025	April	\$ 16,260.18	\$ -	\$ -	\$ 16,260.18
Distributors	2025	July	\$ 79,123.13	\$ -	\$ -	\$ 79,123.13
Allergan	2025	July	\$ 23,015.69	\$ -	\$ -	\$ 23,015.69
Teva	2025	July	\$ 26,495.74	\$ -	\$ -	\$ 26,495.74
CVS	2025	August	\$ 98,720.14	\$ -	\$ -	\$ 98,720.14
Walgreens	2025	December	\$ 72,148.46	\$ -	\$ -	\$ 72,148.46
Distributors	2026	July	\$ 79,123.13	\$ -	\$ -	\$ 79,123.13
Allergan	2026	July	\$ 23,015.69	\$ -	\$ -	\$ 23,015.69
Teva	2026	July	\$ 26,495.74	\$ -	\$ -	\$ 26,495.74
CVS	2026	August	\$ 119,120.44	\$ -	\$ -	\$ 119,120.44
Walgreens	2026	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2027	July	\$ 79,123.13	\$ -	\$ -	\$ 79,123.13
Allergan	2027	July	\$ 23,015.69	\$ -	\$ -	\$ 23,015.69
Teva	2027	July	\$ 11,827.47	\$ -	\$ -	\$ 11,827.47
CVS	2027	August	\$ 119,120.44	\$ -	\$ -	\$ 119,120.44
Walgreens	2027	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2028	July	\$ 93,058.34	\$ -	\$ -	\$ 93,058.34
Allergan	2028	July	\$ 23,015.69	\$ -	\$ -	\$ 23,015.69
Teva	2028	July	\$ 11,827.47	\$ -	\$ -	\$ 11,827.47
CVS	2028	August	\$ 119,120.44	\$ -	\$ -	\$ 119,120.44
Walgreens	2028	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2029	July	\$ 93,058.34	\$ -	\$ -	\$ 93,058.34
Allergan	2029	July	\$ 23,015.69	\$ -	\$ -	\$ 23,015.69
Teva	2029	July	\$ 11,827.47	\$ -	\$ -	\$ 11,827.47
CVS	2029	August	\$ 119,120.44	\$ -	\$ -	\$ 119,120.44
Walgreens	2029	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2030	July	\$ 93,058.34	\$ -	\$ -	\$ 93,058.34
Teva	2030	July	\$ 11,827.47	\$ -	\$ -	\$ 11,827.47
CVS	2030	August	\$ 119,120.44	\$ -	\$ -	\$ 119,120.44
Walgreens	2030	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2031	July	\$ 78,224.92	\$ -	\$ -	\$ 78,224.92
Teva	2031	July	\$ 11,827.47	\$ -	\$ -	\$ 11,827.47
CVS	2031	August	\$ 119,120.44	\$ -	\$ -	\$ 119,120.44
Walgreens	2031	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2032	July	\$ 78,224.92	\$ -	\$ -	\$ 78,224.92
Teva	2032	July	\$ 11,827.47	\$ -	\$ -	\$ 11,827.47
CVS	2032	August	\$ 119,120.44	\$ -	\$ -	\$ 119,120.44
Walgreens	2032	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2033	July	\$ 78,224.92	\$ -	\$ -	\$ 78,224.92
Teva	2033	July	\$ 11,827.47	\$ -	\$ -	\$ 11,827.47
Walgreens	2033	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2034	July	\$ 78,224.92	\$ -	\$ -	\$ 78,224.92
Teva	2034	July	\$ 11,827.47	\$ -	\$ -	\$ 11,827.47
Walgreens	2034	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2035	July	\$ 78,224.92	\$ -	\$ -	\$ 78,224.92
Teva	2035	July	\$ 55,379.36	\$ -	\$ -	\$ 55,379.36
Walgreens	2035	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2036	July	\$ 78,224.92	\$ -	\$ -	\$ 78,224.92
Teva	2036	July	\$ 55,379.36	\$ -	\$ -	\$ 55,379.36
Walgreens	2036	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2037	July	\$ 78,224.92	\$ -	\$ -	\$ 78,224.92
Teva	2037	July	\$ 71,202.03	\$ -	\$ -	\$ 71,202.03
Walgreens	2037	December	\$ 115,473.89	\$ -	\$ -	\$ 115,473.89
Distributors	2038	July	\$ 78,224.92	\$ -	\$ -	\$ 78,224.92
Teva	2038	July	\$ 71,202.03	\$ -	\$ -	\$ 71,202.03
Teva	2039	July	\$ 71,202.03	\$ -	\$ -	\$ 71,202.03
Teva	2040	July	\$ 71,202.03	\$ -	\$ -	\$ 71,202.03
Teva	2041	July	\$ 71,202.03	\$ -	\$ -	\$ 71,202.03
Teva	2041	July	\$ 213,606.10	\$ -	\$ -	\$ 213,606.10
Teva	2042	July	\$ 213,606.10	\$ -	\$ -	\$ 213,606.10
		TOTAL	\$ 6,200,137.80	\$ -	\$ -	\$ 6,200,137.80

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)							
Esmeralda County - Actual and Estimated Allocations							
(assumes no default in payments)							
(CMS Medicaid costs, if any, not deducted)							
(assumes no administrative fees for court appointed third-party administrators)							
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation	
Janssen - J&J	2022	July	\$ 11,847.20	\$ 1,777.08	\$ -	\$ 10,070.12	
Distributors	2022	August	\$ 2,763.08	\$ 414.46	\$ -	\$ 2,348.62	
Distributors	2022	September	\$ 2,903.87	\$ 435.58	\$ -	\$ 2,468.29	
American Drug Stores	2022	December	\$ 418.77	\$ 104.69	\$ -	\$ 314.08	
Mallinckrodt (BK)	2022	December	\$ 516.41	\$ 129.10	\$ -	\$ 387.31	
Distributors	2023	July	\$ 2,903.87	\$ 435.58	\$ -	\$ 2,468.29	
Allergan	2023	July	\$ 1,057.25	\$ 131.70	\$ 928.32	\$ 925.55	
CVS	2023	August	\$ 3,401.11	\$ -	\$ 4,559.93	\$ 3,401.11	
Mallinckrodt (BK)	2023	September	\$ -	\$ (129.10)	\$ -	\$ 129.10	
Walmart	2023	September	\$ 8,998.24	\$ -	\$ 1,202.64	\$ 8,998.24	
Walgreens	2023	December	\$ 2,485.66	\$ -	\$ -	\$ 2,485.66	
Distributors	2024	July	\$ 3,634.60	\$ 545.19	\$ -	\$ 3,089.41	
Allergan	2024	July	\$ 1,057.25	\$ 131.70	\$ -	\$ 925.55	
Teva	2024	July	\$ 912.83	\$ -	\$ -	\$ 912.83	
CVS	2024	August	\$ 3,401.11	\$ -	\$ 4,559.93	\$ 3,401.11	
Purdue (BK)	2024	July	\$ 15,634.05	\$ 3,908.51	\$ -	\$ 11,725.54	
Walgreens	2024	December	\$ 2,485.66	\$ -	\$ 4,972.88	\$ 2,485.66	
Janssen - J&J	2025	April	\$ 746.93	\$ 112.04	\$ -	\$ 634.89	
Distributors	2025	July	\$ 3,634.60	\$ 545.19	\$ -	\$ 3,089.41	
Allergan	2025	July	\$ 1,057.25	\$ 131.70	\$ -	\$ 925.55	
Teva	2025	July	\$ 912.83	\$ -	\$ -	\$ 912.83	
CVS	2025	August	\$ 3,401.11	\$ -	\$ 4,559.93	\$ 3,401.11	
Walgreens	2025	December	\$ 2,485.66	\$ -	\$ 4,972.88	\$ 2,485.66	
Distributors	2026	July	\$ 3,634.60	\$ 545.19	\$ -	\$ 3,089.41	
Allergan	2026	July	\$ 1,057.25	\$ 131.70	\$ -	\$ 925.55	
Teva	2026	July	\$ 912.83	\$ -	\$ -	\$ 912.83	
CVS	2026	August	\$ 4,103.94	\$ -	\$ -	\$ 4,103.94	
Walgreens	2026	December	\$ 3,978.31	\$ -	\$ 4,972.88	\$ 3,978.31	
Distributors	2027	July	\$ 3,634.60	\$ 545.19	\$ -	\$ 3,089.41	
Allergan	2027	July	\$ 1,057.25	\$ 131.70	\$ -	\$ 925.55	
Teva	2027	July	\$ 407.48	\$ -	\$ 1,657.63	\$ 407.48	
CVS	2027	August	\$ 4,103.94	\$ -	\$ -	\$ 4,103.94	
Walgreens	2027	December	\$ 3,978.31	\$ -	\$ 4,972.88	\$ 3,978.31	
Distributors	2028	July	\$ 4,274.73	\$ 641.21	\$ -	\$ 3,633.52	
Allergan	2028	July	\$ 1,057.25	\$ 131.70	\$ -	\$ 925.55	
Teva	2028	July	\$ 407.48	\$ -	\$ 1,657.63	\$ 407.48	
CVS	2028	August	\$ 4,103.94	\$ -	\$ -	\$ 4,103.94	
Walgreens	2028	December	\$ 3,978.31	\$ -	\$ -	\$ 3,978.31	
Distributors	2029	July	\$ 4,274.73	\$ 641.21	\$ -	\$ 3,633.52	
Allergan	2029	July	\$ 1,057.25	\$ 131.70	\$ -	\$ 925.55	
Teva	2029	July	\$ 407.48	\$ -	\$ 1,657.63	\$ 407.48	
CVS	2029	August	\$ 4,103.94	\$ -	\$ -	\$ 4,103.94	
Walgreens	2029	December	\$ 3,978.31	\$ -	\$ -	\$ 3,978.31	
Distributors	2030	July	\$ 4,274.73	\$ 641.21	\$ -	\$ 3,633.52	
Teva	2030	July	\$ 407.48	\$ -	\$ 1,657.63	\$ 407.48	
CVS	2030	August	\$ 4,103.94	\$ -	\$ -	\$ 4,103.94	
Walgreens	2030	December	\$ 3,978.31	\$ -	\$ -	\$ 3,978.31	
Distributors	2031	July	\$ 3,593.34	\$ 539.00	\$ -	\$ 3,054.34	
Teva	2031	July	\$ 407.48	\$ -	\$ 1,657.63	\$ 407.48	
CVS	2031	August	\$ 4,103.94	\$ -	\$ -	\$ 4,103.94	
Walgreens	2031	December	\$ 3,978.31	\$ -	\$ -	\$ 3,978.31	
Distributors	2032	July	\$ 3,593.34	\$ 539.00	\$ -	\$ 3,054.34	
Teva	2032	July	\$ 407.48	\$ -	\$ 1,657.63	\$ 407.48	
CVS	2032	August	\$ 4,103.94	\$ -	\$ -	\$ 4,103.94	
Walgreens	2032	December	\$ 3,978.31	\$ -	\$ -	\$ 3,978.31	
Distributors	2033	July	\$ 3,593.34	\$ 539.00	\$ -	\$ 3,054.34	
Teva	2033	July	\$ 407.48	\$ -	\$ 1,657.63	\$ 407.48	
Walgreens	2033	December	\$ 3,978.31	\$ -	\$ -	\$ 3,978.31	
Distributors	2034	July	\$ 3,593.34	\$ 539.00	\$ -	\$ 3,054.34	
Teva	2034	July	\$ 407.48	\$ -	\$ 1,657.63	\$ 407.48	
Walgreens	2034	December	\$ 3,978.31	\$ -	\$ -	\$ 3,978.31	
Distributors	2035	July	\$ 3,593.34	\$ 539.00	\$ -	\$ 3,054.34	
Teva	2035	July	\$ 1,907.93	\$ -	\$ -	\$ 1,907.93	
Walgreens	2035	December	\$ 3,978.31	\$ -	\$ -	\$ 3,978.31	
Distributors	2036	July	\$ 3,593.34	\$ 539.00	\$ -	\$ 3,054.34	
Teva	2036	July	\$ 1,907.93	\$ -	\$ -	\$ 1,907.93	
Walgreens	2036	December	\$ 3,978.31	\$ -	\$ -	\$ 3,978.31	
Distributors	2037	July	\$ 3,593.34	\$ 539.00	\$ -	\$ 3,054.34	
Teva	2037	July	\$ 2,453.05	\$ -	\$ -	\$ 2,453.05	
Walgreens	2037	December	\$ 3,978.31	\$ -	\$ -	\$ 3,978.31	
Distributors	2038	July	\$ 3,593.34	\$ 539.00	\$ -	\$ 3,054.34	
Teva	2038	July	\$ 2,453.05	\$ -	\$ -	\$ 2,453.05	
Teva	2039	July	\$ 2,453.05	\$ -	\$ -	\$ 2,453.05	
Teva	2040	July	\$ 2,453.05	\$ -	\$ -	\$ 2,453.05	
Teva	2041	July	\$ 2,453.05	\$ -	\$ -	\$ 2,453.05	
Teva	2041	July	\$ 7,359.16	\$ -	\$ -	\$ 7,359.16	
Teva	2042	July	\$ 7,359.16	\$ -	\$ -	\$ 7,359.16	
			TOTAL	\$ 241,167.85	\$ 16,526.23	\$ 48,963.30	\$ 224,641.62

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)						
Eureka County - Actual and Estimated Allocations						
(assumes no default in payments)						
(CMS Medicaid costs, if any, not deducted)						
(assumes no administrative fees for court appointed third-party administrators)						
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 24,623.30	\$ -	\$ -	\$ 24,623.30
Distributors	2022	August	\$ 5,742.81	\$ -	\$ -	\$ 5,742.81
Distributors	2022	September	\$ 6,035.41	\$ -	\$ -	\$ 6,035.41
American Drug Stores	2022	December	\$ 870.37	\$ -	\$ -	\$ 870.37
Mallinckrodt (BK)	2022	December	\$ 1,073.30	\$ -	\$ -	\$ 1,073.30
Distributors	2023	July	\$ 6,035.41	\$ -	\$ -	\$ 6,035.41
Allergan	2023	July	\$ 2,197.39	\$ -	\$ -	\$ 2,197.39
CVS	2023	August	\$ 9,425.18	\$ -	\$ -	\$ 9,425.18
Mallinckrodt (BK)	2023	September	\$ -	\$ -	\$ -	\$ -
Walmart	2023	September	\$ 18,702.00	\$ -	\$ -	\$ 18,702.00
Walgreens	2023	December	\$ 6,888.28	\$ -	\$ -	\$ 6,888.28
Distributors	2024	July	\$ 7,554.18	\$ -	\$ -	\$ 7,554.18
Allergan	2024	July	\$ 2,197.39	\$ -	\$ -	\$ 2,197.39
Teva	2024	July	\$ 2,529.64	\$ -	\$ -	\$ 2,529.64
CVS	2024	August	\$ 9,425.18	\$ -	\$ -	\$ 9,425.18
Purdue (BK)	2024	July	\$ 32,493.90	\$ -	\$ -	\$ 32,493.90
Walgreens	2024	December	\$ 6,888.28	\$ -	\$ -	\$ 6,888.28
Janssen - J&J	2025	April	\$ 1,552.42	\$ -	\$ -	\$ 1,552.42
Distributors	2025	July	\$ 7,554.18	\$ -	\$ -	\$ 7,554.18
Allergan	2025	July	\$ 2,197.39	\$ -	\$ -	\$ 2,197.39
Teva	2025	July	\$ 2,529.64	\$ -	\$ -	\$ 2,529.64
CVS	2025	August	\$ 9,425.18	\$ -	\$ -	\$ 9,425.18
Walgreens	2025	December	\$ 6,888.28	\$ -	\$ -	\$ 6,888.28
Distributors	2026	July	\$ 7,554.18	\$ -	\$ -	\$ 7,554.18
Allergan	2026	July	\$ 2,197.39	\$ -	\$ -	\$ 2,197.39
Teva	2026	July	\$ 2,529.64	\$ -	\$ -	\$ 2,529.64
CVS	2026	August	\$ 11,372.87	\$ -	\$ -	\$ 11,372.87
Walgreens	2026	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2027	July	\$ 7,554.18	\$ -	\$ -	\$ 7,554.18
Allergan	2027	July	\$ 2,197.39	\$ -	\$ -	\$ 2,197.39
Teva	2027	July	\$ 1,129.21	\$ -	\$ -	\$ 1,129.21
CVS	2027	August	\$ 11,372.87	\$ -	\$ -	\$ 11,372.87
Walgreens	2027	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2028	July	\$ 8,884.62	\$ -	\$ -	\$ 8,884.62
Allergan	2028	July	\$ 2,197.39	\$ -	\$ -	\$ 2,197.39
Teva	2028	July	\$ 1,129.21	\$ -	\$ -	\$ 1,129.21
CVS	2028	August	\$ 11,372.87	\$ -	\$ -	\$ 11,372.87
Walgreens	2028	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2029	July	\$ 8,884.62	\$ -	\$ -	\$ 8,884.62
Allergan	2029	July	\$ 2,197.39	\$ -	\$ -	\$ 2,197.39
Teva	2029	July	\$ 1,129.21	\$ -	\$ -	\$ 1,129.21
CVS	2029	August	\$ 11,372.87	\$ -	\$ -	\$ 11,372.87
Walgreens	2029	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2030	July	\$ 8,884.62	\$ -	\$ -	\$ 8,884.62
Teva	2030	July	\$ 1,129.21	\$ -	\$ -	\$ 1,129.21
CVS	2030	August	\$ 11,372.87	\$ -	\$ -	\$ 11,372.87
Walgreens	2030	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2031	July	\$ 7,468.42	\$ -	\$ -	\$ 7,468.42
Teva	2031	July	\$ 1,129.21	\$ -	\$ -	\$ 1,129.21
CVS	2031	August	\$ 11,372.87	\$ -	\$ -	\$ 11,372.87
Walgreens	2031	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2032	July	\$ 7,468.42	\$ -	\$ -	\$ 7,468.42
Teva	2032	July	\$ 1,129.21	\$ -	\$ -	\$ 1,129.21
CVS	2032	August	\$ 11,372.87	\$ -	\$ -	\$ 11,372.87
Walgreens	2032	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2033	July	\$ 7,468.42	\$ -	\$ -	\$ 7,468.42
Teva	2033	July	\$ 1,129.21	\$ -	\$ -	\$ 1,129.21
Walgreens	2033	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2034	July	\$ 7,468.42	\$ -	\$ -	\$ 7,468.42
Teva	2034	July	\$ 1,129.21	\$ -	\$ -	\$ 1,129.21
Walgreens	2034	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2035	July	\$ 7,468.42	\$ -	\$ -	\$ 7,468.42
Teva	2035	July	\$ 5,287.27	\$ -	\$ -	\$ 5,287.27
Walgreens	2035	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2036	July	\$ 7,468.42	\$ -	\$ -	\$ 7,468.42
Teva	2036	July	\$ 5,287.27	\$ -	\$ -	\$ 5,287.27
Walgreens	2036	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2037	July	\$ 7,468.42	\$ -	\$ -	\$ 7,468.42
Teva	2037	July	\$ 6,797.92	\$ -	\$ -	\$ 6,797.92
Walgreens	2037	December	\$ 11,024.72	\$ -	\$ -	\$ 11,024.72
Distributors	2038	July	\$ 7,468.42	\$ -	\$ -	\$ 7,468.42
Teva	2038	July	\$ 6,797.92	\$ -	\$ -	\$ 6,797.92
Teva	2038	July	\$ 6,797.92	\$ -	\$ -	\$ 6,797.92
Teva	2039	July	\$ 6,797.92	\$ -	\$ -	\$ 6,797.92
Teva	2040	July	\$ 6,797.92	\$ -	\$ -	\$ 6,797.92
Teva	2041	July	\$ 6,797.92	\$ -	\$ -	\$ 6,797.92
Teva	2041	July	\$ 20,393.76	\$ -	\$ -	\$ 20,393.76
Teva	2042	July	\$ 20,393.76	\$ -	\$ -	\$ 20,393.76
TOTAL			\$ 591,949.96	\$ -	\$ -	\$ 591,949.96

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Humboldt County - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 242,826.00	\$ 36,423.90	\$ -	\$ 206,402.10
Distributors	2022	August	\$ 56,633.50	\$ 8,495.03	\$ -	\$ 48,138.47
Distributors	2022	September	\$ 59,519.05	\$ 8,927.86	\$ -	\$ 50,591.19
American Drug Stores	2022	December	\$ 8,583.29	\$ 2,145.82	\$ -	\$ 6,437.47
Mallinckrodt (BK)	2022	December	\$ 10,584.54	\$ 2,646.14	\$ -	\$ 7,938.40
Distributors	2023	July	\$ 59,519.05	\$ 8,927.86	\$ -	\$ 50,591.19
Allergan	2023	July	\$ 21,669.88	\$ 2,699.31	\$ 19,027.11	\$ 18,970.57
CVS	2023	August	\$ 69,710.72	\$ -	\$ 93,462.53	\$ 69,710.72
Mallinckrodt (BK)	2023	September	\$ -	\$ (2,646.14)	\$ -	\$ 2,646.14
Walmart	2023	September	\$ 184,432.30	\$ -	\$ 24,649.84	\$ 184,432.30
Walgreens	2023	December	\$ 50,947.26	\$ -	\$ -	\$ 50,947.26
Distributors	2024	July	\$ 74,496.52	\$ 11,174.48	\$ -	\$ 63,322.04
Allergan	2024	July	\$ 21,669.88	\$ 2,699.31	\$ -	\$ 18,970.57
Teva	2024	July	\$ 18,709.83	\$ -	\$ -	\$ 18,709.83
CVS	2024	August	\$ 69,710.72	\$ -	\$ 93,462.53	\$ 69,710.72
Purdue (BK)	2024	July	\$ 320,442.96	\$ 80,110.74	\$ -	\$ 240,332.22
Walgreens	2024	December	\$ 50,947.26	\$ -	\$ 101,926.61	\$ 50,947.26
Janssen - J&J	2025	April	\$ 15,309.39	\$ 2,296.41	\$ -	\$ 13,012.98
Distributors	2025	July	\$ 74,496.52	\$ 11,174.48	\$ -	\$ 63,322.04
Allergan	2025	July	\$ 21,669.88	\$ 2,699.31	\$ -	\$ 18,970.57
Teva	2025	July	\$ 18,709.83	\$ -	\$ -	\$ 18,709.83
CVS	2025	August	\$ 69,710.72	\$ -	\$ 93,462.53	\$ 69,710.72
Walgreens	2025	December	\$ 50,947.26	\$ -	\$ 101,926.61	\$ 50,947.26
Distributors	2026	July	\$ 74,496.52	\$ 11,174.48	\$ -	\$ 63,322.04
Allergan	2026	July	\$ 21,669.88	\$ 2,699.31	\$ -	\$ 18,970.57
Teva	2026	July	\$ 18,709.83	\$ -	\$ -	\$ 18,709.83
CVS	2026	August	\$ 84,116.28	\$ -	\$ -	\$ 84,116.28
Walgreens	2026	December	\$ 81,541.29	\$ -	\$ 101,926.61	\$ 81,541.29
Distributors	2027	July	\$ 74,496.52	\$ 11,174.48	\$ -	\$ 63,322.04
Allergan	2027	July	\$ 21,669.88	\$ 2,699.31	\$ -	\$ 18,970.57
Teva	2027	July	\$ 8,351.91	\$ -	\$ 33,975.54	\$ 8,351.91
CVS	2027	August	\$ 84,116.28	\$ -	\$ -	\$ 84,116.28
Walgreens	2027	December	\$ 81,541.29	\$ -	\$ 101,926.61	\$ 81,541.29
Distributors	2028	July	\$ 87,616.88	\$ 13,142.53	\$ -	\$ 74,474.35
Allergan	2028	July	\$ 21,669.88	\$ 2,699.31	\$ -	\$ 18,970.57
Teva	2028	July	\$ 8,351.91	\$ -	\$ 33,975.54	\$ 8,351.91
CVS	2028	August	\$ 84,116.28	\$ -	\$ -	\$ 84,116.28
Walgreens	2028	December	\$ 81,541.29	\$ -	\$ -	\$ 81,541.29
Distributors	2029	July	\$ 87,616.88	\$ 13,142.53	\$ -	\$ 74,474.35
Allergan	2029	July	\$ 21,669.88	\$ 2,699.31	\$ -	\$ 18,970.57
Teva	2029	July	\$ 8,351.91	\$ -	\$ 33,975.54	\$ 8,351.91
CVS	2029	August	\$ 84,116.28	\$ -	\$ -	\$ 84,116.28
Walgreens	2029	December	\$ 81,541.29	\$ -	\$ -	\$ 81,541.29
Distributors	2030	July	\$ 87,616.88	\$ 13,142.53	\$ -	\$ 74,474.35
Teva	2030	July	\$ 8,351.91	\$ -	\$ 33,975.54	\$ 8,351.91
CVS	2030	August	\$ 84,116.28	\$ -	\$ -	\$ 84,116.28
Walgreens	2030	December	\$ 81,541.29	\$ -	\$ -	\$ 81,541.29
Distributors	2031	July	\$ 73,650.83	\$ 11,047.62	\$ -	\$ 62,603.21
Teva	2031	July	\$ 8,351.91	\$ -	\$ 33,975.54	\$ 8,351.91
CVS	2031	August	\$ 84,116.28	\$ -	\$ -	\$ 84,116.28
Walgreens	2031	December	\$ 81,541.29	\$ -	\$ -	\$ 81,541.29
Distributors	2032	July	\$ 73,650.83	\$ 11,047.62	\$ -	\$ 62,603.21
Teva	2032	July	\$ 8,351.91	\$ -	\$ 33,975.54	\$ 8,351.91
CVS	2032	August	\$ 84,116.28	\$ -	\$ -	\$ 84,116.28
Walgreens	2032	December	\$ 81,541.29	\$ -	\$ -	\$ 81,541.29
Distributors	2033	July	\$ 73,650.83	\$ 11,047.62	\$ -	\$ 62,603.21
Teva	2033	July	\$ 8,351.91	\$ -	\$ 33,975.54	\$ 8,351.91
Walgreens	2033	December	\$ 81,541.29	\$ -	\$ -	\$ 81,541.29
Distributors	2034	July	\$ 73,650.83	\$ 11,047.62	\$ -	\$ 62,603.21
Teva	2034	July	\$ 8,351.91	\$ -	\$ 33,975.54	\$ 8,351.91
Walgreens	2034	December	\$ 81,541.29	\$ -	\$ -	\$ 81,541.29
Distributors	2035	July	\$ 73,650.83	\$ 11,047.62	\$ -	\$ 62,603.21
Teva	2035	July	\$ 39,105.85	\$ -	\$ -	\$ 39,105.85
Walgreens	2035	December	\$ 81,541.29	\$ -	\$ -	\$ 81,541.29
Distributors	2036	July	\$ 73,650.83	\$ 11,047.62	\$ -	\$ 62,603.21
Teva	2036	July	\$ 39,105.85	\$ -	\$ -	\$ 39,105.85
Walgreens	2036	December	\$ 81,541.29	\$ -	\$ -	\$ 81,541.29
Distributors	2037	July	\$ 73,650.83	\$ 11,047.62	\$ -	\$ 62,603.21
Teva	2037	July	\$ 50,278.94	\$ -	\$ -	\$ 50,278.94
Walgreens	2037	December	\$ 81,541.29	\$ -	\$ -	\$ 81,541.29
Distributors	2038	July	\$ 73,650.83	\$ 11,047.62	\$ -	\$ 62,603.21
Teva	2038	July	\$ 50,278.94	\$ -	\$ -	\$ 50,278.94
Teva	2039	July	\$ 50,278.94	\$ -	\$ -	\$ 50,278.94
Teva	2040	July	\$ 50,278.94	\$ -	\$ -	\$ 50,278.94
Teva	2041	July	\$ 50,278.94	\$ -	\$ -	\$ 50,278.94
Teva	2041	July	\$ 150,836.83	\$ -	\$ -	\$ 150,836.83
Teva	2042	July	\$ 150,836.83	\$ -	\$ -	\$ 150,836.83
TOTAL			\$ 4,943,090.81	\$ 338,729.26	\$ 1,003,575.28	\$ 4,604,361.55

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)						
Lander County - Actual and Estimated Allocations						
(assumes no default in payments)						
(CMS Medicaid costs, if any, not deducted)						
(assumes no administrative fees for court appointed third-party administrators)						
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 86,418.15	\$ -	\$ -	\$ 86,418.15
Distributors	2022	August	\$ 20,155.02	\$ -	\$ -	\$ 20,155.02
Distributors	2022	September	\$ 21,181.94	\$ -	\$ -	\$ 21,181.94
American Drug Stores	2022	December	\$ 3,054.67	\$ -	\$ -	\$ 3,054.67
Mallinckrodt (BK)	2022	December	\$ 3,766.88	\$ -	\$ -	\$ 3,766.88
Distributors	2023	July	\$ 21,181.94	\$ -	\$ -	\$ 21,181.94
Allergan	2023	July	\$ 7,711.99	\$ -	\$ -	\$ 7,711.99
CVS	2023	August	\$ 33,078.68	\$ -	\$ -	\$ 33,078.68
Mallinckrodt (BK)	2023	September	\$ -	\$ -	\$ -	\$ -
Walmart	2023	September	\$ 65,636.71	\$ -	\$ -	\$ 65,636.71
Walgreens	2023	December	\$ 24,175.16	\$ -	\$ -	\$ 24,175.16
Distributors	2024	July	\$ 26,512.20	\$ -	\$ -	\$ 26,512.20
Allergan	2024	July	\$ 7,711.99	\$ -	\$ -	\$ 7,711.99
Teva	2024	July	\$ 8,878.06	\$ -	\$ -	\$ 8,878.06
CVS	2024	August	\$ 33,078.68	\$ -	\$ -	\$ 33,078.68
Purdue (BK)	2024	July	\$ 114,040.88	\$ -	\$ -	\$ 114,040.88
Walgreens	2024	December	\$ 24,175.16	\$ -	\$ -	\$ 24,175.16
Janssen - J&J	2025	April	\$ 5,448.38	\$ -	\$ -	\$ 5,448.38
Distributors	2025	July	\$ 26,512.20	\$ -	\$ -	\$ 26,512.20
Allergan	2025	July	\$ 7,711.99	\$ -	\$ -	\$ 7,711.99
Teva	2025	July	\$ 8,878.06	\$ -	\$ -	\$ 8,878.06
CVS	2025	August	\$ 33,078.68	\$ -	\$ -	\$ 33,078.68
Walgreens	2025	December	\$ 24,175.16	\$ -	\$ -	\$ 24,175.16
Distributors	2026	July	\$ 26,512.20	\$ -	\$ -	\$ 26,512.20
Allergan	2026	July	\$ 7,711.99	\$ -	\$ -	\$ 7,711.99
Teva	2026	July	\$ 8,878.06	\$ -	\$ -	\$ 8,878.06
CVS	2026	August	\$ 39,914.31	\$ -	\$ -	\$ 39,914.31
Walgreens	2026	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2027	July	\$ 26,512.20	\$ -	\$ -	\$ 26,512.20
Allergan	2027	July	\$ 7,711.99	\$ -	\$ -	\$ 7,711.99
Teva	2027	July	\$ 3,963.09	\$ -	\$ -	\$ 3,963.09
CVS	2027	August	\$ 39,914.31	\$ -	\$ -	\$ 39,914.31
Walgreens	2027	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2028	July	\$ 31,181.54	\$ -	\$ -	\$ 31,181.54
Allergan	2028	July	\$ 7,711.99	\$ -	\$ -	\$ 7,711.99
Teva	2028	July	\$ 3,963.09	\$ -	\$ -	\$ 3,963.09
CVS	2028	August	\$ 39,914.31	\$ -	\$ -	\$ 39,914.31
Walgreens	2028	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2029	July	\$ 31,181.54	\$ -	\$ -	\$ 31,181.54
Allergan	2029	July	\$ 7,711.99	\$ -	\$ -	\$ 7,711.99
Teva	2029	July	\$ 3,963.09	\$ -	\$ -	\$ 3,963.09
CVS	2029	August	\$ 39,914.31	\$ -	\$ -	\$ 39,914.31
Walgreens	2029	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2030	July	\$ 31,181.54	\$ -	\$ -	\$ 31,181.54
Teva	2030	July	\$ 3,963.09	\$ -	\$ -	\$ 3,963.09
CVS	2030	August	\$ 39,914.31	\$ -	\$ -	\$ 39,914.31
Walgreens	2030	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2031	July	\$ 26,211.23	\$ -	\$ -	\$ 26,211.23
Teva	2031	July	\$ 3,963.09	\$ -	\$ -	\$ 3,963.09
CVS	2031	August	\$ 39,914.31	\$ -	\$ -	\$ 39,914.31
Walgreens	2031	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2032	July	\$ 26,211.23	\$ -	\$ -	\$ 26,211.23
Teva	2032	July	\$ 3,963.09	\$ -	\$ -	\$ 3,963.09
CVS	2032	August	\$ 39,914.31	\$ -	\$ -	\$ 39,914.31
Walgreens	2032	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2033	July	\$ 26,211.23	\$ -	\$ -	\$ 26,211.23
Teva	2033	July	\$ 3,963.09	\$ -	\$ -	\$ 3,963.09
Walgreens	2033	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2034	July	\$ 26,211.23	\$ -	\$ -	\$ 26,211.23
Teva	2034	July	\$ 3,963.09	\$ -	\$ -	\$ 3,963.09
Walgreens	2034	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2035	July	\$ 26,211.23	\$ -	\$ -	\$ 26,211.23
Teva	2035	July	\$ 18,556.25	\$ -	\$ -	\$ 18,556.25
Walgreens	2035	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2036	July	\$ 26,211.23	\$ -	\$ -	\$ 26,211.23
Teva	2036	July	\$ 18,556.25	\$ -	\$ -	\$ 18,556.25
Walgreens	2036	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2037	July	\$ 26,211.23	\$ -	\$ -	\$ 26,211.23
Teva	2037	July	\$ 23,858.04	\$ -	\$ -	\$ 23,858.04
Walgreens	2037	December	\$ 38,692.44	\$ -	\$ -	\$ 38,692.44
Distributors	2038	July	\$ 26,211.23	\$ -	\$ -	\$ 26,211.23
Teva	2038	July	\$ 23,858.04	\$ -	\$ -	\$ 23,858.04
Teva	2039	July	\$ 23,858.04	\$ -	\$ -	\$ 23,858.04
Teva	2040	July	\$ 23,858.04	\$ -	\$ -	\$ 23,858.04
Teva	2041	July	\$ 23,858.04	\$ -	\$ -	\$ 23,858.04
Teva	2041	July	\$ 71,574.11	\$ -	\$ -	\$ 71,574.11
Teva	2042	July	\$ 71,574.11	\$ -	\$ -	\$ 71,574.11
			TOTAL	\$ 2,077,512.55	\$ -	\$ 2,077,512.55

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)							
Lincoln County - Actual and Estimated Allocations							
(assumes no default in payments)							
(CMS Medicaid costs, if any, not deducted)							
(assumes no administrative fees for court appointed third-party administrators)							
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation	
Janssen - J&J	2022	July	\$ 56,539.84	\$ 8,480.98	\$ -	\$ 48,058.86	
Distributors	2022	August	\$ 13,186.60	\$ 1,977.99	\$ -	\$ 11,208.61	
Distributors	2022	September	\$ 13,858.47	\$ 2,078.77	\$ -	\$ 11,779.70	
American Drug Stores	2022	December	\$ 1,998.54	\$ 499.64	\$ -	\$ 1,498.90	
Mallinckrodt (BK)	2022	December	\$ 2,464.51	\$ 616.13	\$ -	\$ 1,848.38	
Distributors	2023	July	\$ 13,858.47	\$ 2,078.77	\$ -	\$ 11,779.70	
Allergan	2023	July	\$ 5,045.64	\$ 628.51	\$ 4,430.29	\$ 4,417.13	
CVS	2023	August	\$ 16,231.51	\$ -	\$ 21,761.91	\$ 16,231.51	
Mallinckrodt (BK)	2023	September	\$ -	\$ (616.13)	\$ -	\$ 616.13	
Walmart	2023	September	\$ 42,943.40	\$ -	\$ 5,739.49	\$ 42,943.40	
Walgreens	2023	December	\$ 11,862.61	\$ -	\$ -	\$ 11,862.61	
Distributors	2024	July	\$ 17,345.84	\$ 2,601.88	\$ -	\$ 14,743.96	
Allergan	2024	July	\$ 5,045.64	\$ 628.51	\$ -	\$ 4,417.13	
Teva	2024	July	\$ 4,356.41	\$ -	\$ -	\$ 4,356.41	
CVS	2024	August	\$ 16,231.51	\$ -	\$ 21,761.91	\$ 16,231.51	
Purdue (BK)	2024	July	\$ 74,612.26	\$ 18,653.07	\$ -	\$ 55,959.19	
Walgreens	2024	December	\$ 11,862.61	\$ -	\$ 23,732.69	\$ 11,862.61	
Janssen - J&J	2025	April	\$ 3,564.65	\$ 534.70	\$ -	\$ 3,029.95	
Distributors	2025	July	\$ 17,345.84	\$ 2,601.88	\$ -	\$ 14,743.96	
Allergan	2025	July	\$ 5,045.64	\$ 628.51	\$ -	\$ 4,417.13	
Teva	2025	July	\$ 4,356.41	\$ -	\$ -	\$ 4,356.41	
CVS	2025	August	\$ 16,231.51	\$ -	\$ 21,761.91	\$ 16,231.51	
Walgreens	2025	December	\$ 11,862.61	\$ -	\$ 23,732.69	\$ 11,862.61	
Distributors	2026	July	\$ 17,345.84	\$ 2,601.88	\$ -	\$ 14,743.96	
Allergan	2026	July	\$ 5,045.64	\$ 628.51	\$ -	\$ 4,417.13	
Teva	2026	July	\$ 4,356.41	\$ -	\$ -	\$ 4,356.41	
CVS	2026	August	\$ 19,585.72	\$ -	\$ -	\$ 19,585.72	
Walgreens	2026	December	\$ 18,986.15	\$ -	\$ 23,732.69	\$ 18,986.15	
Distributors	2027	July	\$ 17,345.84	\$ 2,601.88	\$ -	\$ 14,743.96	
Allergan	2027	July	\$ 5,045.64	\$ 628.51	\$ -	\$ 4,417.13	
Teva	2027	July	\$ 1,944.67	\$ -	\$ 7,910.90	\$ 1,944.67	
CVS	2027	August	\$ 19,585.72	\$ -	\$ -	\$ 19,585.72	
Walgreens	2027	December	\$ 18,986.15	\$ -	\$ 23,732.69	\$ 18,986.15	
Distributors	2028	July	\$ 20,400.80	\$ 3,060.12	\$ -	\$ 17,340.68	
Allergan	2028	July	\$ 5,045.64	\$ 628.51	\$ -	\$ 4,417.13	
Teva	2028	July	\$ 1,944.67	\$ -	\$ 7,910.90	\$ 1,944.67	
CVS	2028	August	\$ 19,585.72	\$ -	\$ -	\$ 19,585.72	
Walgreens	2028	December	\$ 18,986.15	\$ -	\$ -	\$ 18,986.15	
Distributors	2029	July	\$ 20,400.80	\$ 3,060.12	\$ -	\$ 17,340.68	
Allergan	2029	July	\$ 5,045.64	\$ 628.51	\$ -	\$ 4,417.13	
Teva	2029	July	\$ 1,944.67	\$ -	\$ 7,910.90	\$ 1,944.67	
CVS	2029	August	\$ 19,585.72	\$ -	\$ -	\$ 19,585.72	
Walgreens	2029	December	\$ 18,986.15	\$ -	\$ -	\$ 18,986.15	
Distributors	2030	July	\$ 20,400.80	\$ 3,060.12	\$ -	\$ 17,340.68	
Teva	2030	July	\$ 1,944.67	\$ -	\$ 7,910.90	\$ 1,944.67	
CVS	2030	August	\$ 19,585.72	\$ -	\$ -	\$ 19,585.72	
Walgreens	2030	December	\$ 18,986.15	\$ -	\$ -	\$ 18,986.15	
Distributors	2031	July	\$ 17,148.93	\$ 2,572.34	\$ -	\$ 14,576.59	
Teva	2031	July	\$ 1,944.67	\$ -	\$ 7,910.90	\$ 1,944.67	
CVS	2031	August	\$ 19,585.72	\$ -	\$ -	\$ 19,585.72	
Walgreens	2031	December	\$ 18,986.15	\$ -	\$ -	\$ 18,986.15	
Distributors	2032	July	\$ 17,148.93	\$ 2,572.34	\$ -	\$ 14,576.59	
Teva	2032	July	\$ 1,944.67	\$ -	\$ 7,910.90	\$ 1,944.67	
CVS	2032	August	\$ 19,585.72	\$ -	\$ -	\$ 19,585.72	
Walgreens	2032	December	\$ 18,986.15	\$ -	\$ -	\$ 18,986.15	
Distributors	2033	July	\$ 17,148.93	\$ 2,572.34	\$ -	\$ 14,576.59	
Teva	2033	July	\$ 1,944.67	\$ -	\$ 7,910.90	\$ 1,944.67	
Walgreens	2033	December	\$ 18,986.15	\$ -	\$ -	\$ 18,986.15	
Distributors	2034	July	\$ 17,148.93	\$ 2,572.34	\$ -	\$ 14,576.59	
Teva	2034	July	\$ 1,944.67	\$ -	\$ 7,910.90	\$ 1,944.67	
Walgreens	2034	December	\$ 18,986.15	\$ -	\$ -	\$ 18,986.15	
Distributors	2035	July	\$ 17,148.93	\$ 2,572.34	\$ -	\$ 14,576.59	
Teva	2035	July	\$ 9,105.44	\$ -	\$ -	\$ 9,105.44	
Walgreens	2035	December	\$ 18,986.15	\$ -	\$ -	\$ 18,986.15	
Distributors	2036	July	\$ 17,148.93	\$ 2,572.34	\$ -	\$ 14,576.59	
Teva	2036	July	\$ 9,105.44	\$ -	\$ -	\$ 9,105.44	
Walgreens	2036	December	\$ 18,986.15	\$ -	\$ -	\$ 18,986.15	
Distributors	2037	July	\$ 17,148.93	\$ 2,572.34	\$ -	\$ 14,576.59	
Teva	2037	July	\$ 11,707.00	\$ -	\$ -	\$ 11,707.00	
Walgreens	2037	December	\$ 18,986.15	\$ -	\$ -	\$ 18,986.15	
Distributors	2038	July	\$ 17,148.93	\$ 2,572.34	\$ -	\$ 14,576.59	
Teva	2038	July	\$ 11,707.00	\$ -	\$ -	\$ 11,707.00	
Teva	2039	July	\$ 11,707.00	\$ -	\$ -	\$ 11,707.00	
Teva	2040	July	\$ 11,707.00	\$ -	\$ -	\$ 11,707.00	
Teva	2041	July	\$ 11,707.00	\$ -	\$ -	\$ 11,707.00	
Teva	2041	July	\$ 35,121.00	\$ -	\$ -	\$ 35,121.00	
Teva	2042	July	\$ 35,121.00	\$ -	\$ -	\$ 35,121.00	
			TOTAL	\$ 1,150,954.09	\$ 78,870.09	\$ 233,673.46	\$ 1,072,084.00

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Lyon County - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 374,538.11	\$ 56,180.72	\$ -	\$ 318,357.39
Distributors	2022	August	\$ 87,352.28	\$ 13,102.84	\$ -	\$ 74,249.44
Distributors	2022	September	\$ 91,802.98	\$ 13,770.45	\$ -	\$ 78,032.53
American Drug Stores	2022	December	\$ 13,238.99	\$ 3,309.75	\$ -	\$ 9,929.24
Mallinckrodt (BK)	2022	December	\$ 16,325.74	\$ 4,081.44	\$ -	\$ 12,244.30
Distributors	2023	July	\$ 91,802.98	\$ 13,770.45	\$ -	\$ 78,032.53
Allergan	2023	July	\$ 33,423.92	\$ 4,163.46	\$ 29,347.67	\$ 29,260.46
CVS	2023	August	\$ 107,522.75	\$ -	\$ 144,157.87	\$ 107,522.75
Mallinckrodt (BK)	2023	September	\$ -	\$ (4,081.44)	\$ -	\$ 4,081.44
Walmart	2023	September	\$ 284,470.89	\$ -	\$ 38,020.25	\$ 284,470.89
Walgreens	2023	December	\$ 78,581.75	\$ -	\$ -	\$ 78,581.75
Distributors	2024	July	\$ 114,904.44	\$ 17,235.67	\$ -	\$ 97,668.77
Allergan	2024	July	\$ 33,423.92	\$ 4,163.46	\$ -	\$ 29,260.46
Teva	2024	July	\$ 28,858.30	\$ -	\$ -	\$ 28,858.30
CVS	2024	August	\$ 107,522.75	\$ -	\$ 144,157.87	\$ 107,522.75
Purdue (BK)	2024	July	\$ 494,255.57	\$ 123,563.89	\$ -	\$ 370,691.68
Walgreens	2024	December	\$ 78,581.75	\$ -	\$ 157,212.99	\$ 78,581.75
Janssen - J&J	2025	April	\$ 23,613.41	\$ 3,542.01	\$ -	\$ 20,071.40
Distributors	2025	July	\$ 114,904.44	\$ 17,235.67	\$ -	\$ 97,668.77
Allergan	2025	July	\$ 33,423.92	\$ 4,163.46	\$ -	\$ 29,260.46
Teva	2025	July	\$ 28,858.30	\$ -	\$ -	\$ 28,858.30
CVS	2025	August	\$ 107,522.75	\$ -	\$ 144,157.87	\$ 107,522.75
Walgreens	2025	December	\$ 78,581.75	\$ -	\$ 157,212.99	\$ 78,581.75
Distributors	2026	July	\$ 114,904.44	\$ 17,235.67	\$ -	\$ 97,668.77
Allergan	2026	July	\$ 33,423.92	\$ 4,163.46	\$ -	\$ 29,260.46
Teva	2026	July	\$ 28,858.30	\$ -	\$ -	\$ 28,858.30
CVS	2026	August	\$ 129,742.09	\$ -	\$ -	\$ 129,742.09
Walgreens	2026	December	\$ 125,770.39	\$ -	\$ 157,212.99	\$ 125,770.39
Distributors	2027	July	\$ 114,904.44	\$ 17,235.67	\$ -	\$ 97,668.77
Allergan	2027	July	\$ 33,423.92	\$ 4,163.46	\$ -	\$ 29,260.46
Teva	2027	July	\$ 12,882.10	\$ -	\$ 52,404.33	\$ 12,882.10
CVS	2027	August	\$ 129,742.09	\$ -	\$ -	\$ 129,742.09
Walgreens	2027	December	\$ 125,770.39	\$ -	\$ 157,212.99	\$ 125,770.39
Distributors	2028	July	\$ 135,141.46	\$ 20,271.22	\$ -	\$ 114,870.24
Allergan	2028	July	\$ 33,423.92	\$ 4,163.46	\$ -	\$ 29,260.46
Teva	2028	July	\$ 12,882.10	\$ -	\$ 52,404.33	\$ 12,882.10
CVS	2028	August	\$ 129,742.09	\$ -	\$ -	\$ 129,742.09
Walgreens	2028	December	\$ 125,770.39	\$ -	\$ -	\$ 125,770.39
Distributors	2029	July	\$ 135,141.46	\$ 20,271.22	\$ -	\$ 114,870.24
Allergan	2029	July	\$ 33,423.92	\$ 4,163.46	\$ -	\$ 29,260.46
Teva	2029	July	\$ 12,882.10	\$ -	\$ 52,404.33	\$ 12,882.10
CVS	2029	August	\$ 129,742.09	\$ -	\$ -	\$ 129,742.09
Walgreens	2029	December	\$ 125,770.39	\$ -	\$ -	\$ 125,770.39
Distributors	2030	July	\$ 135,141.46	\$ 20,271.22	\$ -	\$ 114,870.24
Teva	2030	July	\$ 12,882.10	\$ -	\$ 52,404.33	\$ 12,882.10
CVS	2030	August	\$ 129,742.09	\$ -	\$ -	\$ 129,742.09
Walgreens	2030	December	\$ 125,770.39	\$ -	\$ -	\$ 125,770.39
Distributors	2031	July	\$ 113,600.04	\$ 17,040.01	\$ -	\$ 96,560.03
Teva	2031	July	\$ 12,882.10	\$ -	\$ 52,404.33	\$ 12,882.10
CVS	2031	August	\$ 129,742.09	\$ -	\$ -	\$ 129,742.09
Walgreens	2031	December	\$ 125,770.39	\$ -	\$ -	\$ 125,770.39
Distributors	2032	July	\$ 113,600.04	\$ 17,040.01	\$ -	\$ 96,560.03
Teva	2032	July	\$ 12,882.10	\$ -	\$ 52,404.33	\$ 12,882.10
CVS	2032	August	\$ 129,742.09	\$ -	\$ -	\$ 129,742.09
Walgreens	2032	December	\$ 125,770.39	\$ -	\$ -	\$ 125,770.39
Distributors	2033	July	\$ 113,600.04	\$ 17,040.01	\$ -	\$ 96,560.03
Teva	2033	July	\$ 12,882.10	\$ -	\$ 52,404.33	\$ 12,882.10
Walgreens	2033	December	\$ 125,770.39	\$ -	\$ -	\$ 125,770.39
Distributors	2034	July	\$ 113,600.04	\$ 17,040.01	\$ -	\$ 96,560.03
Teva	2034	July	\$ 12,882.10	\$ -	\$ 52,404.33	\$ 12,882.10
Walgreens	2034	December	\$ 125,770.39	\$ -	\$ -	\$ 125,770.39
Distributors	2035	July	\$ 113,600.04	\$ 17,040.01	\$ -	\$ 96,560.03
Teva	2035	July	\$ 60,317.39	\$ -	\$ -	\$ 60,317.39
Walgreens	2035	December	\$ 125,770.39	\$ -	\$ -	\$ 125,770.39
Distributors	2036	July	\$ 113,600.04	\$ 17,040.01	\$ -	\$ 96,560.03
Teva	2036	July	\$ 60,317.39	\$ -	\$ -	\$ 60,317.39
Walgreens	2036	December	\$ 125,770.39	\$ -	\$ -	\$ 125,770.39
Distributors	2037	July	\$ 113,600.04	\$ 17,040.01	\$ -	\$ 96,560.03
Teva	2037	July	\$ 77,550.93	\$ -	\$ -	\$ 77,550.93
Walgreens	2037	December	\$ 125,770.39	\$ -	\$ -	\$ 125,770.39
Distributors	2038	July	\$ 113,600.04	\$ 17,040.01	\$ -	\$ 96,560.03
Teva	2038	July	\$ 77,550.93	\$ -	\$ -	\$ 77,550.93
Teva	2039	July	\$ 77,550.93	\$ -	\$ -	\$ 77,550.93
Teva	2040	July	\$ 77,550.93	\$ -	\$ -	\$ 77,550.93
Teva	2041	July	\$ 77,550.93	\$ -	\$ -	\$ 77,550.93
Teva	2041	July	\$ 232,652.78	\$ -	\$ -	\$ 232,652.78
Teva	2042	July	\$ 232,652.78	\$ -	\$ -	\$ 232,652.78
		TOTAL	\$ 7,624,290.35	\$ 522,460.75	\$ 1,547,928.12	\$ 7,101,829.60

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)						
Mineral County - Actual and Estimated Allocations						
(assumes no default in payments)						
(CMS Medicaid costs, if any, not deducted)						
(assumes no administrative fees for court appointed third-party administrators)						
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 142,772.35	\$ 21,415.85	\$ -	\$ 121,356.50
Distributors	2022	August	\$ 33,298.32	\$ 4,994.75	\$ -	\$ 28,303.57
Distributors	2022	September	\$ 34,994.91	\$ 5,249.24	\$ -	\$ 29,745.67
American Drug Stores	2022	December	\$ 5,046.65	\$ 1,261.66	\$ -	\$ 3,784.99
Mallinckrodt (BK)	2022	December	\$ 6,223.30	\$ 1,555.83	\$ -	\$ 4,667.47
Distributors	2023	July	\$ 34,994.91	\$ 5,249.24	\$ -	\$ 29,745.67
Allergan	2023	July	\$ 12,741.06	\$ 1,587.09	\$ 11,187.20	\$ 11,153.97
CVS	2023	August	\$ 40,987.22	\$ -	\$ 54,952.38	\$ 40,987.22
Mallinckrodt (BK)	2023	September	\$ -	\$ (1,555.83)	\$ -	\$ 1,555.83
Walmart	2023	September	\$ 108,439.10	\$ -	\$ 14,493.16	\$ 108,439.10
Walgreens	2023	December	\$ 29,955.03	\$ -	\$ -	\$ 29,955.03
Distributors	2024	July	\$ 43,801.09	\$ 6,570.16	\$ -	\$ 37,230.93
Allergan	2024	July	\$ 12,741.06	\$ 1,587.09	\$ -	\$ 11,153.97
Teva	2024	July	\$ 11,000.66	\$ -	\$ -	\$ 11,000.66
CVS	2024	August	\$ 40,987.22	\$ -	\$ 54,952.38	\$ 40,987.22
Purdue (BK)	2024	July	\$ 188,408.14	\$ 47,102.04	\$ -	\$ 141,306.10
Walgreens	2024	December	\$ 29,955.03	\$ -	\$ 59,928.93	\$ 29,955.03
Janssen - J&J	2025	April	\$ 9,001.33	\$ 1,350.20	\$ -	\$ 7,651.13
Distributors	2025	July	\$ 43,801.09	\$ 6,570.16	\$ -	\$ 37,230.93
Allergan	2025	July	\$ 12,741.06	\$ 1,587.09	\$ -	\$ 11,153.97
Teva	2025	July	\$ 11,000.66	\$ -	\$ -	\$ 11,000.66
CVS	2025	August	\$ 40,987.22	\$ -	\$ 54,952.38	\$ 40,987.22
Walgreens	2025	December	\$ 29,955.03	\$ -	\$ 59,928.93	\$ 29,955.03
Distributors	2026	July	\$ 43,801.09	\$ 6,570.16	\$ -	\$ 37,230.93
Allergan	2026	July	\$ 12,741.06	\$ 1,587.09	\$ -	\$ 11,153.97
Teva	2026	July	\$ 11,000.66	\$ -	\$ -	\$ 11,000.66
CVS	2026	August	\$ 49,457.14	\$ -	\$ -	\$ 49,457.14
Walgreens	2026	December	\$ 47,943.14	\$ -	\$ 59,928.93	\$ 47,943.14
Distributors	2027	July	\$ 43,801.09	\$ 6,570.16	\$ -	\$ 37,230.93
Allergan	2027	July	\$ 12,741.06	\$ 1,587.09	\$ -	\$ 11,153.97
Teva	2027	July	\$ 4,910.60	\$ -	\$ 19,976.31	\$ 4,910.60
CVS	2027	August	\$ 49,457.14	\$ -	\$ -	\$ 49,457.14
Walgreens	2027	December	\$ 47,943.14	\$ -	\$ 59,928.93	\$ 47,943.14
Distributors	2028	July	\$ 51,515.36	\$ 7,727.30	\$ -	\$ 43,788.06
Allergan	2028	July	\$ 12,741.06	\$ 1,587.09	\$ -	\$ 11,153.97
Teva	2028	July	\$ 4,910.60	\$ -	\$ 19,976.31	\$ 4,910.60
CVS	2028	August	\$ 49,457.14	\$ -	\$ -	\$ 49,457.14
Walgreens	2028	December	\$ 47,943.14	\$ -	\$ -	\$ 47,943.14
Distributors	2029	July	\$ 51,515.36	\$ 7,727.30	\$ -	\$ 43,788.06
Allergan	2029	July	\$ 12,741.06	\$ 1,587.09	\$ -	\$ 11,153.97
Teva	2029	July	\$ 4,910.60	\$ -	\$ 19,976.31	\$ 4,910.60
CVS	2029	August	\$ 49,457.14	\$ -	\$ -	\$ 49,457.14
Walgreens	2029	December	\$ 47,943.14	\$ -	\$ -	\$ 47,943.14
Distributors	2030	July	\$ 51,515.36	\$ 7,727.30	\$ -	\$ 43,788.06
Teva	2030	July	\$ 4,910.60	\$ -	\$ 19,976.31	\$ 4,910.60
CVS	2030	August	\$ 49,457.14	\$ -	\$ -	\$ 49,457.14
Walgreens	2030	December	\$ 47,943.14	\$ -	\$ -	\$ 47,943.14
Distributors	2031	July	\$ 43,303.86	\$ 6,495.58	\$ -	\$ 36,808.28
Teva	2031	July	\$ 4,910.60	\$ -	\$ 19,976.31	\$ 4,910.60
CVS	2031	August	\$ 49,457.14	\$ -	\$ -	\$ 49,457.14
Walgreens	2031	December	\$ 47,943.14	\$ -	\$ -	\$ 47,943.14
Distributors	2032	July	\$ 43,303.86	\$ 6,495.58	\$ -	\$ 36,808.28
Teva	2032	July	\$ 4,910.60	\$ -	\$ 19,976.31	\$ 4,910.60
CVS	2032	August	\$ 49,457.14	\$ -	\$ -	\$ 49,457.14
Walgreens	2032	December	\$ 47,943.14	\$ -	\$ -	\$ 47,943.14
Distributors	2033	July	\$ 43,303.86	\$ 6,495.58	\$ -	\$ 36,808.28
Teva	2033	July	\$ 4,910.60	\$ -	\$ 19,976.31	\$ 4,910.60
Walgreens	2033	December	\$ 47,943.14	\$ -	\$ -	\$ 47,943.14
Distributors	2034	July	\$ 43,303.86	\$ 6,495.58	\$ -	\$ 36,808.28
Teva	2034	July	\$ 4,910.60	\$ -	\$ 19,976.31	\$ 4,910.60
Walgreens	2034	December	\$ 47,943.14	\$ -	\$ -	\$ 47,943.14
Distributors	2035	July	\$ 43,303.86	\$ 6,495.58	\$ -	\$ 36,808.28
Teva	2035	July	\$ 22,992.73	\$ -	\$ -	\$ 22,992.73
Walgreens	2035	December	\$ 47,943.14	\$ -	\$ -	\$ 47,943.14
Distributors	2036	July	\$ 43,303.86	\$ 6,495.58	\$ -	\$ 36,808.28
Teva	2036	July	\$ 22,992.73	\$ -	\$ -	\$ 22,992.73
Walgreens	2036	December	\$ 47,943.14	\$ -	\$ -	\$ 47,943.14
Distributors	2037	July	\$ 43,303.86	\$ 6,495.58	\$ -	\$ 36,808.28
Teva	2037	July	\$ 29,562.09	\$ -	\$ -	\$ 29,562.09
Walgreens	2037	December	\$ 47,943.14	\$ -	\$ -	\$ 47,943.14
Distributors	2038	July	\$ 43,303.86	\$ 6,495.58	\$ -	\$ 36,808.28
Teva	2038	July	\$ 29,562.09	\$ -	\$ -	\$ 29,562.09
Teva	2039	July	\$ 29,562.09	\$ -	\$ -	\$ 29,562.09
Teva	2040	July	\$ 29,562.09	\$ -	\$ -	\$ 29,562.09
Teva	2041	July	\$ 29,562.09	\$ -	\$ -	\$ 29,562.09
Teva	2041	July	\$ 88,686.26	\$ -	\$ -	\$ 88,686.26
Teva	2042	July	\$ 88,686.26	\$ -	\$ -	\$ 88,686.26
TOTAL			\$ 2,906,347.37	\$ 199,159.79	\$ 590,063.70	\$ 2,707,187.58

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)						
Nve County - Actual and Estimated Allocations						
(assumes no default in payments)						
(CMS Medicaid costs, if any, not deducted)						
(assumes no administrative fees for court appointed third-party administrators)						
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 381,576.62	\$ 57,236.49	\$ -	\$ 324,340.13
Distributors	2022	August	\$ 88,993.84	\$ 13,349.08	\$ -	\$ 75,644.76
Distributors	2022	September	\$ 93,528.19	\$ 14,029.23	\$ -	\$ 79,498.96
American Drug Stores	2022	December	\$ 13,487.78	\$ 3,371.95	\$ -	\$ 10,115.83
Mallinckrodt (BK)	2022	December	\$ 16,632.54	\$ 4,158.14	\$ -	\$ 12,474.40
Distributors	2023	July	\$ 93,528.19	\$ 14,029.23	\$ -	\$ 79,498.96
Allergan	2023	July	\$ 34,052.04	\$ 4,241.70	\$ 29,899.18	\$ 29,810.34
CVS	2023	August	\$ 109,543.38	\$ -	\$ 146,866.96	\$ 109,543.38
Mallinckrodt (BK)	2023	September	\$ -	\$ (4,158.14)	\$ -	\$ 4,158.14
Walmart	2023	September	\$ 289,816.81	\$ -	\$ 38,734.75	\$ 289,816.81
Walgreens	2023	December	\$ 80,058.49	\$ -	\$ -	\$ 80,058.49
Distributors	2024	July	\$ 117,063.78	\$ 17,559.57	\$ -	\$ 99,504.21
Allergan	2024	July	\$ 34,052.04	\$ 4,241.70	\$ -	\$ 29,810.34
Teva	2024	July	\$ 29,400.61	\$ -	\$ -	\$ 29,400.61
CVS	2024	August	\$ 109,543.38	\$ -	\$ 146,866.96	\$ 109,543.38
Purdue (BK)	2024	July	\$ 503,543.87	\$ 125,885.97	\$ -	\$ 377,657.90
Walgreens	2024	December	\$ 80,058.49	\$ -	\$ 160,167.42	\$ 80,058.49
Janssen - J&J	2025	April	\$ 24,057.17	\$ 3,608.58	\$ -	\$ 20,448.59
Distributors	2025	July	\$ 117,063.78	\$ 17,559.57	\$ -	\$ 99,504.21
Allergan	2025	July	\$ 34,052.04	\$ 4,241.70	\$ -	\$ 29,810.34
Teva	2025	July	\$ 29,400.61	\$ -	\$ -	\$ 29,400.61
CVS	2025	August	\$ 109,543.38	\$ -	\$ 146,866.96	\$ 109,543.38
Walgreens	2025	December	\$ 80,058.49	\$ -	\$ 160,167.42	\$ 80,058.49
Distributors	2026	July	\$ 117,063.78	\$ 17,559.57	\$ -	\$ 99,504.21
Allergan	2026	July	\$ 34,052.04	\$ 4,241.70	\$ -	\$ 29,810.34
Teva	2026	July	\$ 29,400.61	\$ -	\$ -	\$ 29,400.61
CVS	2026	August	\$ 132,180.27	\$ -	\$ -	\$ 132,180.27
Walgreens	2026	December	\$ 128,133.93	\$ -	\$ 160,167.42	\$ 128,133.93
Distributors	2027	July	\$ 117,063.78	\$ 17,559.57	\$ -	\$ 99,504.21
Allergan	2027	July	\$ 34,052.04	\$ 4,241.70	\$ -	\$ 29,810.34
Teva	2027	July	\$ 13,124.18	\$ -	\$ 53,389.14	\$ 13,124.18
CVS	2027	August	\$ 132,180.27	\$ -	\$ -	\$ 132,180.27
Walgreens	2027	December	\$ 128,133.93	\$ -	\$ 160,167.42	\$ 128,133.93
Distributors	2028	July	\$ 137,681.11	\$ 20,652.17	\$ -	\$ 117,028.94
Allergan	2028	July	\$ 34,052.04	\$ 4,241.70	\$ -	\$ 29,810.34
Teva	2028	July	\$ 13,124.18	\$ -	\$ 53,389.14	\$ 13,124.18
CVS	2028	August	\$ 132,180.27	\$ -	\$ -	\$ 132,180.27
Walgreens	2028	December	\$ 128,133.93	\$ -	\$ -	\$ 128,133.93
Distributors	2029	July	\$ 137,681.11	\$ 20,652.17	\$ -	\$ 117,028.94
Allergan	2029	July	\$ 34,052.04	\$ 4,241.70	\$ -	\$ 29,810.34
Teva	2029	July	\$ 13,124.18	\$ -	\$ 53,389.14	\$ 13,124.18
CVS	2029	August	\$ 132,180.27	\$ -	\$ -	\$ 132,180.27
Walgreens	2029	December	\$ 128,133.93	\$ -	\$ -	\$ 128,133.93
Distributors	2030	July	\$ 137,681.11	\$ 20,652.17	\$ -	\$ 117,028.94
Teva	2030	July	\$ 13,124.18	\$ -	\$ 53,389.14	\$ 13,124.18
CVS	2030	August	\$ 132,180.27	\$ -	\$ -	\$ 132,180.27
Walgreens	2030	December	\$ 128,133.93	\$ -	\$ -	\$ 128,133.93
Distributors	2031	July	\$ 115,734.87	\$ 17,360.23	\$ -	\$ 98,374.64
Teva	2031	July	\$ 13,124.18	\$ -	\$ 53,389.14	\$ 13,124.18
CVS	2031	August	\$ 132,180.27	\$ -	\$ -	\$ 132,180.27
Walgreens	2031	December	\$ 128,133.93	\$ -	\$ -	\$ 128,133.93
Distributors	2032	July	\$ 115,734.87	\$ 17,360.23	\$ -	\$ 98,374.64
Teva	2032	July	\$ 13,124.18	\$ -	\$ 53,389.14	\$ 13,124.18
CVS	2032	August	\$ 132,180.27	\$ -	\$ -	\$ 132,180.27
Walgreens	2032	December	\$ 128,133.93	\$ -	\$ -	\$ 128,133.93
Distributors	2033	July	\$ 115,734.87	\$ 17,360.23	\$ -	\$ 98,374.64
Teva	2033	July	\$ 13,124.18	\$ -	\$ 53,389.14	\$ 13,124.18
Walgreens	2033	December	\$ 128,133.93	\$ -	\$ -	\$ 128,133.93
Distributors	2034	July	\$ 115,734.87	\$ 17,360.23	\$ -	\$ 98,374.64
Teva	2034	July	\$ 13,124.18	\$ -	\$ 53,389.14	\$ 13,124.18
Walgreens	2034	December	\$ 128,133.93	\$ -	\$ -	\$ 128,133.93
Distributors	2035	July	\$ 115,734.87	\$ 17,360.23	\$ -	\$ 98,374.64
Teva	2035	July	\$ 61,450.90	\$ -	\$ -	\$ 61,450.90
Walgreens	2035	December	\$ 128,133.93	\$ -	\$ -	\$ 128,133.93
Distributors	2036	July	\$ 115,734.87	\$ 17,360.23	\$ -	\$ 98,374.64
Teva	2036	July	\$ 61,450.90	\$ -	\$ -	\$ 61,450.90
Walgreens	2036	December	\$ 128,133.93	\$ -	\$ -	\$ 128,133.93
Distributors	2037	July	\$ 115,734.87	\$ 17,360.23	\$ -	\$ 98,374.64
Teva	2037	July	\$ 79,008.30	\$ -	\$ -	\$ 79,008.30
Walgreens	2037	December	\$ 128,133.93	\$ -	\$ -	\$ 128,133.93
Distributors	2038	July	\$ 115,734.87	\$ 17,360.23	\$ -	\$ 98,374.64
Teva	2038	July	\$ 79,008.30	\$ -	\$ -	\$ 79,008.30
Teva	2039	July	\$ 79,008.30	\$ -	\$ -	\$ 79,008.30
Teva	2040	July	\$ 79,008.30	\$ -	\$ -	\$ 79,008.30
Teva	2041	July	\$ 79,008.30	\$ -	\$ -	\$ 79,008.30
Teva	2041	July	\$ 237,024.91	\$ -	\$ -	\$ 237,024.91
Teva	2042	July	\$ 237,024.91	\$ -	\$ -	\$ 237,024.91
TOTAL			\$ 7,767,569.75	\$ 532,279.06	\$ 1,577,017.58	\$ 7,235,290.69

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Pershing County - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 86,348.11	\$ -	\$ -	\$ 86,348.11
Distributors	2022	August	\$ 20,138.68	\$ -	\$ -	\$ 20,138.68
Distributors	2022	September	\$ 21,164.77	\$ -	\$ -	\$ 21,164.77
American Drug Stores	2022	December	\$ 3,052.19	\$ -	\$ -	\$ 3,052.19
Mallinckrodt (BK)	2022	December	\$ 3,763.83	\$ -	\$ -	\$ 3,763.83
Distributors	2023	July	\$ 21,164.77	\$ -	\$ -	\$ 21,164.77
Allergan	2023	July	\$ 7,705.74	\$ -	\$ -	\$ 7,705.74
CVS	2023	August	\$ 33,051.87	\$ -	\$ -	\$ 33,051.87
Mallinckrodt (BK)	2023	September	\$ -	\$ -	\$ -	\$ -
Walmart	2023	September	\$ 65,583.51	\$ -	\$ -	\$ 65,583.51
Walgreens	2023	December	\$ 24,155.57	\$ -	\$ -	\$ 24,155.57
Distributors	2024	July	\$ 26,490.71	\$ -	\$ -	\$ 26,490.71
Allergan	2024	July	\$ 7,705.74	\$ -	\$ -	\$ 7,705.74
Teva	2024	July	\$ 8,870.87	\$ -	\$ -	\$ 8,870.87
CVS	2024	August	\$ 33,051.87	\$ -	\$ -	\$ 33,051.87
Purdue (BK)	2024	July	\$ 113,948.44	\$ -	\$ -	\$ 113,948.44
Walgreens	2024	December	\$ 24,155.57	\$ -	\$ -	\$ 24,155.57
Janssen - J&J	2025	April	\$ 5,443.97	\$ -	\$ -	\$ 5,443.97
Distributors	2025	July	\$ 26,490.71	\$ -	\$ -	\$ 26,490.71
Allergan	2025	July	\$ 7,705.74	\$ -	\$ -	\$ 7,705.74
Teva	2025	July	\$ 8,870.87	\$ -	\$ -	\$ 8,870.87
CVS	2025	August	\$ 33,051.87	\$ -	\$ -	\$ 33,051.87
Walgreens	2025	December	\$ 24,155.57	\$ -	\$ -	\$ 24,155.57
Distributors	2026	July	\$ 26,490.71	\$ -	\$ -	\$ 26,490.71
Allergan	2026	July	\$ 7,705.74	\$ -	\$ -	\$ 7,705.74
Teva	2026	July	\$ 8,870.87	\$ -	\$ -	\$ 8,870.87
CVS	2026	August	\$ 39,881.96	\$ -	\$ -	\$ 39,881.96
Walgreens	2026	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2027	July	\$ 26,490.71	\$ -	\$ -	\$ 26,490.71
Allergan	2027	July	\$ 7,705.74	\$ -	\$ -	\$ 7,705.74
Teva	2027	July	\$ 3,959.88	\$ -	\$ -	\$ 3,959.88
CVS	2027	August	\$ 39,881.96	\$ -	\$ -	\$ 39,881.96
Walgreens	2027	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2028	July	\$ 31,156.27	\$ -	\$ -	\$ 31,156.27
Allergan	2028	July	\$ 7,705.74	\$ -	\$ -	\$ 7,705.74
Teva	2028	July	\$ 3,959.88	\$ -	\$ -	\$ 3,959.88
CVS	2028	August	\$ 39,881.96	\$ -	\$ -	\$ 39,881.96
Walgreens	2028	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2029	July	\$ 31,156.27	\$ -	\$ -	\$ 31,156.27
Allergan	2029	July	\$ 7,705.74	\$ -	\$ -	\$ 7,705.74
Teva	2029	July	\$ 3,959.88	\$ -	\$ -	\$ 3,959.88
CVS	2029	August	\$ 39,881.96	\$ -	\$ -	\$ 39,881.96
Walgreens	2029	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2030	July	\$ 31,156.27	\$ -	\$ -	\$ 31,156.27
Teva	2030	July	\$ 3,959.88	\$ -	\$ -	\$ 3,959.88
CVS	2030	August	\$ 39,881.96	\$ -	\$ -	\$ 39,881.96
Walgreens	2030	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2031	July	\$ 26,189.99	\$ -	\$ -	\$ 26,189.99
Teva	2031	July	\$ 3,959.88	\$ -	\$ -	\$ 3,959.88
CVS	2031	August	\$ 39,881.96	\$ -	\$ -	\$ 39,881.96
Walgreens	2031	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2032	July	\$ 26,189.99	\$ -	\$ -	\$ 26,189.99
Teva	2032	July	\$ 3,959.88	\$ -	\$ -	\$ 3,959.88
CVS	2032	August	\$ 39,881.96	\$ -	\$ -	\$ 39,881.96
Walgreens	2032	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2033	July	\$ 26,189.99	\$ -	\$ -	\$ 26,189.99
Teva	2033	July	\$ 3,959.88	\$ -	\$ -	\$ 3,959.88
Walgreens	2033	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2034	July	\$ 26,189.99	\$ -	\$ -	\$ 26,189.99
Teva	2034	July	\$ 3,959.88	\$ -	\$ -	\$ 3,959.88
Walgreens	2034	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2035	July	\$ 26,189.99	\$ -	\$ -	\$ 26,189.99
Teva	2035	July	\$ 18,541.21	\$ -	\$ -	\$ 18,541.21
Walgreens	2035	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2036	July	\$ 26,189.99	\$ -	\$ -	\$ 26,189.99
Teva	2036	July	\$ 18,541.21	\$ -	\$ -	\$ 18,541.21
Walgreens	2036	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2037	July	\$ 26,189.99	\$ -	\$ -	\$ 26,189.99
Teva	2037	July	\$ 23,838.70	\$ -	\$ -	\$ 23,838.70
Walgreens	2037	December	\$ 38,661.08	\$ -	\$ -	\$ 38,661.08
Distributors	2038	July	\$ 26,189.99	\$ -	\$ -	\$ 26,189.99
Teva	2038	July	\$ 23,838.70	\$ -	\$ -	\$ 23,838.70
Teva	2039	July	\$ 23,838.70	\$ -	\$ -	\$ 23,838.70
Teva	2040	July	\$ 23,838.70	\$ -	\$ -	\$ 23,838.70
Teva	2041	July	\$ 23,838.70	\$ -	\$ -	\$ 23,838.70
Teva	2041	July	\$ 71,516.10	\$ -	\$ -	\$ 71,516.10
Teva	2042	July	\$ 71,516.10	\$ -	\$ -	\$ 71,516.10
TOTAL			\$ 2,075,828.79	\$ -	\$ -	\$ 2,075,828.79

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Storey County - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medical costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 30,110.68	\$ -	\$ -	\$ 30,110.68
Distributors	2022	August	\$ 7,022.61	\$ -	\$ -	\$ 7,022.61
Distributors	2022	September	\$ 7,380.42	\$ -	\$ -	\$ 7,380.42
American Drug Stores	2022	December	\$ 1,064.34	\$ -	\$ -	\$ 1,064.34
Mallinckrodt (BK)	2022	December	\$ 1,312.49	\$ -	\$ -	\$ 1,312.49
Distributors	2023	July	\$ 7,380.42	\$ -	\$ -	\$ 7,380.42
Allergan	2023	July	\$ 2,687.09	\$ -	\$ -	\$ 2,687.09
CVS	2023	August	\$ 11,525.60	\$ -	\$ -	\$ 11,525.60
Mallinckrodt (BK)	2023	September	\$ -	\$ -	\$ -	\$ -
Walmart	2023	September	\$ 22,869.80	\$ -	\$ -	\$ 22,869.80
Walgreens	2023	December	\$ 8,423.35	\$ -	\$ -	\$ 8,423.35
Distributors	2024	July	\$ 9,237.65	\$ -	\$ -	\$ 9,237.65
Allergan	2024	July	\$ 2,687.09	\$ -	\$ -	\$ 2,687.09
Teva	2024	July	\$ 3,093.38	\$ -	\$ -	\$ 3,093.38
CVS	2024	August	\$ 11,525.60	\$ -	\$ -	\$ 11,525.60
Purdue (BK)	2024	July	\$ 39,735.26	\$ -	\$ -	\$ 39,735.26
Walgreens	2024	December	\$ 8,423.35	\$ -	\$ -	\$ 8,423.35
Janssen - J&J	2025	April	\$ 1,898.38	\$ -	\$ -	\$ 1,898.38
Distributors	2025	July	\$ 9,237.65	\$ -	\$ -	\$ 9,237.65
Allergan	2025	July	\$ 2,687.09	\$ -	\$ -	\$ 2,687.09
Teva	2025	July	\$ 3,093.38	\$ -	\$ -	\$ 3,093.38
CVS	2025	August	\$ 11,525.60	\$ -	\$ -	\$ 11,525.60
Walgreens	2025	December	\$ 8,423.35	\$ -	\$ -	\$ 8,423.35
Distributors	2026	July	\$ 9,237.65	\$ -	\$ -	\$ 9,237.65
Allergan	2026	July	\$ 2,687.09	\$ -	\$ -	\$ 2,687.09
Teva	2026	July	\$ 3,093.38	\$ -	\$ -	\$ 3,093.38
CVS	2026	August	\$ 13,907.34	\$ -	\$ -	\$ 13,907.34
Walgreens	2026	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2027	July	\$ 9,237.65	\$ -	\$ -	\$ 9,237.65
Allergan	2027	July	\$ 2,687.09	\$ -	\$ -	\$ 2,687.09
Teva	2027	July	\$ 1,380.86	\$ -	\$ -	\$ 1,380.86
CVS	2027	August	\$ 13,907.34	\$ -	\$ -	\$ 13,907.34
Walgreens	2027	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2028	July	\$ 10,864.59	\$ -	\$ -	\$ 10,864.59
Allergan	2028	July	\$ 2,687.09	\$ -	\$ -	\$ 2,687.09
Teva	2028	July	\$ 1,380.86	\$ -	\$ -	\$ 1,380.86
CVS	2028	August	\$ 13,907.34	\$ -	\$ -	\$ 13,907.34
Walgreens	2028	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2029	July	\$ 10,864.59	\$ -	\$ -	\$ 10,864.59
Allergan	2029	July	\$ 2,687.09	\$ -	\$ -	\$ 2,687.09
Teva	2029	July	\$ 1,380.86	\$ -	\$ -	\$ 1,380.86
CVS	2029	August	\$ 13,907.34	\$ -	\$ -	\$ 13,907.34
Walgreens	2029	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2030	July	\$ 10,864.59	\$ -	\$ -	\$ 10,864.59
Teva	2030	July	\$ 1,380.86	\$ -	\$ -	\$ 1,380.86
CVS	2030	August	\$ 13,907.34	\$ -	\$ -	\$ 13,907.34
Walgreens	2030	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2031	July	\$ 9,132.78	\$ -	\$ -	\$ 9,132.78
Teva	2031	July	\$ 1,380.86	\$ -	\$ -	\$ 1,380.86
CVS	2031	August	\$ 13,907.34	\$ -	\$ -	\$ 13,907.34
Walgreens	2031	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2032	July	\$ 9,132.78	\$ -	\$ -	\$ 9,132.78
Teva	2032	July	\$ 1,380.86	\$ -	\$ -	\$ 1,380.86
CVS	2032	August	\$ 13,907.34	\$ -	\$ -	\$ 13,907.34
Walgreens	2032	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2033	July	\$ 9,132.78	\$ -	\$ -	\$ 9,132.78
Teva	2033	July	\$ 1,380.86	\$ -	\$ -	\$ 1,380.86
Walgreens	2033	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2034	July	\$ 9,132.78	\$ -	\$ -	\$ 9,132.78
Teva	2034	July	\$ 1,380.86	\$ -	\$ -	\$ 1,380.86
Walgreens	2034	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2035	July	\$ 9,132.78	\$ -	\$ -	\$ 9,132.78
Teva	2035	July	\$ 6,465.55	\$ -	\$ -	\$ 6,465.55
Walgreens	2035	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2036	July	\$ 9,132.78	\$ -	\$ -	\$ 9,132.78
Teva	2036	July	\$ 6,465.55	\$ -	\$ -	\$ 6,465.55
Walgreens	2036	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2037	July	\$ 9,132.78	\$ -	\$ -	\$ 9,132.78
Teva	2037	July	\$ 8,312.86	\$ -	\$ -	\$ 8,312.86
Walgreens	2037	December	\$ 13,481.61	\$ -	\$ -	\$ 13,481.61
Distributors	2038	July	\$ 9,132.78	\$ -	\$ -	\$ 9,132.78
Teva	2038	July	\$ 8,312.86	\$ -	\$ -	\$ 8,312.86
Teva	2039	July	\$ 8,312.86	\$ -	\$ -	\$ 8,312.86
Teva	2040	July	\$ 8,312.86	\$ -	\$ -	\$ 8,312.86
Teva	2041	July	\$ 8,312.86	\$ -	\$ -	\$ 8,312.86
Teva	2041	July	\$ 24,938.57	\$ -	\$ -	\$ 24,938.57
Teva	2042	July	\$ 24,938.57	\$ -	\$ -	\$ 24,938.57
TOTAL			\$ 723,867.75	\$ -	\$ -	\$ 723,867.75

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Washoe County - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation	
Janssen - J&J	2022	July	\$ 2,171,258.18	\$ 325,688.73	\$ -	\$ 1,845,569.45	
Distributors	2022	August	\$ 506,395.31	\$ 75,959.30	\$ -	\$ 430,436.01	
Distributors	2022	September	\$ 532,196.78	\$ 79,829.52	\$ -	\$ 452,367.26	
American Drug Stores	2022	December	\$ 76,748.56	\$ 19,187.14	\$ -	\$ 57,561.42	
Mallinckrodt (BK)	2022	December	\$ 94,642.94	\$ 23,660.74	\$ -	\$ 70,982.20	
Distributors	2023	July	\$ 532,196.78	\$ 79,829.52	\$ -	\$ 452,367.26	
Allergan	2023	July	\$ 193,763.90	\$ 24,136.24	\$ 170,133.15	\$ 169,627.66	
CVS	2023	August	\$ 623,326.82	\$ -	\$ 835,706.58	\$ 623,326.82	
Mallinckrodt (BK)	2023	September	\$ -	\$ (23,660.74)	\$ -	\$ 23,660.74	
Walmart	2023	September	\$ 1,649,123.87	\$ -	\$ 220,409.56	\$ 1,649,123.87	
Walgreens	2023	December	\$ 455,551.14	\$ -	\$ -	\$ 455,551.14	
Distributors	2024	July	\$ 666,119.66	\$ 99,917.95	\$ -	\$ 566,201.71	
Allergan	2024	July	\$ 193,763.90	\$ 24,136.24	\$ -	\$ 169,627.66	
Teva	2024	July	\$ 167,296.21	\$ -	\$ -	\$ 167,296.21	
CVS	2024	August	\$ 623,326.82	\$ -	\$ 835,706.58	\$ 623,326.82	
Purdue (BK)	2024	July	\$ 2,865,279.70	\$ 716,319.93	\$ -	\$ 2,148,959.77	
Walgreens	2024	December	\$ 455,551.14	\$ -	\$ 911,389.19	\$ 455,551.14	
Janssen - J&J	2025	April	\$ 136,890.77	\$ 20,533.62	\$ -	\$ 116,357.15	
Distributors	2025	July	\$ 666,119.66	\$ 99,917.95	\$ -	\$ 566,201.71	
Allergan	2025	July	\$ 193,763.90	\$ 24,136.24	\$ -	\$ 169,627.66	
Teva	2025	July	\$ 167,296.21	\$ -	\$ -	\$ 167,296.21	
CVS	2025	August	\$ 623,326.82	\$ -	\$ 835,706.58	\$ 623,326.82	
Walgreens	2025	December	\$ 455,551.14	\$ -	\$ 911,389.19	\$ 455,551.14	
Distributors	2026	July	\$ 666,119.66	\$ 99,917.95	\$ -	\$ 566,201.71	
Allergan	2026	July	\$ 193,763.90	\$ 24,136.24	\$ -	\$ 169,627.66	
Teva	2026	July	\$ 167,296.21	\$ -	\$ -	\$ 167,296.21	
CVS	2026	August	\$ 752,135.92	\$ -	\$ -	\$ 752,135.92	
Walgreens	2026	December	\$ 729,111.35	\$ -	\$ 911,389.19	\$ 729,111.35	
Distributors	2027	July	\$ 666,119.66	\$ 99,917.95	\$ -	\$ 566,201.71	
Allergan	2027	July	\$ 193,763.90	\$ 24,136.24	\$ -	\$ 169,627.66	
Teva	2027	July	\$ 74,679.60	\$ -	\$ 303,796.40	\$ 74,679.60	
CVS	2027	August	\$ 752,135.92	\$ -	\$ -	\$ 752,135.92	
Walgreens	2027	December	\$ 729,111.35	\$ -	\$ 911,389.19	\$ 729,111.35	
Distributors	2028	July	\$ 783,436.98	\$ 117,515.55	\$ -	\$ 665,921.43	
Allergan	2028	July	\$ 193,763.90	\$ 24,136.24	\$ -	\$ 169,627.66	
Teva	2028	July	\$ 74,679.60	\$ -	\$ 303,796.40	\$ 74,679.60	
CVS	2028	August	\$ 752,135.92	\$ -	\$ -	\$ 752,135.92	
Walgreens	2028	December	\$ 729,111.35	\$ -	\$ -	\$ 729,111.35	
Distributors	2029	July	\$ 783,436.98	\$ 117,515.55	\$ -	\$ 665,921.43	
Allergan	2029	July	\$ 193,763.90	\$ 24,136.24	\$ -	\$ 169,627.66	
Teva	2029	July	\$ 74,679.60	\$ -	\$ 303,796.40	\$ 74,679.60	
CVS	2029	August	\$ 752,135.92	\$ -	\$ -	\$ 752,135.92	
Walgreens	2029	December	\$ 729,111.35	\$ -	\$ -	\$ 729,111.35	
Distributors	2030	July	\$ 783,436.98	\$ 117,515.55	\$ -	\$ 665,921.43	
Teva	2030	July	\$ 74,679.60	\$ -	\$ 303,796.40	\$ 74,679.60	
CVS	2030	August	\$ 752,135.92	\$ -	\$ -	\$ 752,135.92	
Walgreens	2030	December	\$ 729,111.35	\$ -	\$ -	\$ 729,111.35	
Distributors	2031	July	\$ 658,557.85	\$ 98,783.68	\$ -	\$ 559,774.17	
Teva	2031	July	\$ 74,679.60	\$ -	\$ 303,796.40	\$ 74,679.60	
CVS	2031	August	\$ 752,135.92	\$ -	\$ -	\$ 752,135.92	
Walgreens	2031	December	\$ 729,111.35	\$ -	\$ -	\$ 729,111.35	
Distributors	2032	July	\$ 658,557.85	\$ 98,783.68	\$ -	\$ 559,774.17	
Teva	2032	July	\$ 74,679.60	\$ -	\$ 303,796.40	\$ 74,679.60	
CVS	2032	August	\$ 752,135.92	\$ -	\$ -	\$ 752,135.92	
Walgreens	2032	December	\$ 729,111.35	\$ -	\$ -	\$ 729,111.35	
Distributors	2033	July	\$ 658,557.85	\$ 98,783.68	\$ -	\$ 559,774.17	
Teva	2033	July	\$ 74,679.60	\$ -	\$ 303,796.40	\$ 74,679.60	
Walgreens	2033	December	\$ 729,111.35	\$ -	\$ -	\$ 729,111.35	
Distributors	2034	July	\$ 658,557.85	\$ 98,783.68	\$ -	\$ 559,774.17	
Teva	2034	July	\$ 74,679.60	\$ -	\$ 303,796.40	\$ 74,679.60	
Walgreens	2034	December	\$ 729,111.35	\$ -	\$ -	\$ 729,111.35	
Distributors	2035	July	\$ 658,557.85	\$ 98,783.68	\$ -	\$ 559,774.17	
Teva	2035	July	\$ 349,669.68	\$ -	\$ -	\$ 349,669.68	
Walgreens	2035	December	\$ 729,111.35	\$ -	\$ -	\$ 729,111.35	
Distributors	2036	July	\$ 658,557.85	\$ 98,783.68	\$ -	\$ 559,774.17	
Teva	2036	July	\$ 349,669.68	\$ -	\$ -	\$ 349,669.68	
Walgreens	2036	December	\$ 729,111.35	\$ -	\$ -	\$ 729,111.35	
Distributors	2037	July	\$ 658,557.85	\$ 98,783.68	\$ -	\$ 559,774.17	
Teva	2037	July	\$ 449,575.30	\$ -	\$ -	\$ 449,575.30	
Walgreens	2037	December	\$ 729,111.35	\$ -	\$ -	\$ 729,111.35	
Distributors	2038	July	\$ 658,557.85	\$ 98,783.68	\$ -	\$ 559,774.17	
Teva	2038	July	\$ 449,575.30	\$ -	\$ -	\$ 449,575.30	
Teva	2039	July	\$ 449,575.30	\$ -	\$ -	\$ 449,575.30	
Teva	2040	July	\$ 449,575.30	\$ -	\$ -	\$ 449,575.30	
Teva	2041	July	\$ 449,575.30	\$ -	\$ -	\$ 449,575.30	
Teva	2041	July	\$ 1,348,725.90	\$ -	\$ -	\$ 1,348,725.90	
Teva	2042	July	\$ 1,348,725.90	\$ -	\$ -	\$ 1,348,725.90	
			TOTAL	\$ 44,199,247.18	\$ 3,028,789.33	\$ 8,973,590.40	\$ 41,170,457.85

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)						
West Wendover City - Actual and Estimated Allocations						
(assumes no default in payments)						
(CMS Medicaid costs, if any, not deducted)						
(assumes no administrative fees for court appointed third-party administrators)						
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 13,436.81	\$ 2,015.52	\$ -	\$ 11,421.29
Distributors	2022	August	\$ 3,133.82	\$ 470.07	\$ -	\$ 2,663.75
Distributors	2022	September	\$ 3,293.49	\$ 494.02	\$ -	\$ 2,799.47
American Drug Stores	2022	December	\$ 474.96	\$ 118.74	\$ -	\$ 356.22
Mallinckrodt (BK)	2022	December	\$ 585.70	\$ 146.43	\$ -	\$ 439.27
Distributors	2023	July	\$ 3,293.49	\$ 494.02	\$ -	\$ 2,799.47
Allergan	2023	July	\$ 1,199.11	\$ 149.37	\$ 1,052.87	\$ 1,049.74
CVS	2023	August	\$ 3,857.46	\$ -	\$ 5,171.76	\$ 3,857.46
Mallinckrodt (BK)	2023	September	\$ -	\$ (146.43)	\$ -	\$ 146.43
Walmart	2023	September	\$ 10,205.59	\$ -	\$ 1,364.00	\$ 10,205.59
Walgreens	2023	December	\$ 2,819.18	\$ -	\$ -	\$ 2,819.18
Distributors	2024	July	\$ 4,122.28	\$ 618.34	\$ -	\$ 3,503.94
Allergan	2024	July	\$ 1,199.11	\$ 149.37	\$ -	\$ 1,049.74
Teva	2024	July	\$ 1,035.31	\$ -	\$ -	\$ 1,035.31
CVS	2024	August	\$ 3,857.46	\$ -	\$ 5,171.76	\$ 3,857.46
Purdue (BK)	2024	July	\$ 17,731.76	\$ 4,432.94	\$ -	\$ 13,298.82
Walgreens	2024	December	\$ 2,819.18	\$ -	\$ 5,640.12	\$ 2,819.18
Janssen - J&J	2025	April	\$ 847.15	\$ 127.07	\$ -	\$ 720.08
Distributors	2025	July	\$ 4,122.28	\$ 618.34	\$ -	\$ 3,503.94
Allergan	2025	July	\$ 1,199.11	\$ 149.37	\$ -	\$ 1,049.74
Teva	2025	July	\$ 1,035.31	\$ -	\$ -	\$ 1,035.31
CVS	2025	August	\$ 3,857.46	\$ -	\$ 5,171.76	\$ 3,857.46
Walgreens	2025	December	\$ 2,819.18	\$ -	\$ 5,640.12	\$ 2,819.18
Distributors	2026	July	\$ 4,122.28	\$ 618.34	\$ -	\$ 3,503.94
Allergan	2026	July	\$ 1,199.11	\$ 149.37	\$ -	\$ 1,049.74
Teva	2026	July	\$ 1,035.31	\$ -	\$ -	\$ 1,035.31
CVS	2026	August	\$ 4,654.59	\$ -	\$ -	\$ 4,654.59
Walgreens	2026	December	\$ 4,512.10	\$ -	\$ 5,640.12	\$ 4,512.10
Distributors	2027	July	\$ 4,122.28	\$ 618.34	\$ -	\$ 3,503.94
Allergan	2027	July	\$ 1,199.11	\$ 149.37	\$ -	\$ 1,049.74
Teva	2027	July	\$ 462.15	\$ -	\$ 1,880.04	\$ 462.15
CVS	2027	August	\$ 4,654.59	\$ -	\$ -	\$ 4,654.59
Walgreens	2027	December	\$ 4,512.10	\$ -	\$ 5,640.12	\$ 4,512.10
Distributors	2028	July	\$ 4,848.29	\$ 727.24	\$ -	\$ 4,121.05
Allergan	2028	July	\$ 1,199.11	\$ 149.37	\$ -	\$ 1,049.74
Teva	2028	July	\$ 462.15	\$ -	\$ 1,880.04	\$ 462.15
CVS	2028	August	\$ 4,654.59	\$ -	\$ -	\$ 4,654.59
Walgreens	2028	December	\$ 4,512.10	\$ -	\$ -	\$ 4,512.10
Distributors	2029	July	\$ 4,848.29	\$ 727.24	\$ -	\$ 4,121.05
Allergan	2029	July	\$ 1,199.11	\$ 149.37	\$ -	\$ 1,049.74
Teva	2029	July	\$ 462.15	\$ -	\$ 1,880.04	\$ 462.15
CVS	2029	August	\$ 4,654.59	\$ -	\$ -	\$ 4,654.59
Walgreens	2029	December	\$ 4,512.10	\$ -	\$ -	\$ 4,512.10
Distributors	2030	July	\$ 4,848.29	\$ 727.24	\$ -	\$ 4,121.05
Teva	2030	July	\$ 462.15	\$ -	\$ 1,880.04	\$ 462.15
CVS	2030	August	\$ 4,654.59	\$ -	\$ -	\$ 4,654.59
Walgreens	2030	December	\$ 4,512.10	\$ -	\$ -	\$ 4,512.10
Distributors	2031	July	\$ 4,075.48	\$ 611.32	\$ -	\$ 3,464.16
Teva	2031	July	\$ 462.15	\$ -	\$ 1,880.04	\$ 462.15
CVS	2031	August	\$ 4,654.59	\$ -	\$ -	\$ 4,654.59
Walgreens	2031	December	\$ 4,512.10	\$ -	\$ -	\$ 4,512.10
Distributors	2032	July	\$ 4,075.48	\$ 611.32	\$ -	\$ 3,464.16
Teva	2032	July	\$ 462.15	\$ -	\$ 1,880.04	\$ 462.15
CVS	2032	August	\$ 4,654.59	\$ -	\$ -	\$ 4,654.59
Walgreens	2032	December	\$ 4,512.10	\$ -	\$ -	\$ 4,512.10
Distributors	2033	July	\$ 4,075.48	\$ 611.32	\$ -	\$ 3,464.16
Teva	2033	July	\$ 462.15	\$ -	\$ 1,880.04	\$ 462.15
Walgreens	2033	December	\$ 4,512.10	\$ -	\$ -	\$ 4,512.10
Distributors	2034	July	\$ 4,075.48	\$ 611.32	\$ -	\$ 3,464.16
Teva	2034	July	\$ 462.15	\$ -	\$ 1,880.04	\$ 462.15
Walgreens	2034	December	\$ 4,512.10	\$ -	\$ -	\$ 4,512.10
Distributors	2035	July	\$ 4,075.48	\$ 611.32	\$ -	\$ 3,464.16
Teva	2035	July	\$ 2,163.93	\$ -	\$ -	\$ 2,163.93
Walgreens	2035	December	\$ 4,512.10	\$ -	\$ -	\$ 4,512.10
Distributors	2036	July	\$ 4,075.48	\$ 611.32	\$ -	\$ 3,464.16
Teva	2036	July	\$ 2,163.93	\$ -	\$ -	\$ 2,163.93
Walgreens	2036	December	\$ 4,512.10	\$ -	\$ -	\$ 4,512.10
Distributors	2037	July	\$ 4,075.48	\$ 611.32	\$ -	\$ 3,464.16
Teva	2037	July	\$ 2,782.19	\$ -	\$ -	\$ 2,782.19
Walgreens	2037	December	\$ 4,512.10	\$ -	\$ -	\$ 4,512.10
Distributors	2038	July	\$ 4,075.48	\$ 611.32	\$ -	\$ 3,464.16
Teva	2038	July	\$ 2,782.19	\$ -	\$ -	\$ 2,782.19
Teva	2039	July	\$ 2,782.19	\$ -	\$ -	\$ 2,782.19
Teva	2040	July	\$ 2,782.19	\$ -	\$ -	\$ 2,782.19
Teva	2041	July	\$ 2,782.19	\$ -	\$ -	\$ 2,782.19
Teva	2041	July	\$ 8,346.58	\$ -	\$ -	\$ 8,346.58
Teva	2042	July	\$ 8,346.58	\$ -	\$ -	\$ 8,346.58
TOTAL			\$ 273,526.72	\$ 18,743.61	\$ 55,532.97	\$ 254,783.11

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

White Pine County - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 249,159.51	\$ 37,373.93	\$ -	\$ 211,785.58
Distributors	2022	August	\$ 58,110.64	\$ 8,716.60	\$ -	\$ 49,394.04
Distributors	2022	September	\$ 61,071.45	\$ 9,160.72	\$ -	\$ 51,910.73
American Drug Stores	2022	December	\$ 8,807.17	\$ 2,201.79	\$ -	\$ 6,605.38
Mallinckrodt (BK)	2022	December	\$ 10,860.61	\$ 2,715.15	\$ -	\$ 8,145.46
Distributors	2023	July	\$ 61,071.45	\$ 9,160.72	\$ -	\$ 51,910.73
Allergan	2023	July	\$ 22,235.09	\$ 2,769.72	\$ 19,523.38	\$ 19,465.37
CVS	2023	August	\$ 71,528.94	\$ -	\$ 95,900.27	\$ 71,528.94
Mallinckrodt (BK)	2023	September	\$ -	\$ (2,715.15)	\$ -	\$ 2,715.15
Walmart	2023	September	\$ 189,242.76	\$ -	\$ 25,292.77	\$ 189,242.76
Walgreens	2023	December	\$ 52,276.09	\$ -	\$ -	\$ 52,276.09
Distributors	2024	July	\$ 76,439.57	\$ 11,465.94	\$ -	\$ 64,973.63
Allergan	2024	July	\$ 22,235.09	\$ 2,769.72	\$ -	\$ 19,465.37
Teva	2024	July	\$ 19,197.82	\$ -	\$ -	\$ 19,197.82
CVS	2024	August	\$ 71,528.94	\$ -	\$ 95,900.27	\$ 71,528.94
Purdue (BK)	2024	July	\$ 328,800.91	\$ 82,200.23	\$ -	\$ 246,600.68
Walgreens	2024	December	\$ 52,276.09	\$ -	\$ 104,585.11	\$ 52,276.09
Janssen - J&J	2025	April	\$ 15,708.70	\$ 2,356.31	\$ -	\$ 13,352.39
Distributors	2025	July	\$ 76,439.57	\$ 11,465.94	\$ -	\$ 64,973.63
Allergan	2025	July	\$ 22,235.09	\$ 2,769.72	\$ -	\$ 19,465.37
Teva	2025	July	\$ 19,197.82	\$ -	\$ -	\$ 19,197.82
CVS	2025	August	\$ 71,528.94	\$ -	\$ 95,900.27	\$ 71,528.94
Walgreens	2025	December	\$ 52,276.09	\$ -	\$ 104,585.11	\$ 52,276.09
Distributors	2026	July	\$ 76,439.57	\$ 11,465.94	\$ -	\$ 64,973.63
Allergan	2026	July	\$ 22,235.09	\$ 2,769.72	\$ -	\$ 19,465.37
Teva	2026	July	\$ 19,197.82	\$ -	\$ -	\$ 19,197.82
CVS	2026	August	\$ 86,310.24	\$ -	\$ -	\$ 86,310.24
Walgreens	2026	December	\$ 83,668.09	\$ -	\$ 104,585.11	\$ 83,668.09
Distributors	2027	July	\$ 76,439.57	\$ 11,465.94	\$ -	\$ 64,973.63
Allergan	2027	July	\$ 22,235.09	\$ 2,769.72	\$ -	\$ 19,465.37
Teva	2027	July	\$ 8,569.75	\$ -	\$ 34,861.70	\$ 8,569.75
CVS	2027	August	\$ 86,310.24	\$ -	\$ -	\$ 86,310.24
Walgreens	2027	December	\$ 83,668.09	\$ -	\$ 104,585.11	\$ 83,668.09
Distributors	2028	July	\$ 89,902.15	\$ 13,485.32	\$ -	\$ 76,416.83
Allergan	2028	July	\$ 22,235.09	\$ 2,769.72	\$ -	\$ 19,465.37
Teva	2028	July	\$ 8,569.75	\$ -	\$ 34,861.70	\$ 8,569.75
CVS	2028	August	\$ 86,310.24	\$ -	\$ -	\$ 86,310.24
Walgreens	2028	December	\$ 83,668.09	\$ -	\$ -	\$ 83,668.09
Distributors	2029	July	\$ 89,902.15	\$ 13,485.32	\$ -	\$ 76,416.83
Allergan	2029	July	\$ 22,235.09	\$ 2,769.72	\$ -	\$ 19,465.37
Teva	2029	July	\$ 8,569.75	\$ -	\$ 34,861.70	\$ 8,569.75
CVS	2029	August	\$ 86,310.24	\$ -	\$ -	\$ 86,310.24
Walgreens	2029	December	\$ 83,668.09	\$ -	\$ -	\$ 83,668.09
Distributors	2030	July	\$ 89,902.15	\$ 13,485.32	\$ -	\$ 76,416.83
Teva	2030	July	\$ 8,569.75	\$ -	\$ 34,861.70	\$ 8,569.75
CVS	2030	August	\$ 86,310.24	\$ -	\$ -	\$ 86,310.24
Walgreens	2030	December	\$ 83,668.09	\$ -	\$ -	\$ 83,668.09
Distributors	2031	July	\$ 75,571.83	\$ 11,335.77	\$ -	\$ 64,236.06
Teva	2031	July	\$ 8,569.75	\$ -	\$ 34,861.70	\$ 8,569.75
CVS	2031	August	\$ 86,310.24	\$ -	\$ -	\$ 86,310.24
Walgreens	2031	December	\$ 83,668.09	\$ -	\$ -	\$ 83,668.09
Distributors	2032	July	\$ 75,571.83	\$ 11,335.77	\$ -	\$ 64,236.06
Teva	2032	July	\$ 8,569.75	\$ -	\$ 34,861.70	\$ 8,569.75
CVS	2032	August	\$ 86,310.24	\$ -	\$ -	\$ 86,310.24
Walgreens	2032	December	\$ 83,668.09	\$ -	\$ -	\$ 83,668.09
Distributors	2033	July	\$ 75,571.83	\$ 11,335.77	\$ -	\$ 64,236.06
Teva	2033	July	\$ 8,569.75	\$ -	\$ 34,861.70	\$ 8,569.75
Walgreens	2033	December	\$ 83,668.09	\$ -	\$ -	\$ 83,668.09
Distributors	2034	July	\$ 75,571.83	\$ 11,335.77	\$ -	\$ 64,236.06
Teva	2034	July	\$ 8,569.75	\$ -	\$ 34,861.70	\$ 8,569.75
Walgreens	2034	December	\$ 83,668.09	\$ -	\$ -	\$ 83,668.09
Distributors	2035	July	\$ 75,571.83	\$ 11,335.77	\$ -	\$ 64,236.06
Teva	2035	July	\$ 40,125.82	\$ -	\$ -	\$ 40,125.82
Walgreens	2035	December	\$ 83,668.09	\$ -	\$ -	\$ 83,668.09
Distributors	2036	July	\$ 75,571.83	\$ 11,335.77	\$ -	\$ 64,236.06
Teva	2036	July	\$ 40,125.82	\$ -	\$ -	\$ 40,125.82
Walgreens	2036	December	\$ 83,668.09	\$ -	\$ -	\$ 83,668.09
Distributors	2037	July	\$ 75,571.83	\$ 11,335.77	\$ -	\$ 64,236.06
Teva	2037	July	\$ 51,590.35	\$ -	\$ -	\$ 51,590.35
Walgreens	2037	December	\$ 83,668.09	\$ -	\$ -	\$ 83,668.09
Distributors	2038	July	\$ 75,571.83	\$ 11,335.77	\$ -	\$ 64,236.06
Teva	2038	July	\$ 51,590.35	\$ -	\$ -	\$ 51,590.35
Teva	2039	July	\$ 51,590.35	\$ -	\$ -	\$ 51,590.35
Teva	2040	July	\$ 51,590.35	\$ -	\$ -	\$ 51,590.35
Teva	2041	July	\$ 51,590.35	\$ -	\$ -	\$ 51,590.35
Teva	2041	July	\$ 154,771.04	\$ -	\$ -	\$ 154,771.04
Teva	2042	July	\$ 154,771.04	\$ -	\$ -	\$ 154,771.04
		TOTAL	\$ 5,072,018.98	\$ 347,564.22	\$ 1,029,751.04	\$ 4,724,454.76

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Boulder City - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation	
Janssen - J&J	2022	July	\$ 35,226.81	\$ 5,284.02	\$ -	\$ 29,942.79	
Distributors	2022	August	\$ 8,215.83	\$ 1,232.37	\$ -	\$ 6,983.46	
Distributors	2022	September	\$ 8,634.44	\$ 1,295.17	\$ -	\$ 7,339.27	
American Drug Stores	2022	December	\$ 1,245.18	\$ 311.30	\$ -	\$ 933.88	
Mallinckrodt (BK)	2022	December	\$ 1,535.50	\$ 383.88	\$ -	\$ 1,151.62	
Distributors	2023	July	\$ 8,634.44	\$ 1,295.17	\$ -	\$ 7,339.27	
Allergan	2023	July	\$ 3,143.65	\$ 391.59	\$ 2,760.27	\$ 2,752.06	
CVS	2023	August	\$ 10,112.94	\$ -	\$ 13,558.63	\$ 10,112.94	
Mallinckrodt (BK)	2023	September	\$ -	\$ (383.88)	\$ -	\$ 383.88	
Walmart	2023	September	\$ 26,755.63	\$ -	\$ 3,575.96	\$ 26,755.63	
Walgreens	2023	December	\$ 7,390.93	\$ -	\$ -	\$ 7,390.93	
Distributors	2024	July	\$ 10,807.22	\$ 1,621.08	\$ -	\$ 9,186.14	
Allergan	2024	July	\$ 3,143.65	\$ 391.59	\$ -	\$ 2,752.06	
Teva	2024	July	\$ 2,714.24	\$ -	\$ -	\$ 2,714.24	
CVS	2024	August	\$ 10,112.94	\$ -	\$ 13,558.63	\$ 10,112.94	
Purdue (BK)	2024	July	\$ 46,486.72	\$ 11,621.68	\$ -	\$ 34,865.04	
Walgreens	2024	December	\$ 7,390.93	\$ -	\$ 14,786.51	\$ 7,390.93	
Janssen - J&J	2025	April	\$ 2,220.94	\$ 333.14	\$ -	\$ 1,887.80	
Distributors	2025	July	\$ 10,807.22	\$ 1,621.08	\$ -	\$ 9,186.14	
Allergan	2025	July	\$ 3,143.65	\$ 391.59	\$ -	\$ 2,752.06	
Teva	2025	July	\$ 2,714.24	\$ -	\$ -	\$ 2,714.24	
CVS	2025	August	\$ 10,112.94	\$ -	\$ 13,558.63	\$ 10,112.94	
Walgreens	2025	December	\$ 7,390.93	\$ -	\$ 14,786.51	\$ 7,390.93	
Distributors	2026	July	\$ 10,807.22	\$ 1,621.08	\$ -	\$ 9,186.14	
Allergan	2026	July	\$ 3,143.65	\$ 391.59	\$ -	\$ 2,752.06	
Teva	2026	July	\$ 2,714.24	\$ -	\$ -	\$ 2,714.24	
CVS	2026	August	\$ 12,202.76	\$ -	\$ -	\$ 12,202.76	
Walgreens	2026	December	\$ 11,829.21	\$ -	\$ 14,786.51	\$ 11,829.21	
Distributors	2027	July	\$ 10,807.22	\$ 1,621.08	\$ -	\$ 9,186.14	
Allergan	2027	July	\$ 3,143.65	\$ 391.59	\$ -	\$ 2,752.06	
Teva	2027	July	\$ 1,211.61	\$ -	\$ 4,928.84	\$ 1,211.61	
CVS	2027	August	\$ 12,202.76	\$ -	\$ -	\$ 12,202.76	
Walgreens	2027	December	\$ 11,829.21	\$ -	\$ 14,786.51	\$ 11,829.21	
Distributors	2028	July	\$ 12,710.60	\$ 1,906.59	\$ -	\$ 10,804.01	
Allergan	2028	July	\$ 3,143.65	\$ 391.59	\$ -	\$ 2,752.06	
Teva	2028	July	\$ 1,211.61	\$ -	\$ 4,928.84	\$ 1,211.61	
CVS	2028	August	\$ 12,202.76	\$ -	\$ -	\$ 12,202.76	
Walgreens	2028	December	\$ 11,829.21	\$ -	\$ -	\$ 11,829.21	
Distributors	2029	July	\$ 12,710.60	\$ 1,906.59	\$ -	\$ 10,804.01	
Allergan	2029	July	\$ 3,143.65	\$ 391.59	\$ -	\$ 2,752.06	
Teva	2029	July	\$ 1,211.61	\$ -	\$ 4,928.84	\$ 1,211.61	
CVS	2029	August	\$ 12,202.76	\$ -	\$ -	\$ 12,202.76	
Walgreens	2029	December	\$ 11,829.21	\$ -	\$ -	\$ 11,829.21	
Distributors	2030	July	\$ 12,710.60	\$ 1,906.59	\$ -	\$ 10,804.01	
Teva	2030	July	\$ 1,211.61	\$ -	\$ 4,928.84	\$ 1,211.61	
CVS	2030	August	\$ 12,202.76	\$ -	\$ -	\$ 12,202.76	
Walgreens	2030	December	\$ 11,829.21	\$ -	\$ -	\$ 11,829.21	
Distributors	2031	July	\$ 10,684.54	\$ 1,602.68	\$ -	\$ 9,081.86	
Teva	2031	July	\$ 1,211.61	\$ -	\$ 4,928.84	\$ 1,211.61	
CVS	2031	August	\$ 12,202.76	\$ -	\$ -	\$ 12,202.76	
Walgreens	2031	December	\$ 11,829.21	\$ -	\$ -	\$ 11,829.21	
Distributors	2032	July	\$ 10,684.54	\$ 1,602.68	\$ -	\$ 9,081.86	
Teva	2032	July	\$ 1,211.61	\$ -	\$ 4,928.84	\$ 1,211.61	
CVS	2032	August	\$ 12,202.76	\$ -	\$ -	\$ 12,202.76	
Walgreens	2032	December	\$ 11,829.21	\$ -	\$ -	\$ 11,829.21	
Distributors	2033	July	\$ 10,684.54	\$ 1,602.68	\$ -	\$ 9,081.86	
Teva	2033	July	\$ 1,211.61	\$ -	\$ 4,928.84	\$ 1,211.61	
Walgreens	2033	December	\$ 11,829.21	\$ -	\$ -	\$ 11,829.21	
Distributors	2034	July	\$ 10,684.54	\$ 1,602.68	\$ -	\$ 9,081.86	
Teva	2034	July	\$ 1,211.61	\$ -	\$ 4,928.84	\$ 1,211.61	
Walgreens	2034	December	\$ 11,829.21	\$ -	\$ -	\$ 11,829.21	
Distributors	2035	July	\$ 10,684.54	\$ 1,602.68	\$ -	\$ 9,081.86	
Teva	2035	July	\$ 5,673.09	\$ -	\$ -	\$ 5,673.09	
Walgreens	2035	December	\$ 11,829.21	\$ -	\$ -	\$ 11,829.21	
Distributors	2036	July	\$ 10,684.54	\$ 1,602.68	\$ -	\$ 9,081.86	
Teva	2036	July	\$ 5,673.09	\$ -	\$ -	\$ 5,673.09	
Walgreens	2036	December	\$ 11,829.21	\$ -	\$ -	\$ 11,829.21	
Distributors	2037	July	\$ 10,684.54	\$ 1,602.68	\$ -	\$ 9,081.86	
Teva	2037	July	\$ 7,293.98	\$ -	\$ -	\$ 7,293.98	
Walgreens	2037	December	\$ 11,829.21	\$ -	\$ -	\$ 11,829.21	
Distributors	2038	July	\$ 10,684.54	\$ 1,602.68	\$ -	\$ 9,081.86	
Teva	2038	July	\$ 7,293.98	\$ -	\$ -	\$ 7,293.98	
Teva	2039	July	\$ 7,293.98	\$ -	\$ -	\$ 7,293.98	
Teva	2040	July	\$ 7,293.98	\$ -	\$ -	\$ 7,293.98	
Teva	2041	July	\$ 7,293.98	\$ -	\$ -	\$ 7,293.98	
Teva	2041	July	\$ 21,881.93	\$ -	\$ -	\$ 21,881.93	
Teva	2042	July	\$ 21,881.93	\$ -	\$ -	\$ 21,881.93	
			TOTAL	\$ 717,095.03	\$ 49,139.51	\$ 145,588.87	\$ 667,955.52

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Ely City - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation	
Janssen - J&J	2022	July	\$ 1,576.46	\$ 236.47	\$ -	\$ 1,339.99	
Distributors	2022	August	\$ 367.67	\$ 55.15	\$ -	\$ 312.52	
Distributors	2022	September	\$ 386.41	\$ 57.96	\$ -	\$ 328.45	
American Drug Stores	2022	December	\$ 55.72	\$ 13.93	\$ -	\$ 41.79	
Mallinckrodt (BK)	2022	December	\$ 68.72	\$ 17.18	\$ -	\$ 51.54	
Distributors	2023	July	\$ 386.41	\$ 57.96	\$ -	\$ 328.45	
Allergan	2023	July	\$ 140.68	\$ 17.52	\$ 123.53	\$ 123.16	
CVS	2023	August	\$ 452.58	\$ -	\$ 606.77	\$ 452.58	
Mallinckrodt (BK)	2023	September	\$ -	\$ (17.18)	\$ -	\$ 17.18	
Walmart	2023	September	\$ 1,197.36	\$ -	\$ 160.03	\$ 1,197.36	
Walgreens	2023	December	\$ 330.76	\$ -	\$ -	\$ 330.76	
Distributors	2024	July	\$ 483.64	\$ 72.55	\$ -	\$ 411.09	
Allergan	2024	July	\$ 140.68	\$ 17.52	\$ -	\$ 123.16	
Teva	2024	July	\$ 121.47	\$ -	\$ -	\$ 121.47	
CVS	2024	August	\$ 452.58	\$ -	\$ 606.77	\$ 452.58	
Purdue (BK)	2024	July	\$ 2,080.37	\$ 520.09	\$ -	\$ 1,560.28	
Walgreens	2024	December	\$ 330.76	\$ -	\$ 661.73	\$ 330.76	
Janssen - J&J	2025	April	\$ 99.39	\$ 14.91	\$ -	\$ 84.48	
Distributors	2025	July	\$ 483.64	\$ 72.55	\$ -	\$ 411.09	
Allergan	2025	July	\$ 140.68	\$ 17.52	\$ -	\$ 123.16	
Teva	2025	July	\$ 121.47	\$ -	\$ -	\$ 121.47	
CVS	2025	August	\$ 452.58	\$ -	\$ 606.77	\$ 452.58	
Walgreens	2025	December	\$ 330.76	\$ -	\$ 661.73	\$ 330.76	
Distributors	2026	July	\$ 483.64	\$ 72.55	\$ -	\$ 411.09	
Allergan	2026	July	\$ 140.68	\$ 17.52	\$ -	\$ 123.16	
Teva	2026	July	\$ 121.47	\$ -	\$ -	\$ 121.47	
CVS	2026	August	\$ 546.10	\$ -	\$ -	\$ 546.10	
Walgreens	2026	December	\$ 529.38	\$ -	\$ 661.73	\$ 529.38	
Distributors	2027	July	\$ 483.64	\$ 72.55	\$ -	\$ 411.09	
Allergan	2027	July	\$ 140.68	\$ 17.52	\$ -	\$ 123.16	
Teva	2027	July	\$ 54.22	\$ -	\$ 220.58	\$ 54.22	
CVS	2027	August	\$ 546.10	\$ -	\$ -	\$ 546.10	
Walgreens	2027	December	\$ 529.38	\$ -	\$ 661.73	\$ 529.38	
Distributors	2028	July	\$ 568.82	\$ 85.32	\$ -	\$ 483.50	
Allergan	2028	July	\$ 140.68	\$ 17.52	\$ -	\$ 123.16	
Teva	2028	July	\$ 54.22	\$ -	\$ 220.58	\$ 54.22	
CVS	2028	August	\$ 546.10	\$ -	\$ -	\$ 546.10	
Walgreens	2028	December	\$ 529.38	\$ -	\$ -	\$ 529.38	
Distributors	2029	July	\$ 568.82	\$ 85.32	\$ -	\$ 483.50	
Allergan	2029	July	\$ 140.68	\$ 17.52	\$ -	\$ 123.16	
Teva	2029	July	\$ 54.22	\$ -	\$ 220.58	\$ 54.22	
CVS	2029	August	\$ 546.10	\$ -	\$ -	\$ 546.10	
Walgreens	2029	December	\$ 529.38	\$ -	\$ -	\$ 529.38	
Distributors	2030	July	\$ 568.82	\$ 85.32	\$ -	\$ 483.50	
Teva	2030	July	\$ 54.22	\$ -	\$ 220.58	\$ 54.22	
CVS	2030	August	\$ 546.10	\$ -	\$ -	\$ 546.10	
Walgreens	2030	December	\$ 529.38	\$ -	\$ -	\$ 529.38	
Distributors	2031	July	\$ 478.15	\$ 71.72	\$ -	\$ 406.43	
Teva	2031	July	\$ 54.22	\$ -	\$ 220.58	\$ 54.22	
CVS	2031	August	\$ 546.10	\$ -	\$ -	\$ 546.10	
Walgreens	2031	December	\$ 529.38	\$ -	\$ -	\$ 529.38	
Distributors	2032	July	\$ 478.15	\$ 71.72	\$ -	\$ 406.43	
Teva	2032	July	\$ 54.22	\$ -	\$ 220.58	\$ 54.22	
CVS	2032	August	\$ 546.10	\$ -	\$ -	\$ 546.10	
Walgreens	2032	December	\$ 529.38	\$ -	\$ -	\$ 529.38	
Distributors	2033	July	\$ 478.15	\$ 71.72	\$ -	\$ 406.43	
Teva	2033	July	\$ 54.22	\$ -	\$ 220.58	\$ 54.22	
Walgreens	2033	December	\$ 529.38	\$ -	\$ -	\$ 529.38	
Distributors	2034	July	\$ 478.15	\$ 71.72	\$ -	\$ 406.43	
Teva	2034	July	\$ 54.22	\$ -	\$ 220.58	\$ 54.22	
Walgreens	2034	December	\$ 529.38	\$ -	\$ -	\$ 529.38	
Distributors	2035	July	\$ 478.15	\$ 71.72	\$ -	\$ 406.43	
Teva	2035	July	\$ 253.88	\$ -	\$ -	\$ 253.88	
Walgreens	2035	December	\$ 529.38	\$ -	\$ -	\$ 529.38	
Distributors	2036	July	\$ 478.15	\$ 71.72	\$ -	\$ 406.43	
Teva	2036	July	\$ 253.88	\$ -	\$ -	\$ 253.88	
Walgreens	2036	December	\$ 529.38	\$ -	\$ -	\$ 529.38	
Distributors	2037	July	\$ 478.15	\$ 71.72	\$ -	\$ 406.43	
Teva	2037	July	\$ 326.42	\$ -	\$ -	\$ 326.42	
Walgreens	2037	December	\$ 529.38	\$ -	\$ -	\$ 529.38	
Distributors	2038	July	\$ 478.15	\$ 71.72	\$ -	\$ 406.43	
Teva	2038	July	\$ 326.42	\$ -	\$ -	\$ 326.42	
Teva	2039	July	\$ 326.42	\$ -	\$ -	\$ 326.42	
Teva	2040	July	\$ 326.42	\$ -	\$ -	\$ 326.42	
Teva	2041	July	\$ 326.42	\$ -	\$ -	\$ 326.42	
Teva	2041	July	\$ 979.26	\$ -	\$ -	\$ 979.26	
Teva	2042	July	\$ 979.26	\$ -	\$ -	\$ 979.26	
			TOTAL	\$ 32,091.32	\$ 2,199.03	\$ 6,515.37	\$ 29,892.29

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Fernley City - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation	
Janssen - J&J	2022	July	\$ 3,442.66	\$ 516.40	\$ -	\$ 2,926.26	
Distributors	2022	August	\$ 802.92	\$ 120.44	\$ -	\$ 682.48	
Distributors	2022	September	\$ 843.83	\$ 126.57	\$ -	\$ 717.26	
American Drug Stores	2022	December	\$ 121.69	\$ 30.42	\$ -	\$ 91.27	
Mallinckrodt (BK)	2022	December	\$ 150.06	\$ 37.52	\$ -	\$ 112.54	
Distributors	2023	July	\$ 843.83	\$ 126.57	\$ -	\$ 717.26	
Allergan	2023	July	\$ 307.22	\$ 38.27	\$ 269.75	\$ 268.95	
CVS	2023	August	\$ 988.33	\$ -	\$ 1,325.06	\$ 988.33	
Mallinckrodt (BK)	2023	September	\$ -	\$ (37.52)	\$ -	\$ 37.52	
Walmart	2023	September	\$ 2,614.78	\$ -	\$ 349.47	\$ 2,614.78	
Walgreens	2023	December	\$ 722.30	\$ -	\$ -	\$ 722.30	
Distributors	2024	July	\$ 1,056.17	\$ 158.43	\$ -	\$ 897.74	
Allergan	2024	July	\$ 307.22	\$ 38.27	\$ -	\$ 268.95	
Teva	2024	July	\$ 265.26	\$ -	\$ -	\$ 265.26	
CVS	2024	August	\$ 988.33	\$ -	\$ 1,325.06	\$ 988.33	
Purdue (BK)	2024	July	\$ 4,543.07	\$ 1,135.77	\$ -	\$ 3,407.30	
Walgreens	2024	December	\$ 722.30	\$ -	\$ 1,445.06	\$ 722.30	
Janssen - J&J	2025	April	\$ 217.05	\$ 32.56	\$ -	\$ 184.49	
Distributors	2025	July	\$ 1,056.17	\$ 158.43	\$ -	\$ 897.74	
Allergan	2025	July	\$ 307.22	\$ 38.27	\$ -	\$ 268.95	
Teva	2025	July	\$ 265.26	\$ -	\$ -	\$ 265.26	
CVS	2025	August	\$ 988.33	\$ -	\$ 1,325.06	\$ 988.33	
Walgreens	2025	December	\$ 722.30	\$ -	\$ 1,445.06	\$ 722.30	
Distributors	2026	July	\$ 1,056.17	\$ 158.43	\$ -	\$ 897.74	
Allergan	2026	July	\$ 307.22	\$ 38.27	\$ -	\$ 268.95	
Teva	2026	July	\$ 265.26	\$ -	\$ -	\$ 265.26	
CVS	2026	August	\$ 1,192.56	\$ -	\$ -	\$ 1,192.56	
Walgreens	2026	December	\$ 1,156.05	\$ -	\$ 1,445.06	\$ 1,156.05	
Distributors	2027	July	\$ 1,056.17	\$ 158.43	\$ -	\$ 897.74	
Allergan	2027	July	\$ 307.22	\$ 38.27	\$ -	\$ 268.95	
Teva	2027	July	\$ 118.41	\$ -	\$ 481.69	\$ 118.41	
CVS	2027	August	\$ 1,192.56	\$ -	\$ -	\$ 1,192.56	
Walgreens	2027	December	\$ 1,156.05	\$ -	\$ 1,445.06	\$ 1,156.05	
Distributors	2028	July	\$ 1,242.18	\$ 186.33	\$ -	\$ 1,055.85	
Allergan	2028	July	\$ 307.22	\$ 38.27	\$ -	\$ 268.95	
Teva	2028	July	\$ 118.41	\$ -	\$ 481.69	\$ 118.41	
CVS	2028	August	\$ 1,192.56	\$ -	\$ -	\$ 1,192.56	
Walgreens	2028	December	\$ 1,156.05	\$ -	\$ -	\$ 1,156.05	
Distributors	2029	July	\$ 1,242.18	\$ 186.33	\$ -	\$ 1,055.85	
Allergan	2029	July	\$ 307.22	\$ 38.27	\$ -	\$ 268.95	
Teva	2029	July	\$ 118.41	\$ -	\$ 481.69	\$ 118.41	
CVS	2029	August	\$ 1,192.56	\$ -	\$ -	\$ 1,192.56	
Walgreens	2029	December	\$ 1,156.05	\$ -	\$ -	\$ 1,156.05	
Distributors	2030	July	\$ 1,242.18	\$ 186.33	\$ -	\$ 1,055.85	
Teva	2030	July	\$ 118.41	\$ -	\$ 481.69	\$ 118.41	
CVS	2030	August	\$ 1,192.56	\$ -	\$ -	\$ 1,192.56	
Walgreens	2030	December	\$ 1,156.05	\$ -	\$ -	\$ 1,156.05	
Distributors	2031	July	\$ 1,044.18	\$ 156.63	\$ -	\$ 887.55	
Teva	2031	July	\$ 118.41	\$ -	\$ 481.69	\$ 118.41	
CVS	2031	August	\$ 1,192.56	\$ -	\$ -	\$ 1,192.56	
Walgreens	2031	December	\$ 1,156.05	\$ -	\$ -	\$ 1,156.05	
Distributors	2032	July	\$ 1,044.18	\$ 156.63	\$ -	\$ 887.55	
Teva	2032	July	\$ 118.41	\$ -	\$ 481.69	\$ 118.41	
CVS	2032	August	\$ 1,192.56	\$ -	\$ -	\$ 1,192.56	
Walgreens	2032	December	\$ 1,156.05	\$ -	\$ -	\$ 1,156.05	
Distributors	2033	July	\$ 1,044.18	\$ 156.63	\$ -	\$ 887.55	
Teva	2033	July	\$ 118.41	\$ -	\$ 481.69	\$ 118.41	
Walgreens	2033	December	\$ 1,156.05	\$ -	\$ -	\$ 1,156.05	
Distributors	2034	July	\$ 1,044.18	\$ 156.63	\$ -	\$ 887.55	
Teva	2034	July	\$ 118.41	\$ -	\$ 481.69	\$ 118.41	
Walgreens	2034	December	\$ 1,156.05	\$ -	\$ -	\$ 1,156.05	
Distributors	2035	July	\$ 1,044.18	\$ 156.63	\$ -	\$ 887.55	
Teva	2035	July	\$ 554.42	\$ -	\$ -	\$ 554.42	
Walgreens	2035	December	\$ 1,156.05	\$ -	\$ -	\$ 1,156.05	
Distributors	2036	July	\$ 1,044.18	\$ 156.63	\$ -	\$ 887.55	
Teva	2036	July	\$ 554.42	\$ -	\$ -	\$ 554.42	
Walgreens	2036	December	\$ 1,156.05	\$ -	\$ -	\$ 1,156.05	
Distributors	2037	July	\$ 1,044.18	\$ 156.63	\$ -	\$ 887.55	
Teva	2037	July	\$ 712.83	\$ -	\$ -	\$ 712.83	
Walgreens	2037	December	\$ 1,156.05	\$ -	\$ -	\$ 1,156.05	
Distributors	2038	July	\$ 1,044.18	\$ 156.63	\$ -	\$ 887.55	
Teva	2038	July	\$ 712.83	\$ -	\$ -	\$ 712.83	
Teva	2039	July	\$ 712.83	\$ -	\$ -	\$ 712.83	
Teva	2040	July	\$ 712.83	\$ -	\$ -	\$ 712.83	
Teva	2041	July	\$ 712.83	\$ -	\$ -	\$ 712.83	
Teva	2041	July	\$ 2,138.48	\$ -	\$ -	\$ 2,138.48	
Teva	2042	July	\$ 2,138.48	\$ -	\$ -	\$ 2,138.48	
			TOTAL	\$ 70,080.51	\$ 4,802.37	\$ 14,228.14	\$ 65,278.14

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Henderson City - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 548,431.44	\$ 82,264.72	\$ -	\$ 466,166.72
Distributors	2022	August	\$ 127,908.84	\$ 19,186.33	\$ -	\$ 108,722.51
Distributors	2022	September	\$ 134,425.95	\$ 20,163.89	\$ -	\$ 114,262.06
American Drug Stores	2022	December	\$ 19,385.68	\$ 4,846.42	\$ -	\$ 14,539.26
Mallinckrodt (BK)	2022	December	\$ 23,905.57	\$ 5,976.39	\$ -	\$ 17,929.18
Distributors	2023	July	\$ 134,425.95	\$ 20,163.89	\$ -	\$ 114,262.06
Allergan	2023	July	\$ 48,942.23	\$ 6,096.50	\$ 42,973.41	\$ 42,845.73
CVS	2023	August	\$ 157,444.21	\$ -	\$ 211,088.56	\$ 157,444.21
Mallinckrodt (BK)	2023	September	\$ -	\$ (5,976.39)	\$ -	\$ 5,976.39
Walmart	2023	September	\$ 416,547.14	\$ -	\$ 55,672.58	\$ 416,547.14
Walgreens	2023	December	\$ 115,066.27	\$ -	\$ -	\$ 115,066.27
Distributors	2024	July	\$ 168,253.12	\$ 25,237.97	\$ -	\$ 143,015.15
Allergan	2024	July	\$ 48,942.23	\$ 6,096.50	\$ -	\$ 42,845.73
Teva	2024	July	\$ 42,256.83	\$ -	\$ -	\$ 42,256.83
CVS	2024	August	\$ 157,444.21	\$ -	\$ 211,088.56	\$ 157,444.21
Purdue (BK)	2024	July	\$ 723,732.21	\$ 180,933.05	\$ -	\$ 542,799.16
Walgreens	2024	December	\$ 115,066.27	\$ -	\$ 230,205.00	\$ 115,066.27
Janssen - J&J	2025	April	\$ 34,576.82	\$ 5,186.52	\$ -	\$ 29,390.30
Distributors	2025	July	\$ 168,253.12	\$ 25,237.97	\$ -	\$ 143,015.15
Allergan	2025	July	\$ 48,942.23	\$ 6,096.50	\$ -	\$ 42,845.73
Teva	2025	July	\$ 42,256.83	\$ -	\$ -	\$ 42,256.83
CVS	2025	August	\$ 157,444.21	\$ -	\$ 211,088.56	\$ 157,444.21
Walgreens	2025	December	\$ 115,066.27	\$ -	\$ 230,205.00	\$ 115,066.27
Distributors	2026	July	\$ 168,253.12	\$ 25,237.97	\$ -	\$ 143,015.15
Allergan	2026	July	\$ 48,942.23	\$ 6,096.50	\$ -	\$ 42,845.73
Teva	2026	July	\$ 42,256.83	\$ -	\$ -	\$ 42,256.83
CVS	2026	August	\$ 189,979.71	\$ -	\$ -	\$ 189,979.71
Walgreens	2026	December	\$ 184,164.00	\$ -	\$ 230,205.00	\$ 184,164.00
Distributors	2027	July	\$ 168,253.12	\$ 25,237.97	\$ -	\$ 143,015.15
Allergan	2027	July	\$ 48,942.23	\$ 6,096.50	\$ -	\$ 42,845.73
Teva	2027	July	\$ 18,863.09	\$ -	\$ 76,735.00	\$ 18,863.09
CVS	2027	August	\$ 189,979.71	\$ -	\$ -	\$ 189,979.71
Walgreens	2027	December	\$ 184,164.00	\$ -	\$ 230,205.00	\$ 184,164.00
Distributors	2028	July	\$ 197,885.94	\$ 29,682.89	\$ -	\$ 168,203.05
Allergan	2028	July	\$ 48,942.23	\$ 6,096.50	\$ -	\$ 42,845.73
Teva	2028	July	\$ 18,863.09	\$ -	\$ 76,735.00	\$ 18,863.09
CVS	2028	August	\$ 189,979.71	\$ -	\$ -	\$ 189,979.71
Walgreens	2028	December	\$ 184,164.00	\$ -	\$ -	\$ 184,164.00
Distributors	2029	July	\$ 197,885.94	\$ 29,682.89	\$ -	\$ 168,203.05
Allergan	2029	July	\$ 48,942.23	\$ 6,096.50	\$ -	\$ 42,845.73
Teva	2029	July	\$ 18,863.09	\$ -	\$ 76,735.00	\$ 18,863.09
CVS	2029	August	\$ 189,979.71	\$ -	\$ -	\$ 189,979.71
Walgreens	2029	December	\$ 184,164.00	\$ -	\$ -	\$ 184,164.00
Distributors	2030	July	\$ 197,885.94	\$ 29,682.89	\$ -	\$ 168,203.05
Teva	2030	July	\$ 18,863.09	\$ -	\$ 76,735.00	\$ 18,863.09
CVS	2030	August	\$ 189,979.71	\$ -	\$ -	\$ 189,979.71
Walgreens	2030	December	\$ 184,164.00	\$ -	\$ -	\$ 184,164.00
Distributors	2031	July	\$ 166,343.11	\$ 24,951.47	\$ -	\$ 141,391.64
CVS	2031	July	\$ 18,863.09	\$ -	\$ 76,735.00	\$ 18,863.09
Teva	2031	August	\$ 189,979.71	\$ -	\$ -	\$ 189,979.71
Walgreens	2031	December	\$ 184,164.00	\$ -	\$ -	\$ 184,164.00
Distributors	2032	July	\$ 166,343.11	\$ 24,951.47	\$ -	\$ 141,391.64
Teva	2032	July	\$ 18,863.09	\$ -	\$ 76,735.00	\$ 18,863.09
CVS	2032	August	\$ 189,979.71	\$ -	\$ -	\$ 189,979.71
Walgreens	2032	December	\$ 184,164.00	\$ -	\$ -	\$ 184,164.00
Distributors	2033	July	\$ 166,343.11	\$ 24,951.47	\$ -	\$ 141,391.64
Teva	2033	July	\$ 18,863.09	\$ -	\$ 76,735.00	\$ 18,863.09
Walgreens	2033	December	\$ 184,164.00	\$ -	\$ -	\$ 184,164.00
Distributors	2034	July	\$ 166,343.11	\$ 24,951.47	\$ -	\$ 141,391.64
Teva	2034	July	\$ 18,863.09	\$ -	\$ 76,735.00	\$ 18,863.09
Walgreens	2034	December	\$ 184,164.00	\$ -	\$ -	\$ 184,164.00
Distributors	2035	July	\$ 166,343.11	\$ 24,951.47	\$ -	\$ 141,391.64
Teva	2035	July	\$ 88,321.99	\$ -	\$ -	\$ 88,321.99
Walgreens	2035	December	\$ 184,164.00	\$ -	\$ -	\$ 184,164.00
Distributors	2036	July	\$ 166,343.11	\$ 24,951.47	\$ -	\$ 141,391.64
Teva	2036	July	\$ 88,321.99	\$ -	\$ -	\$ 88,321.99
Walgreens	2036	December	\$ 184,164.00	\$ -	\$ -	\$ 184,164.00
Distributors	2037	July	\$ 166,343.11	\$ 24,951.47	\$ -	\$ 141,391.64
Teva	2037	July	\$ 113,556.85	\$ -	\$ -	\$ 113,556.85
Walgreens	2037	December	\$ 184,164.00	\$ -	\$ -	\$ 184,164.00
Distributors	2038	July	\$ 166,343.11	\$ 24,951.47	\$ -	\$ 141,391.64
Teva	2038	July	\$ 113,556.85	\$ -	\$ -	\$ 113,556.85
Teva	2039	July	\$ 113,556.85	\$ -	\$ -	\$ 113,556.85
Teva	2040	July	\$ 113,556.85	\$ -	\$ -	\$ 113,556.85
Teva	2041	July	\$ 113,556.85	\$ -	\$ -	\$ 113,556.85
Teva	2041	July	\$ 340,670.54	\$ -	\$ -	\$ 340,670.54
Teva	2042	July	\$ 340,670.54	\$ -	\$ -	\$ 340,670.54
TOTAL			\$ 11,164,152.32	\$ 765,032.63	\$ 2,266,611.67	\$ 10,399,119.69

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)						
Las Vegas City - Actual and Estimated Allocations						
(assumes no default in payments)						
(CMS Medicaid costs, if any, not deducted)						
(assumes no administrative fees for court appointed third-party administrators)						
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 1,124,633.49	\$ 168,695.02	\$ -	\$ 955,938.47
Distributors	2022	August	\$ 262,294.52	\$ 39,344.18	\$ -	\$ 222,950.34
Distributors	2022	September	\$ 275,658.75	\$ 41,348.81	\$ -	\$ 234,309.94
American Drug Stores	2022	December	\$ 99,752.99	\$ 9,938.25	\$ -	\$ 29,814.74
Mallinckrodt (BK)	2022	December	\$ 49,021.63	\$ 12,255.41	\$ -	\$ 36,766.22
Distributors	2023	July	\$ 275,658.75	\$ 41,348.81	\$ -	\$ 234,309.94
Allergan	2023	July	\$ 100,362.72	\$ 12,501.70	\$ 88,122.84	\$ 87,861.02
CVS	2023	August	\$ 322,860.83	\$ -	\$ 432,865.89	\$ 322,860.83
Mallinckrodt (BK)	2023	September	\$ -	\$ (12,255.41)	\$ -	\$ 12,255.41
Walmart	2023	September	\$ 854,186.73	\$ -	\$ 114,164.21	\$ 854,186.73
Walgreens	2023	December	\$ 235,959.08	\$ -	\$ -	\$ 235,959.08
Distributors	2024	July	\$ 345,025.98	\$ 51,753.90	\$ -	\$ 293,272.08
Allergan	2024	July	\$ 100,362.72	\$ 12,501.70	\$ -	\$ 87,861.02
Teva	2024	July	\$ 86,653.40	\$ -	\$ -	\$ 86,653.40
CVS	2024	August	\$ 322,860.83	\$ -	\$ 432,865.89	\$ 322,860.83
Purdue (BK)	2024	July	\$ 1,484,111.63	\$ 371,027.91	\$ -	\$ 1,113,083.72
Walgreens	2024	December	\$ 235,959.08	\$ -	\$ 472,066.76	\$ 235,959.08
Janssen - J&J	2025	April	\$ 70,904.48	\$ 10,635.67	\$ -	\$ 60,268.81
Distributors	2025	July	\$ 345,025.98	\$ 51,753.90	\$ -	\$ 293,272.08
Allergan	2025	July	\$ 100,362.72	\$ 12,501.70	\$ -	\$ 87,861.02
Teva	2025	July	\$ 86,653.40	\$ -	\$ -	\$ 86,653.40
CVS	2025	August	\$ 322,860.83	\$ -	\$ 432,865.89	\$ 322,860.83
Walgreens	2025	December	\$ 235,959.08	\$ -	\$ 472,066.76	\$ 235,959.08
Distributors	2026	July	\$ 345,025.98	\$ 51,753.90	\$ -	\$ 293,272.08
Allergan	2026	July	\$ 100,362.72	\$ 12,501.70	\$ -	\$ 87,861.02
Teva	2026	July	\$ 86,653.40	\$ -	\$ -	\$ 86,653.40
CVS	2026	August	\$ 389,579.30	\$ -	\$ -	\$ 389,579.30
Walgreens	2026	December	\$ 377,653.41	\$ -	\$ 472,066.76	\$ 377,653.41
Distributors	2027	July	\$ 345,025.98	\$ 51,753.90	\$ -	\$ 293,272.08
Allergan	2027	July	\$ 100,362.72	\$ 12,501.70	\$ -	\$ 87,861.02
Teva	2027	July	\$ 38,681.34	\$ -	\$ 157,355.59	\$ 38,681.34
CVS	2027	August	\$ 389,579.30	\$ -	\$ -	\$ 389,579.30
Walgreens	2027	December	\$ 377,653.41	\$ -	\$ 472,066.76	\$ 377,653.41
Distributors	2028	July	\$ 405,792.12	\$ 60,868.82	\$ -	\$ 344,923.30
Allergan	2028	July	\$ 100,362.72	\$ 12,501.70	\$ -	\$ 87,861.02
Teva	2028	July	\$ 38,681.34	\$ -	\$ 157,355.59	\$ 38,681.34
CVS	2028	August	\$ 389,579.30	\$ -	\$ -	\$ 389,579.30
Walgreens	2028	December	\$ 377,653.41	\$ -	\$ -	\$ 377,653.41
Distributors	2029	July	\$ 405,792.12	\$ 60,868.82	\$ -	\$ 344,923.30
Allergan	2029	July	\$ 100,362.72	\$ 12,501.70	\$ -	\$ 87,861.02
Teva	2029	July	\$ 38,681.34	\$ -	\$ 157,355.59	\$ 38,681.34
CVS	2029	August	\$ 389,579.30	\$ -	\$ -	\$ 389,579.30
Walgreens	2029	December	\$ 377,653.41	\$ -	\$ -	\$ 377,653.41
Distributors	2030	July	\$ 405,792.12	\$ 60,868.82	\$ -	\$ 344,923.30
Teva	2030	July	\$ 38,681.34	\$ -	\$ 157,355.59	\$ 38,681.34
CVS	2030	August	\$ 389,579.30	\$ -	\$ -	\$ 389,579.30
Walgreens	2030	December	\$ 377,653.41	\$ -	\$ -	\$ 377,653.41
Distributors	2031	July	\$ 341,109.23	\$ 51,166.38	\$ -	\$ 289,942.85
Teva	2031	July	\$ 38,681.34	\$ -	\$ 157,355.59	\$ 38,681.34
CVS	2031	August	\$ 389,579.30	\$ -	\$ -	\$ 389,579.30
Walgreens	2031	December	\$ 377,653.41	\$ -	\$ -	\$ 377,653.41
Distributors	2032	July	\$ 341,109.23	\$ 51,166.38	\$ -	\$ 289,942.85
Teva	2032	July	\$ 38,681.34	\$ -	\$ 157,355.59	\$ 38,681.34
CVS	2032	August	\$ 389,579.30	\$ -	\$ -	\$ 389,579.30
Walgreens	2032	December	\$ 377,653.41	\$ -	\$ -	\$ 377,653.41
Distributors	2033	July	\$ 341,109.23	\$ 51,166.38	\$ -	\$ 289,942.85
Teva	2033	July	\$ 38,681.34	\$ -	\$ 157,355.59	\$ 38,681.34
Walgreens	2033	December	\$ 377,653.41	\$ -	\$ -	\$ 377,653.41
Distributors	2034	July	\$ 341,109.23	\$ 51,166.38	\$ -	\$ 289,942.85
Teva	2034	July	\$ 38,681.34	\$ -	\$ 157,355.59	\$ 38,681.34
Walgreens	2034	December	\$ 377,653.41	\$ -	\$ -	\$ 377,653.41
Distributors	2035	July	\$ 341,109.23	\$ 51,166.38	\$ -	\$ 289,942.85
Teva	2035	July	\$ 181,116.29	\$ -	\$ -	\$ 181,116.29
Walgreens	2035	December	\$ 377,653.41	\$ -	\$ -	\$ 377,653.41
Distributors	2036	July	\$ 341,109.23	\$ 51,166.38	\$ -	\$ 289,942.85
Teva	2036	July	\$ 181,116.29	\$ -	\$ -	\$ 181,116.29
Walgreens	2036	December	\$ 377,653.41	\$ -	\$ -	\$ 377,653.41
Distributors	2037	July	\$ 341,109.23	\$ 51,166.38	\$ -	\$ 289,942.85
Teva	2037	July	\$ 232,863.80	\$ -	\$ -	\$ 232,863.80
Walgreens	2037	December	\$ 377,653.41	\$ -	\$ -	\$ 377,653.41
Distributors	2038	July	\$ 341,109.23	\$ 51,166.38	\$ -	\$ 289,942.85
Teva	2038	July	\$ 232,863.80	\$ -	\$ -	\$ 232,863.80
Teva	2039	July	\$ 232,863.80	\$ -	\$ -	\$ 232,863.80
Teva	2040	July	\$ 232,863.80	\$ -	\$ -	\$ 232,863.80
Teva	2041	July	\$ 698,591.41	\$ -	\$ -	\$ 698,591.41
Teva	2042	July	\$ 698,591.41	\$ -	\$ -	\$ 698,591.41
			TOTAL	\$ 1,568,803.65	\$ 4,647,996.44	\$ 21,324,813.55

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Mesquite City - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 34,903.03	\$ 5,235.45	\$ -	\$ 29,667.58
Distributors	2022	August	\$ 8,140.32	\$ 1,221.05	\$ -	\$ 6,919.27
Distributors	2022	September	\$ 8,555.08	\$ 1,283.26	\$ -	\$ 7,271.82
American Drug Stores	2022	December	\$ 1,233.74	\$ 308.44	\$ -	\$ 925.30
Mallinckrodt (BK)	2022	December	\$ 1,521.39	\$ 380.35	\$ -	\$ 1,141.04
Distributors	2023	July	\$ 8,555.08	\$ 1,283.26	\$ -	\$ 7,271.82
Allergan	2023	July	\$ 3,114.76	\$ 387.99	\$ 2,734.90	\$ 2,726.77
CVS	2023	August	\$ 10,019.99	\$ -	\$ 13,434.00	\$ 10,019.99
Mallinckrodt (BK)	2023	September	\$ -	\$ (380.35)	\$ -	\$ 380.35
Walmart	2023	September	\$ 26,509.71	\$ -	\$ 3,543.09	\$ 26,509.71
Walgreens	2023	December	\$ 7,322.99	\$ -	\$ -	\$ 7,322.99
Distributors	2024	July	\$ 10,707.89	\$ 1,606.18	\$ -	\$ 9,101.71
Allergan	2024	July	\$ 3,114.76	\$ 387.99	\$ -	\$ 2,726.77
Teva	2024	July	\$ 2,689.29	\$ -	\$ -	\$ 2,689.29
CVS	2024	August	\$ 10,019.99	\$ -	\$ 13,434.00	\$ 10,019.99
Purdue (BK)	2024	July	\$ 46,059.44	\$ 11,514.86	\$ -	\$ 34,544.58
Walgreens	2024	December	\$ 7,322.99	\$ -	\$ 14,650.60	\$ 7,322.99
Janssen - J&J	2025	April	\$ 2,200.52	\$ 330.08	\$ -	\$ 1,870.44
Distributors	2025	July	\$ 10,707.89	\$ 1,606.18	\$ -	\$ 9,101.71
Allergan	2025	July	\$ 3,114.76	\$ 387.99	\$ -	\$ 2,726.77
Teva	2025	July	\$ 2,689.29	\$ -	\$ -	\$ 2,689.29
CVS	2025	August	\$ 10,019.99	\$ -	\$ 13,434.00	\$ 10,019.99
Walgreens	2025	December	\$ 7,322.99	\$ -	\$ 14,650.60	\$ 7,322.99
Distributors	2026	July	\$ 10,707.89	\$ 1,606.18	\$ -	\$ 9,101.71
Allergan	2026	July	\$ 3,114.76	\$ 387.99	\$ -	\$ 2,726.77
Teva	2026	July	\$ 2,689.29	\$ -	\$ -	\$ 2,689.29
CVS	2026	August	\$ 12,090.60	\$ -	\$ -	\$ 12,090.60
Walgreens	2026	December	\$ 11,720.48	\$ -	\$ 14,650.60	\$ 11,720.48
Distributors	2027	July	\$ 10,707.89	\$ 1,606.18	\$ -	\$ 9,101.71
Allergan	2027	July	\$ 3,114.76	\$ 387.99	\$ -	\$ 2,726.77
Teva	2027	July	\$ 1,200.48	\$ -	\$ 4,883.54	\$ 1,200.48
CVS	2027	August	\$ 12,090.60	\$ -	\$ -	\$ 12,090.60
Walgreens	2027	December	\$ 11,720.48	\$ -	\$ 14,650.60	\$ 11,720.48
Distributors	2028	July	\$ 12,593.77	\$ 1,889.07	\$ -	\$ 10,704.70
Allergan	2028	July	\$ 3,114.76	\$ 387.99	\$ -	\$ 2,726.77
Teva	2028	July	\$ 1,200.48	\$ -	\$ 4,883.54	\$ 1,200.48
CVS	2028	August	\$ 12,090.60	\$ -	\$ -	\$ 12,090.60
Walgreens	2028	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Distributors	2029	July	\$ 12,593.77	\$ 1,889.07	\$ -	\$ 10,704.70
Allergan	2029	July	\$ 3,114.76	\$ 387.99	\$ -	\$ 2,726.77
Teva	2029	July	\$ 1,200.48	\$ -	\$ 4,883.54	\$ 1,200.48
CVS	2029	August	\$ 12,090.60	\$ -	\$ -	\$ 12,090.60
Walgreens	2029	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Distributors	2030	July	\$ 12,593.77	\$ 1,889.07	\$ -	\$ 10,704.70
Teva	2030	July	\$ 1,200.48	\$ -	\$ 4,883.54	\$ 1,200.48
CVS	2030	August	\$ 12,090.60	\$ -	\$ -	\$ 12,090.60
Walgreens	2030	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Distributors	2031	July	\$ 10,586.33	\$ 1,587.95	\$ -	\$ 8,998.38
Teva	2031	July	\$ 1,200.48	\$ -	\$ 4,883.54	\$ 1,200.48
CVS	2031	August	\$ 12,090.60	\$ -	\$ -	\$ 12,090.60
Walgreens	2031	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Distributors	2032	July	\$ 10,586.33	\$ 1,587.95	\$ -	\$ 8,998.38
Teva	2032	July	\$ 1,200.48	\$ -	\$ 4,883.54	\$ 1,200.48
CVS	2032	August	\$ 12,090.60	\$ -	\$ -	\$ 12,090.60
Walgreens	2032	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Distributors	2033	July	\$ 10,586.33	\$ 1,587.95	\$ -	\$ 8,998.38
Teva	2033	July	\$ 1,200.48	\$ -	\$ 4,883.54	\$ 1,200.48
CVS	2033	August	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Walgreens	2033	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Distributors	2034	July	\$ 10,586.33	\$ 1,587.95	\$ -	\$ 8,998.38
Teva	2034	July	\$ 1,200.48	\$ -	\$ 4,883.54	\$ 1,200.48
CVS	2034	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Walgreens	2034	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Distributors	2035	July	\$ 10,586.33	\$ 1,587.95	\$ -	\$ 8,998.38
Teva	2035	July	\$ 5,620.95	\$ -	\$ -	\$ 5,620.95
CVS	2035	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Walgreens	2035	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Distributors	2036	July	\$ 10,586.33	\$ 1,587.95	\$ -	\$ 8,998.38
Teva	2036	July	\$ 5,620.95	\$ -	\$ -	\$ 5,620.95
CVS	2036	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Walgreens	2036	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Distributors	2037	July	\$ 10,586.33	\$ 1,587.95	\$ -	\$ 8,998.38
Teva	2037	July	\$ 7,226.93	\$ -	\$ -	\$ 7,226.93
CVS	2037	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Walgreens	2037	December	\$ 11,720.48	\$ -	\$ -	\$ 11,720.48
Distributors	2038	July	\$ 10,586.33	\$ 1,587.95	\$ -	\$ 8,998.38
Teva	2038	July	\$ 7,226.93	\$ -	\$ -	\$ 7,226.93
CVS	2039	July	\$ 7,226.93	\$ -	\$ -	\$ 7,226.93
Teva	2040	July	\$ 7,226.93	\$ -	\$ -	\$ 7,226.93
Teva	2041	July	\$ 7,226.93	\$ -	\$ -	\$ 7,226.93
Teva	2041	July	\$ 21,680.80	\$ -	\$ -	\$ 21,680.80
Teva	2042	July	\$ 21,680.80	\$ -	\$ -	\$ 21,680.80
TOTAL			\$ 710,503.90	\$ 48,687.86	\$ 144,250.68	\$ 661,816.04

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

North Las Vegas City - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 577,930.20	\$ 86,689.53	\$ -	\$ 491,240.67
Distributors	2022	August	\$ 134,788.74	\$ 20,218.31	\$ -	\$ 114,570.43
Distributors	2022	September	\$ 141,656.39	\$ 21,248.46	\$ -	\$ 120,407.93
American Drug Stores	2022	December	\$ 20,428.39	\$ 5,107.10	\$ -	\$ 15,321.29
Mallinckrodt (BK)	2022	December	\$ 25,191.39	\$ 6,297.85	\$ -	\$ 18,893.54
Distributors	2023	July	\$ 141,656.39	\$ 21,248.46	\$ -	\$ 120,407.93
Allergan	2023	July	\$ 51,574.71	\$ 6,424.41	\$ 45,284.84	\$ 45,150.30
CVS	2023	August	\$ 165,912.74	\$ -	\$ 222,442.49	\$ 165,912.74
Mallinckrodt (BK)	2023	September	\$ -	\$ (6,297.85)	\$ -	\$ 6,297.85
Walmart	2023	September	\$ 438,952.17	\$ -	\$ 58,667.06	\$ 438,952.17
Walgreens	2023	December	\$ 121,255.39	\$ -	\$ -	\$ 121,255.39
Distributors	2024	July	\$ 177,303.04	\$ 26,595.46	\$ -	\$ 150,707.58
Allergan	2024	July	\$ 51,574.71	\$ 6,424.41	\$ -	\$ 45,150.30
Teva	2024	July	\$ 44,529.72	\$ -	\$ -	\$ 44,529.72
CVS	2024	August	\$ 165,912.74	\$ -	\$ 222,442.49	\$ 165,912.74
Purdue (BK)	2024	July	\$ 762,659.96	\$ 190,664.99	\$ -	\$ 571,994.97
Walgreens	2024	December	\$ 121,255.39	\$ -	\$ 242,587.15	\$ 121,255.39
Janssen - J&J	2025	April	\$ 36,436.62	\$ 5,465.49	\$ -	\$ 30,971.13
Distributors	2025	July	\$ 177,303.04	\$ 26,595.46	\$ -	\$ 150,707.58
Allergan	2025	July	\$ 51,574.71	\$ 6,424.41	\$ -	\$ 45,150.30
Teva	2025	July	\$ 44,529.72	\$ -	\$ -	\$ 44,529.72
CVS	2025	August	\$ 165,912.74	\$ -	\$ 222,442.49	\$ 165,912.74
Walgreens	2025	December	\$ 121,255.39	\$ -	\$ 242,587.15	\$ 121,255.39
Distributors	2026	July	\$ 177,303.04	\$ 26,595.46	\$ -	\$ 150,707.58
Allergan	2026	July	\$ 51,574.71	\$ 6,424.41	\$ -	\$ 45,150.30
Teva	2026	July	\$ 44,529.72	\$ -	\$ -	\$ 44,529.72
CVS	2026	August	\$ 200,198.24	\$ -	\$ -	\$ 200,198.24
Walgreens	2026	December	\$ 194,069.72	\$ -	\$ 242,587.15	\$ 194,069.72
Distributors	2027	July	\$ 177,303.04	\$ 26,595.46	\$ -	\$ 150,707.58
Allergan	2027	July	\$ 51,574.71	\$ 6,424.41	\$ -	\$ 45,150.30
Teva	2027	July	\$ 19,877.69	\$ -	\$ 80,862.39	\$ 19,877.69
CVS	2027	August	\$ 200,198.24	\$ -	\$ -	\$ 200,198.24
Walgreens	2027	December	\$ 194,069.72	\$ -	\$ 242,587.15	\$ 194,069.72
Distributors	2028	July	\$ 208,529.73	\$ 31,279.46	\$ -	\$ 177,250.27
Allergan	2028	July	\$ 51,574.71	\$ 6,424.41	\$ -	\$ 45,150.30
Teva	2028	July	\$ 19,877.69	\$ -	\$ 80,862.39	\$ 19,877.69
CVS	2028	August	\$ 200,198.24	\$ -	\$ -	\$ 200,198.24
Walgreens	2028	December	\$ 194,069.72	\$ -	\$ -	\$ 194,069.72
Distributors	2029	July	\$ 208,529.73	\$ 31,279.46	\$ -	\$ 177,250.27
Allergan	2029	July	\$ 51,574.71	\$ 6,424.41	\$ -	\$ 45,150.30
Teva	2029	July	\$ 19,877.69	\$ -	\$ 80,862.39	\$ 19,877.69
CVS	2029	August	\$ 200,198.24	\$ -	\$ -	\$ 200,198.24
Walgreens	2029	December	\$ 194,069.72	\$ -	\$ -	\$ 194,069.72
Distributors	2030	July	\$ 208,529.73	\$ 31,279.46	\$ -	\$ 177,250.27
Teva	2030	July	\$ 19,877.69	\$ -	\$ 80,862.39	\$ 19,877.69
CVS	2030	August	\$ 200,198.24	\$ -	\$ -	\$ 200,198.24
Walgreens	2030	December	\$ 194,069.72	\$ -	\$ -	\$ 194,069.72
Distributors	2031	July	\$ 175,290.29	\$ 26,293.54	\$ -	\$ 148,996.75
Teva	2031	July	\$ 19,877.69	\$ -	\$ 80,862.39	\$ 19,877.69
CVS	2031	August	\$ 200,198.24	\$ -	\$ -	\$ 200,198.24
Walgreens	2031	December	\$ 194,069.72	\$ -	\$ -	\$ 194,069.72
Distributors	2032	July	\$ 175,290.29	\$ 26,293.54	\$ -	\$ 148,996.75
Teva	2032	July	\$ 19,877.69	\$ -	\$ 80,862.39	\$ 19,877.69
CVS	2032	August	\$ 200,198.24	\$ -	\$ -	\$ 200,198.24
Walgreens	2032	December	\$ 194,069.72	\$ -	\$ -	\$ 194,069.72
Distributors	2033	July	\$ 175,290.29	\$ 26,293.54	\$ -	\$ 148,996.75
Teva	2033	July	\$ 19,877.69	\$ -	\$ 80,862.39	\$ 19,877.69
Walgreens	2033	December	\$ 194,069.72	\$ -	\$ -	\$ 194,069.72
Distributors	2034	July	\$ 175,290.29	\$ 26,293.54	\$ -	\$ 148,996.75
Teva	2034	July	\$ 19,877.69	\$ -	\$ 80,862.39	\$ 19,877.69
Walgreens	2034	December	\$ 194,069.72	\$ -	\$ -	\$ 194,069.72
Distributors	2035	July	\$ 175,290.29	\$ 26,293.54	\$ -	\$ 148,996.75
Teva	2035	July	\$ 93,072.61	\$ -	\$ -	\$ 93,072.61
Walgreens	2035	December	\$ 194,069.72	\$ -	\$ -	\$ 194,069.72
Distributors	2036	July	\$ 175,290.29	\$ 26,293.54	\$ -	\$ 148,996.75
Teva	2036	July	\$ 93,072.61	\$ -	\$ -	\$ 93,072.61
Walgreens	2036	December	\$ 194,069.72	\$ -	\$ -	\$ 194,069.72
Distributors	2037	July	\$ 175,290.29	\$ 26,293.54	\$ -	\$ 148,996.75
Teva	2037	July	\$ 119,664.79	\$ -	\$ -	\$ 119,664.79
Walgreens	2037	December	\$ 194,069.72	\$ -	\$ -	\$ 194,069.72
Distributors	2038	July	\$ 175,290.29	\$ 26,293.54	\$ -	\$ 148,996.75
Teva	2038	July	\$ 119,664.79	\$ -	\$ -	\$ 119,664.79
Teva	2039	July	\$ 119,664.79	\$ -	\$ -	\$ 119,664.79
Teva	2040	July	\$ 119,664.79	\$ -	\$ -	\$ 119,664.79
Teva	2041	July	\$ 119,664.79	\$ -	\$ -	\$ 119,664.79
Teva	2041	July	\$ 358,994.36	\$ -	\$ -	\$ 358,994.36
Teva	2042	July	\$ 358,994.36	\$ -	\$ -	\$ 358,994.36
TOTAL			\$ 11,764,644.17	\$ 806,181.75	\$ 2,388,527.06	\$ 10,958,462.42

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)

Reno City - Actual and Estimated Allocations

(assumes no default in payments)

(CMS Medicaid costs, if any, not deducted)

(assumes no administrative fees for court appointed third-party administrators)

Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation
Janssen - J&J	2022	July	\$ 323,114.37	\$ 48,467.16	\$ -	\$ 274,647.21
Distributors	2022	August	\$ 75,358.89	\$ 11,303.83	\$ -	\$ 64,055.06
Distributors	2022	September	\$ 79,198.52	\$ 11,879.78	\$ -	\$ 67,318.74
American Drug Stores	2022	December	\$ 11,421.29	\$ 2,855.32	\$ -	\$ 8,565.97
Mallinckrodt (BK)	2022	December	\$ 14,084.23	\$ 3,521.06	\$ -	\$ 10,563.17
Distributors	2023	July	\$ 79,198.52	\$ 11,879.78	\$ -	\$ 67,318.74
Allergan	2023	July	\$ 28,834.85	\$ 3,591.82	\$ 25,318.26	\$ 25,243.03
CVS	2023	August	\$ 92,759.98	\$ -	\$ 124,365.13	\$ 92,759.98
Mallinckrodt (BK)	2023	September	\$ -	\$ (3,521.06)	\$ -	\$ 3,521.06
Walmart	2023	September	\$ 245,413.29	\$ -	\$ 32,800.11	\$ 245,413.29
Walgreens	2023	December	\$ 67,792.55	\$ -	\$ -	\$ 67,792.55
Distributors	2024	July	\$ 99,128.16	\$ 14,869.22	\$ -	\$ 84,258.94
Allergan	2024	July	\$ 28,834.85	\$ 3,591.82	\$ -	\$ 25,243.03
Teva	2024	July	\$ 24,896.07	\$ -	\$ -	\$ 24,896.07
CVS	2024	August	\$ 92,759.98	\$ -	\$ 124,365.13	\$ 92,759.98
Purdue (BK)	2024	July	\$ 426,394.72	\$ 106,598.68	\$ -	\$ 319,796.04
Walgreens	2024	December	\$ 67,792.55	\$ -	\$ 135,627.79	\$ 67,792.55
Janssen - J&J	2025	April	\$ 20,371.31	\$ 3,055.70	\$ -	\$ 17,315.61
Distributors	2025	July	\$ 99,128.16	\$ 14,869.22	\$ -	\$ 84,258.94
Allergan	2025	July	\$ 28,834.85	\$ 3,591.82	\$ -	\$ 25,243.03
Teva	2025	July	\$ 24,896.07	\$ -	\$ -	\$ 24,896.07
CVS	2025	August	\$ 92,759.98	\$ -	\$ 124,365.13	\$ 92,759.98
Walgreens	2025	December	\$ 67,792.55	\$ -	\$ 135,627.79	\$ 67,792.55
Distributors	2026	July	\$ 99,128.16	\$ 14,869.22	\$ -	\$ 84,258.94
Allergan	2026	July	\$ 28,834.85	\$ 3,591.82	\$ -	\$ 25,243.03
Teva	2026	July	\$ 24,896.07	\$ -	\$ -	\$ 24,896.07
CVS	2026	August	\$ 111,928.62	\$ -	\$ -	\$ 111,928.62
Walgreens	2026	December	\$ 108,502.23	\$ -	\$ 135,627.79	\$ 108,502.23
Distributors	2027	July	\$ 99,128.16	\$ 14,869.22	\$ -	\$ 84,258.94
Allergan	2027	July	\$ 28,834.85	\$ 3,591.82	\$ -	\$ 25,243.03
Teva	2027	July	\$ 11,113.40	\$ -	\$ 45,209.26	\$ 11,113.40
CVS	2027	August	\$ 111,928.62	\$ -	\$ -	\$ 111,928.62
Walgreens	2027	December	\$ 108,502.23	\$ -	\$ 135,627.79	\$ 108,502.23
Distributors	2028	July	\$ 116,586.66	\$ 17,488.00	\$ -	\$ 99,098.66
Allergan	2028	July	\$ 28,834.85	\$ 3,591.82	\$ -	\$ 25,243.03
Teva	2028	July	\$ 11,113.40	\$ -	\$ 45,209.26	\$ 11,113.40
CVS	2028	August	\$ 111,928.62	\$ -	\$ -	\$ 111,928.62
Walgreens	2028	December	\$ 108,502.23	\$ -	\$ -	\$ 108,502.23
Distributors	2029	July	\$ 116,586.66	\$ 17,488.00	\$ -	\$ 99,098.66
Allergan	2029	July	\$ 28,834.85	\$ 3,591.82	\$ -	\$ 25,243.03
Teva	2029	July	\$ 11,113.40	\$ -	\$ 45,209.26	\$ 11,113.40
CVS	2029	August	\$ 111,928.62	\$ -	\$ -	\$ 111,928.62
Walgreens	2029	December	\$ 108,502.23	\$ -	\$ -	\$ 108,502.23
Distributors	2030	July	\$ 116,586.66	\$ 17,488.00	\$ -	\$ 99,098.66
Teva	2030	July	\$ 11,113.40	\$ -	\$ 45,209.26	\$ 11,113.40
CVS	2030	August	\$ 111,928.62	\$ -	\$ -	\$ 111,928.62
Walgreens	2030	December	\$ 108,502.23	\$ -	\$ -	\$ 108,502.23
Distributors	2031	July	\$ 98,002.85	\$ 14,700.43	\$ -	\$ 83,302.42
Teva	2031	July	\$ 11,113.40	\$ -	\$ 45,209.26	\$ 11,113.40
CVS	2031	August	\$ 111,928.62	\$ -	\$ -	\$ 111,928.62
Walgreens	2031	December	\$ 108,502.23	\$ -	\$ -	\$ 108,502.23
Distributors	2032	July	\$ 98,002.85	\$ 14,700.43	\$ -	\$ 83,302.42
Teva	2032	July	\$ 11,113.40	\$ -	\$ 45,209.26	\$ 11,113.40
CVS	2032	August	\$ 111,928.62	\$ -	\$ -	\$ 111,928.62
Walgreens	2032	December	\$ 108,502.23	\$ -	\$ -	\$ 108,502.23
Distributors	2033	July	\$ 98,002.85	\$ 14,700.43	\$ -	\$ 83,302.42
Teva	2033	July	\$ 11,113.40	\$ -	\$ 45,209.26	\$ 11,113.40
Walgreens	2033	December	\$ 108,502.23	\$ -	\$ -	\$ 108,502.23
Distributors	2034	July	\$ 98,002.85	\$ 14,700.43	\$ -	\$ 83,302.42
Teva	2034	July	\$ 11,113.40	\$ -	\$ 45,209.26	\$ 11,113.40
Walgreens	2034	December	\$ 108,502.23	\$ -	\$ -	\$ 108,502.23
Distributors	2035	July	\$ 98,002.85	\$ 14,700.43	\$ -	\$ 83,302.42
Teva	2035	July	\$ 52,035.86	\$ -	\$ -	\$ 52,035.86
Walgreens	2035	December	\$ 108,502.23	\$ -	\$ -	\$ 108,502.23
Distributors	2036	July	\$ 98,002.85	\$ 14,700.43	\$ -	\$ 83,302.42
Teva	2036	July	\$ 52,035.86	\$ -	\$ -	\$ 52,035.86
Walgreens	2036	December	\$ 108,502.23	\$ -	\$ -	\$ 108,502.23
Distributors	2037	July	\$ 98,002.85	\$ 14,700.43	\$ -	\$ 83,302.42
Teva	2037	July	\$ 66,903.25	\$ -	\$ -	\$ 66,903.25
Walgreens	2037	December	\$ 108,502.23	\$ -	\$ -	\$ 108,502.23
Distributors	2038	July	\$ 98,002.85	\$ 14,700.43	\$ -	\$ 83,302.42
Teva	2038	July	\$ 66,903.25	\$ -	\$ -	\$ 66,903.25
Teva	2039	July	\$ 66,903.25	\$ -	\$ -	\$ 66,903.25
Teva	2040	July	\$ 66,903.25	\$ -	\$ -	\$ 66,903.25
Teva	2041	July	\$ 66,903.25	\$ -	\$ -	\$ 66,903.25
Teva	2041	July	\$ 200,709.76	\$ -	\$ -	\$ 200,709.76
Teva	2042	July	\$ 200,709.76	\$ -	\$ -	\$ 200,709.76
		TOTAL	\$ 6,577,482.10	\$ 450,727.31	\$ 1,335,399.01	\$ 6,126,754.79

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)							
Sparks City - Actual and Estimated Allocations							
(assumes no default in payments)							
(CMS Medicaid costs, if any, not deducted)							
(assumes no administrative fees for court appointed third-party administrators)							
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation	
Janssen - J&J	2022	July	\$ 101,326.65	\$ 15,199.00	\$ -	\$ 86,127.65	
Distributors	2022	August	\$ 23,632.08	\$ 3,544.81	\$ -	\$ 20,087.27	
Distributors	2022	September	\$ 24,836.16	\$ 3,725.42	\$ -	\$ 21,110.74	
American Drug Stores	2022	December	\$ 3,581.64	\$ 895.41	\$ -	\$ 2,686.23	
Mallinckrodt (BK)	2022	December	\$ 4,416.73	\$ 1,104.18	\$ -	\$ 3,312.55	
Distributors	2023	July	\$ 24,836.16	\$ 3,725.42	\$ -	\$ 21,110.74	
Allergan	2023	July	\$ 9,042.43	\$ 1,126.37	\$ 7,939.65	\$ 7,916.06	
CVS	2023	August	\$ 29,088.95	\$ -	\$ 39,000.13	\$ 29,088.95	
Mallinckrodt (BK)	2023	September	\$ -	\$ (1,104.18)	\$ -	\$ 1,104.18	
Walmart	2023	September	\$ 76,960.07	\$ -	\$ 10,285.91	\$ 76,960.07	
Walgreens	2023	December	\$ 21,259.32	\$ -	\$ -	\$ 21,259.32	
Distributors	2024	July	\$ 31,085.97	\$ 4,662.90	\$ -	\$ 26,423.07	
Allergan	2024	July	\$ 9,042.43	\$ 1,126.37	\$ -	\$ 7,916.06	
Teva	2024	July	\$ 7,807.25	\$ -	\$ -	\$ 7,807.25	
CVS	2024	August	\$ 29,088.95	\$ -	\$ 39,000.13	\$ 29,088.95	
Purdue (BK)	2024	July	\$ 133,714.72	\$ 33,428.68	\$ -	\$ 100,286.04	
Walgreens	2024	December	\$ 21,259.32	\$ -	\$ 42,532.03	\$ 21,259.32	
Janssen - J&J	2025	April	\$ 6,388.32	\$ 958.25	\$ -	\$ 5,430.07	
Distributors	2025	July	\$ 31,085.97	\$ 4,662.90	\$ -	\$ 26,423.07	
Allergan	2025	July	\$ 9,042.43	\$ 1,126.37	\$ -	\$ 7,916.06	
Teva	2025	July	\$ 7,807.25	\$ -	\$ -	\$ 7,807.25	
CVS	2025	August	\$ 29,088.95	\$ -	\$ 39,000.13	\$ 29,088.95	
Walgreens	2025	December	\$ 21,259.32	\$ -	\$ 42,532.03	\$ 21,259.32	
Distributors	2026	July	\$ 31,085.97	\$ 4,662.90	\$ -	\$ 26,423.07	
Allergan	2026	July	\$ 9,042.43	\$ 1,126.37	\$ -	\$ 7,916.06	
Teva	2026	July	\$ 7,807.25	\$ -	\$ -	\$ 7,807.25	
CVS	2026	August	\$ 35,100.12	\$ -	\$ -	\$ 35,100.12	
Walgreens	2026	December	\$ 34,025.62	\$ -	\$ 42,532.03	\$ 34,025.62	
Distributors	2027	July	\$ 31,085.97	\$ 4,662.90	\$ -	\$ 26,423.07	
Allergan	2027	July	\$ 9,042.43	\$ 1,126.37	\$ -	\$ 7,916.06	
Teva	2027	July	\$ 3,485.09	\$ -	\$ 14,177.34	\$ 3,485.09	
CVS	2027	August	\$ 35,100.12	\$ -	\$ -	\$ 35,100.12	
Walgreens	2027	December	\$ 34,025.62	\$ -	\$ 42,532.03	\$ 34,025.62	
Distributors	2028	July	\$ 36,560.85	\$ 5,484.13	\$ -	\$ 31,076.72	
Allergan	2028	July	\$ 9,042.43	\$ 1,126.37	\$ -	\$ 7,916.06	
Teva	2028	July	\$ 3,485.09	\$ -	\$ 14,177.34	\$ 3,485.09	
CVS	2028	August	\$ 35,100.12	\$ -	\$ -	\$ 35,100.12	
Walgreens	2028	December	\$ 34,025.62	\$ -	\$ -	\$ 34,025.62	
Distributors	2029	July	\$ 36,560.85	\$ 5,484.13	\$ -	\$ 31,076.72	
Allergan	2029	July	\$ 9,042.43	\$ 1,126.37	\$ -	\$ 7,916.06	
Teva	2029	July	\$ 3,485.09	\$ -	\$ 14,177.34	\$ 3,485.09	
CVS	2029	August	\$ 35,100.12	\$ -	\$ -	\$ 35,100.12	
Walgreens	2029	December	\$ 34,025.62	\$ -	\$ -	\$ 34,025.62	
Distributors	2030	July	\$ 36,560.85	\$ 5,484.13	\$ -	\$ 31,076.72	
Teva	2030	July	\$ 3,485.09	\$ -	\$ 14,177.34	\$ 3,485.09	
CVS	2030	August	\$ 35,100.12	\$ -	\$ -	\$ 35,100.12	
Walgreens	2030	December	\$ 34,025.62	\$ -	\$ -	\$ 34,025.62	
Distributors	2031	July	\$ 30,733.08	\$ 4,609.96	\$ -	\$ 26,123.12	
Teva	2031	July	\$ 3,485.09	\$ -	\$ 14,177.34	\$ 3,485.09	
CVS	2031	August	\$ 35,100.12	\$ -	\$ -	\$ 35,100.12	
Walgreens	2031	December	\$ 34,025.62	\$ -	\$ -	\$ 34,025.62	
Distributors	2032	July	\$ 30,733.08	\$ 4,609.96	\$ -	\$ 26,123.12	
Teva	2032	July	\$ 3,485.09	\$ -	\$ 14,177.34	\$ 3,485.09	
CVS	2032	August	\$ 35,100.12	\$ -	\$ -	\$ 35,100.12	
Walgreens	2032	December	\$ 34,025.62	\$ -	\$ -	\$ 34,025.62	
Distributors	2033	July	\$ 30,733.08	\$ 4,609.96	\$ -	\$ 26,123.12	
Teva	2033	July	\$ 3,485.09	\$ -	\$ 14,177.34	\$ 3,485.09	
Walgreens	2033	December	\$ 34,025.62	\$ -	\$ -	\$ 34,025.62	
Distributors	2034	July	\$ 30,733.08	\$ 4,609.96	\$ -	\$ 26,123.12	
Teva	2034	July	\$ 3,485.09	\$ -	\$ 14,177.34	\$ 3,485.09	
Walgreens	2034	December	\$ 34,025.62	\$ -	\$ -	\$ 34,025.62	
Distributors	2035	July	\$ 30,733.08	\$ 4,609.96	\$ -	\$ 26,123.12	
Teva	2035	July	\$ 16,318.12	\$ -	\$ -	\$ 16,318.12	
Walgreens	2035	December	\$ 34,025.62	\$ -	\$ -	\$ 34,025.62	
Distributors	2036	July	\$ 30,733.08	\$ 4,609.96	\$ -	\$ 26,123.12	
Teva	2036	July	\$ 16,318.12	\$ -	\$ -	\$ 16,318.12	
Walgreens	2036	December	\$ 34,025.62	\$ -	\$ -	\$ 34,025.62	
Distributors	2037	July	\$ 30,733.08	\$ 4,609.96	\$ -	\$ 26,123.12	
Teva	2037	July	\$ 20,980.44	\$ -	\$ -	\$ 20,980.44	
Walgreens	2037	December	\$ 34,025.62	\$ -	\$ -	\$ 34,025.62	
Distributors	2038	July	\$ 30,733.08	\$ 4,609.96	\$ -	\$ 26,123.12	
Teva	2038	July	\$ 20,980.44	\$ -	\$ -	\$ 20,980.44	
Teva	2039	July	\$ 20,980.44	\$ -	\$ -	\$ 20,980.44	
Teva	2040	July	\$ 20,980.44	\$ -	\$ -	\$ 20,980.44	
Teva	2041	July	\$ 20,980.44	\$ -	\$ -	\$ 20,980.44	
Teva	2041	July	\$ 62,941.33	\$ -	\$ -	\$ 62,941.33	
Teva	2042	July	\$ 62,941.33	\$ -	\$ -	\$ 62,941.33	
			TOTAL	\$ 2,062,657.27	\$ 141,345.25	\$ 418,772.80	\$ 1,921,312.02

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)							
Central Lyon Fire Protection District - Actual and Estimated Allocations							
(assumes no default in payments)							
(CMS Medicaid costs, if any, not deducted)							
(assumes no administrative fees for court appointed third-party administrators)							
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation	
Janssen - J&J	2022	July	\$ 3,595.50	\$ 539.33	\$ -	\$ 3,056.17	
Distributors	2022	August	\$ 838.57	\$ 125.79	\$ -	\$ 712.78	
Distributors	2022	September	\$ 881.29	\$ 132.19	\$ -	\$ 749.10	
American Drug Stores	2022	December	\$ 127.09	\$ 31.77	\$ -	\$ 95.32	
Mallinckrodt (BK)	2022	December	\$ 156.72	\$ 39.18	\$ -	\$ 117.54	
Distributors	2023	July	\$ 881.29	\$ 132.19	\$ -	\$ 749.10	
Allergan	2023	July	\$ 320.86	\$ 39.97	\$ 281.73	\$ 280.89	
CVS	2023	August	\$ 1,032.20	\$ -	\$ 1,383.89	\$ 1,032.20	
Mallinckrodt (BK)	2023	September	\$ -	\$ (39.18)	\$ -	\$ 39.18	
Walmart	2023	September	\$ 2,730.87	\$ -	\$ 364.99	\$ 2,730.87	
Walgreens	2023	December	\$ 754.37	\$ -	\$ -	\$ 754.37	
Distributors	2024	July	\$ 1,103.06	\$ 165.46	\$ -	\$ 937.60	
Allergan	2024	July	\$ 320.86	\$ 39.97	\$ -	\$ 280.89	
Teva	2024	July	\$ 277.04	\$ -	\$ -	\$ 277.04	
CVS	2024	August	\$ 1,032.20	\$ -	\$ 1,383.89	\$ 1,032.20	
Purdue (BK)	2024	July	\$ 4,744.77	\$ 1,186.19	\$ -	\$ 3,558.58	
Walgreens	2024	December	\$ 754.37	\$ -	\$ 1,509.22	\$ 754.37	
Janssen - J&J	2025	April	\$ 226.68	\$ 34.00	\$ -	\$ 192.68	
Distributors	2025	July	\$ 1,103.06	\$ 165.46	\$ -	\$ 937.60	
Allergan	2025	July	\$ 320.86	\$ 39.97	\$ -	\$ 280.89	
Teva	2025	July	\$ 277.04	\$ -	\$ -	\$ 277.04	
CVS	2025	August	\$ 1,032.20	\$ -	\$ 1,383.89	\$ 1,032.20	
Walgreens	2025	December	\$ 754.37	\$ -	\$ 1,509.22	\$ 754.37	
Distributors	2026	July	\$ 1,103.06	\$ 165.46	\$ -	\$ 937.60	
Allergan	2026	July	\$ 320.86	\$ 39.97	\$ -	\$ 280.89	
Teva	2026	July	\$ 277.04	\$ -	\$ -	\$ 277.04	
CVS	2026	August	\$ 1,245.50	\$ -	\$ -	\$ 1,245.50	
Walgreens	2026	December	\$ 1,207.37	\$ -	\$ 1,509.22	\$ 1,207.37	
Distributors	2027	July	\$ 1,103.06	\$ 165.46	\$ -	\$ 937.60	
Allergan	2027	July	\$ 320.86	\$ 39.97	\$ -	\$ 280.89	
Teva	2027	July	\$ 123.67	\$ -	\$ 503.07	\$ 123.67	
CVS	2027	August	\$ 1,245.50	\$ -	\$ -	\$ 1,245.50	
Walgreens	2027	December	\$ 1,207.37	\$ -	\$ 1,509.22	\$ 1,207.37	
Distributors	2028	July	\$ 1,297.33	\$ 194.60	\$ -	\$ 1,102.73	
Allergan	2028	July	\$ 320.86	\$ 39.97	\$ -	\$ 280.89	
Teva	2028	July	\$ 123.67	\$ -	\$ 503.07	\$ 123.67	
CVS	2028	August	\$ 1,245.50	\$ -	\$ -	\$ 1,245.50	
Walgreens	2028	December	\$ 1,207.37	\$ -	\$ -	\$ 1,207.37	
Distributors	2029	July	\$ 1,297.33	\$ 194.60	\$ -	\$ 1,102.73	
Allergan	2029	July	\$ 320.86	\$ 39.97	\$ -	\$ 280.89	
Teva	2029	July	\$ 123.67	\$ -	\$ 503.07	\$ 123.67	
CVS	2029	August	\$ 1,245.50	\$ -	\$ -	\$ 1,245.50	
Walgreens	2029	December	\$ 1,207.37	\$ -	\$ -	\$ 1,207.37	
Distributors	2030	July	\$ 1,297.33	\$ 194.60	\$ -	\$ 1,102.73	
Teva	2030	July	\$ 123.67	\$ -	\$ 503.07	\$ 123.67	
CVS	2030	August	\$ 1,245.50	\$ -	\$ -	\$ 1,245.50	
Walgreens	2030	December	\$ 1,207.37	\$ -	\$ -	\$ 1,207.37	
Distributors	2031	July	\$ 1,090.54	\$ 163.58	\$ -	\$ 926.96	
Teva	2031	July	\$ 123.67	\$ -	\$ 503.07	\$ 123.67	
CVS	2031	August	\$ 1,245.50	\$ -	\$ -	\$ 1,245.50	
Walgreens	2031	December	\$ 1,207.37	\$ -	\$ -	\$ 1,207.37	
Distributors	2032	July	\$ 1,090.54	\$ 163.58	\$ -	\$ 926.96	
Teva	2032	July	\$ 123.67	\$ -	\$ 503.07	\$ 123.67	
CVS	2032	August	\$ 1,245.50	\$ -	\$ -	\$ 1,245.50	
Walgreens	2032	December	\$ 1,207.37	\$ -	\$ -	\$ 1,207.37	
Distributors	2033	July	\$ 1,090.54	\$ 163.58	\$ -	\$ 926.96	
Teva	2033	July	\$ 123.67	\$ -	\$ 503.07	\$ 123.67	
Walgreens	2033	December	\$ 1,207.37	\$ -	\$ -	\$ 1,207.37	
Distributors	2034	July	\$ 1,090.54	\$ 163.58	\$ -	\$ 926.96	
Teva	2034	July	\$ 123.67	\$ -	\$ 503.07	\$ 123.67	
Walgreens	2034	December	\$ 1,207.37	\$ -	\$ -	\$ 1,207.37	
Distributors	2035	July	\$ 1,090.54	\$ 163.58	\$ -	\$ 926.96	
Teva	2035	July	\$ 579.04	\$ -	\$ -	\$ 579.04	
Walgreens	2035	December	\$ 1,207.37	\$ -	\$ -	\$ 1,207.37	
Distributors	2036	July	\$ 1,090.54	\$ 163.58	\$ -	\$ 926.96	
Teva	2036	July	\$ 579.04	\$ -	\$ -	\$ 579.04	
Walgreens	2036	December	\$ 1,207.37	\$ -	\$ -	\$ 1,207.37	
Distributors	2037	July	\$ 1,090.54	\$ 163.58	\$ -	\$ 926.96	
Teva	2037	July	\$ 744.48	\$ -	\$ -	\$ 744.48	
Walgreens	2037	December	\$ 1,207.37	\$ -	\$ -	\$ 1,207.37	
Distributors	2038	July	\$ 1,090.54	\$ 163.58	\$ -	\$ 926.96	
Teva	2038	July	\$ 744.48	\$ -	\$ -	\$ 744.48	
Teva	2039	July	\$ 744.48	\$ -	\$ -	\$ 744.48	
Teva	2040	July	\$ 744.48	\$ -	\$ -	\$ 744.48	
Teva	2041	July	\$ 744.48	\$ -	\$ -	\$ 744.48	
Teva	2041	July	\$ 2,233.43	\$ -	\$ -	\$ 2,233.43	
Teva	2042	July	\$ 2,233.43	\$ -	\$ -	\$ 2,233.43	
			TOTAL	\$ 73,191.82	\$ 5,015.53	\$ 14,859.84	\$ 68,176.29

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 09-01-2023)							
North Lyon Fire Protection District - Actual and Estimated Allocations							
(assumes no default in payments)							
(CMS Medicaid costs, if any, not deducted)							
(assumes no administrative fees for court appointed third-party administrators)							
Settlement Name	Estimated/Actual Allocation Year	Estimated/Actual Allocation Month	Total Annual Allocation	Attorney Fees (Deducted)	Attorney Fees (Through Settlement)	Net Allocation	
Janssen - J&J	2022	July	\$ 1,234.75	\$ 185.21	\$ -	\$ 1,049.54	
Distributors	2022	August	\$ 287.98	\$ 43.20	\$ -	\$ 244.78	
Distributors	2022	September	\$ 302.65	\$ 45.40	\$ -	\$ 257.25	
American Drug Stores	2022	December	\$ 43.65	\$ 10.91	\$ -	\$ 32.74	
Mallinckrodt (BK)	2022	December	\$ 53.82	\$ 13.46	\$ -	\$ 40.36	
Distributors	2023	July	\$ 302.65	\$ 45.40	\$ -	\$ 257.25	
Allergan	2023	July	\$ 110.19	\$ 13.73	\$ 96.75	\$ 96.46	
CVS	2023	August	\$ 354.47	\$ -	\$ 475.25	\$ 354.47	
Mallinckrodt (BK)	2023	September	\$ -	\$ (13.46)	\$ -	\$ 13.46	
Walmart	2023	September	\$ 937.82	\$ -	\$ 125.34	\$ 937.82	
Walgreens	2023	December	\$ 259.06	\$ -	\$ -	\$ 259.06	
Distributors	2024	July	\$ 378.81	\$ 56.82	\$ -	\$ 321.99	
Allergan	2024	July	\$ 110.19	\$ 13.73	\$ -	\$ 96.46	
Teva	2024	July	\$ 95.14	\$ -	\$ -	\$ 95.14	
CVS	2024	August	\$ 354.47	\$ -	\$ 475.25	\$ 354.47	
Purdue (BK)	2024	July	\$ 1,629.43	\$ 407.36	\$ -	\$ 1,222.07	
Walgreens	2024	December	\$ 259.06	\$ -	\$ 518.29	\$ 259.06	
Janssen - J&J	2025	April	\$ 77.85	\$ 11.68	\$ -	\$ 66.17	
Distributors	2025	July	\$ 378.81	\$ 56.82	\$ -	\$ 321.99	
Allergan	2025	July	\$ 110.19	\$ 13.73	\$ -	\$ 96.46	
Teva	2025	July	\$ 95.14	\$ -	\$ -	\$ 95.14	
CVS	2025	August	\$ 354.47	\$ -	\$ 475.25	\$ 354.47	
Walgreens	2025	December	\$ 259.06	\$ -	\$ 518.29	\$ 259.06	
Distributors	2026	July	\$ 378.81	\$ 56.82	\$ -	\$ 321.99	
Allergan	2026	July	\$ 110.19	\$ 13.73	\$ -	\$ 96.46	
Teva	2026	July	\$ 95.14	\$ -	\$ -	\$ 95.14	
CVS	2026	August	\$ 427.72	\$ -	\$ -	\$ 427.72	
Walgreens	2026	December	\$ 414.63	\$ -	\$ 518.29	\$ 414.63	
Distributors	2027	July	\$ 378.81	\$ 56.82	\$ -	\$ 321.99	
Allergan	2027	July	\$ 110.19	\$ 13.73	\$ -	\$ 96.46	
Teva	2027	July	\$ 42.47	\$ -	\$ 172.76	\$ 42.47	
CVS	2027	August	\$ 427.72	\$ -	\$ -	\$ 427.72	
Walgreens	2027	December	\$ 414.63	\$ -	\$ 518.29	\$ 414.63	
Distributors	2028	July	\$ 445.52	\$ 66.83	\$ -	\$ 378.69	
Allergan	2028	July	\$ 110.19	\$ 13.73	\$ -	\$ 96.46	
Teva	2028	July	\$ 42.47	\$ -	\$ 172.76	\$ 42.47	
CVS	2028	August	\$ 427.72	\$ -	\$ -	\$ 427.72	
Walgreens	2028	December	\$ 414.63	\$ -	\$ -	\$ 414.63	
Distributors	2029	July	\$ 445.52	\$ 66.83	\$ -	\$ 378.69	
Allergan	2029	July	\$ 110.19	\$ 13.73	\$ -	\$ 96.46	
Teva	2029	July	\$ 42.47	\$ -	\$ 172.76	\$ 42.47	
CVS	2029	August	\$ 427.72	\$ -	\$ -	\$ 427.72	
Walgreens	2029	December	\$ 414.63	\$ -	\$ -	\$ 414.63	
Distributors	2030	July	\$ 445.52	\$ 66.83	\$ -	\$ 378.69	
Teva	2030	July	\$ 42.47	\$ -	\$ 172.76	\$ 42.47	
CVS	2030	August	\$ 427.72	\$ -	\$ -	\$ 427.72	
Walgreens	2030	December	\$ 414.63	\$ -	\$ -	\$ 414.63	
Distributors	2031	July	\$ 374.51	\$ 56.18	\$ -	\$ 318.33	
Teva	2031	July	\$ 42.47	\$ -	\$ 172.76	\$ 42.47	
CVS	2031	August	\$ 427.72	\$ -	\$ -	\$ 427.72	
Walgreens	2031	December	\$ 414.63	\$ -	\$ -	\$ 414.63	
Distributors	2032	July	\$ 374.51	\$ 56.18	\$ -	\$ 318.33	
Teva	2032	July	\$ 42.47	\$ -	\$ 172.76	\$ 42.47	
CVS	2032	August	\$ 427.72	\$ -	\$ -	\$ 427.72	
Walgreens	2032	December	\$ 414.63	\$ -	\$ -	\$ 414.63	
Distributors	2033	July	\$ 374.51	\$ 56.18	\$ -	\$ 318.33	
Teva	2033	July	\$ 42.47	\$ -	\$ 172.76	\$ 42.47	
Walgreens	2033	December	\$ 414.63	\$ -	\$ -	\$ 414.63	
Distributors	2034	July	\$ 374.51	\$ 56.18	\$ -	\$ 318.33	
Teva	2034	July	\$ 42.47	\$ -	\$ 172.76	\$ 42.47	
Walgreens	2034	December	\$ 414.63	\$ -	\$ -	\$ 414.63	
Distributors	2035	July	\$ 374.51	\$ 56.18	\$ -	\$ 318.33	
Teva	2035	July	\$ 198.85	\$ -	\$ -	\$ 198.85	
Walgreens	2035	December	\$ 414.63	\$ -	\$ -	\$ 414.63	
Distributors	2036	July	\$ 374.51	\$ 56.18	\$ -	\$ 318.33	
Teva	2036	July	\$ 198.85	\$ -	\$ -	\$ 198.85	
Walgreens	2036	December	\$ 414.63	\$ -	\$ -	\$ 414.63	
Distributors	2037	July	\$ 374.51	\$ 56.18	\$ -	\$ 318.33	
Teva	2037	July	\$ 255.66	\$ -	\$ -	\$ 255.66	
Walgreens	2037	December	\$ 414.63	\$ -	\$ -	\$ 414.63	
Distributors	2038	July	\$ 374.51	\$ 56.18	\$ -	\$ 318.33	
Teva	2038	July	\$ 255.66	\$ -	\$ -	\$ 255.66	
Teva	2039	July	\$ 255.66	\$ -	\$ -	\$ 255.66	
Teva	2040	July	\$ 255.66	\$ -	\$ -	\$ 255.66	
Teva	2041	July	\$ 255.66	\$ -	\$ -	\$ 255.66	
Teva	2041	July	\$ 766.99	\$ -	\$ -	\$ 766.99	
Teva	2042	July	\$ 766.99	\$ -	\$ -	\$ 766.99	
			TOTAL	\$ 25,135.16	\$ 1,722.48	\$ 5,103.10	\$ 23,412.68

COPY

Douglas County, Nevada, State of Nevada

CERTIFIED COPY

I certify that the document to which this certificate is attached is a full and correct copy of the original record on file in the Clerk-Treasurer's Office on this

14 day of November, 20 23

By [Signature] Deputy